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The use of pharmaceutically active peptides and proteins has increased significantly 
over the last 30 years.  Topical delivery of growth factors to chronic wounds to 
enhance wound management and repair have been of particular interest.  The aim of 
the work in this thesis was to evaluate the ability of the PVA-borate hydrogel 
formulation to deliver biologically active protein payloads.  The unique viscoelastic 
properties of PVA-borate hydrogels are advantageous for application to wounds.  
The hydrogel can flow into the wound crevasses providing maximal surface area for 
drug delivery.  Yet, they maintain enough cohesive integrity of its cross-linked 
network to allow for complete and intact removal from the wound, without causing 
any trauma to newly formed tissue.  The ability of the PVA-borate hydrogel to 
maintain a moist environment and also absorb small volumes of exudate from low 
exuding wounds also aids wound healing. 
 Several model payloads (BSA, haemoglobin, trypsin and pepsin) were 
incorporated into the hydrogel.  These proteins where found to change the 
viscoelastic properties of the PVA-borate hydrogel, but, were released in a sustained 
manner from the hydrogel without undergoing any degradation.  This investigation 
indicated that the PVA-borate hydrogel is capable of providing a sustained release of 
protein payloads with certain physical and chemical characteristics. 
 Insulin-like growth factor-1 (IGF-1) was incorporated into the hydrogel and 
found not to effect the viscoelastic properties of the hydrogel.  In vitro release studies 
confirmed that the hydrogel provided a sustained release of IGF-1, which had 
maintained its biological activity and not experienced any degradation. 
 Cell culture studies confirmed that IGF-1-loaded PVA-borate hydrogels can 
stimulate fibroblast and keratinocyte migration and proliferation.  Therefore, the 
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work in this thesis demonstrates that IGF-1-loaded hydrogels may have a beneficial 
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By definition, a wound is the loss of integrity and continuity of the epithelial layer of 
the skin, which may also include damage to the structure and function of underlying 
tissue (Enoch & Leaper, 2008).  Wounds can be classified clinically as either acute 
or chronic according to the period of time that it takes the wound to heal (Velnar et 
al., 2009).  An acute wound usually fully repairs within 5 to 10 days, and within a 
maximum of six months.  Acute wounds can be accidental due to a traumatic event, 
such as a laceration or abrasion, but can also be deliberate, such as an incision made 
by a surgeon.  A chronic wound is one which has not progressed through the normal 
phases of healing within the expected time frame.  The healing process may be 
disrupted at one or more of the stages resulting in the chronic state.  Patient 
comorbidities and medication can also complicate the wound healing process 
(Menke et al., 2007).  In 2008, it was reported that 200,000 people in the UK had a 
chronic wound, costing the NHS an estimated £2.3–3.1 billion per year (Posnett & 
Franks, 2008). 
 
 Normal wound healing 
Normal wound healing involves a highly regulated, complex series of events 
involving multiple growth factors and cytokines that results in the damaged tissue 
returning fully to its normal anatomical structure and function (Enoch & Leaper, 
2008).  The wound healing process involves three main stages, inflammatory, 
proliferation and remodelling.  Some authors document a fourth initial stage known 
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as haemostasis, which is an immediate response by the vascular tissue to stop the 
bleeding (Li et al., 2007).  The different phases have a degree of overlap between 
them; however, they are still well defined with specific cell types only being present 
during specific phases of the healing process (Enoch & Leaper, 2008).  
 
1.2.1 Haemostasis 
Haemostasis is an immediate response to injury of blood vessels, with the main aim 
being to prevent severe blood loss and protect vital organs.  The two main processes 
that occur during haemostasis are the development of a fibrin clot and coagulation 
(Li et al., 2007).  Platelets are the first cells to appear after injury and are activated 
when exposed to adhesive proteins, such as collagen and fibronectin of the 
extracellular matrix.  Aggregation of the platelets triggers Hageman factor XII 
enzyme, which in turn initiates the intrinsic coagulation pathway (Figure 1.1).  This 
concludes with the conversion of prothrombin to the active serine protease thrombin 
(Li et al., 2007).   
Thrombin carries out the proteolytic cleavage of soluble fibrinogen to insoluble 
fibrin.  The fibrin strands are then cross-linked by factor XIII resulting in formation 
of a clot through the direct binding of fibrin to the platelets (Li et al., 2007).  The 
damaged tissue, along with activated endothelial cells and monocytes, express a 
lipoprotein known as tissue factor, which triggers the extrinsic coagulation pathway, 
which can be seen in Figure 1.1 (Li et al., 2007).  The fibrin clot not only has an 
important role initially in the healing process but also throughout the different phases 
of the wound healing, even though its degradation by plasminogen begins briefly 
after the formation of the clot.  The fibrin clot acts as a structural frame for the 
migration of several cells, such as keratinocytes, fibroblasts, leukocytes and 
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endothelial cells, as well as a reservoir for growth factors, such as fibroblast growth 
factor-2 (FGF-2), vascular endothelial growth factor (VEGF), insulin-like growth 
factor-1 (IGF-1) that promote regeneration of the wound (Baum & Arpey, 2005). 
 
Figure 1.1 A schematic diagram showing the coagulation pathways of the haemostasis phase of 
wound healing.  
 
1.2.2 Inflammatory Phase 
The inflammatory phase follows on from haemostasis and can be characterised by 
oedema, erythema, heat and pain.  It is divided into two sub-phases known as the 
early and late inflammatory phases (Hart 2002).  The overall aim of inflammation is 
to mount an immune response in order to protect the body against foreign 
microorganisms.  In the early phase, activation of the highly complex classical and 
alternative pathways of the complement cascade by IgG and IgM antibodies occurs 
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C5a, as well as transforming growth factor-β (TGF-β) and components of the 
extracellular matrix, are chemo-attractants for circulating neutrophils.  The 
neutrophils adhere to the endothelial cells and then infiltrate into the wound site by 
diapedesis, within 24-48 hours of injury (Baum & Arpey, 2005; Enoch & Leaper, 
2008; Nesargikar et al., 2012).  Neutrophils clear the wound site of any bacteria, cell 
debris and foreign material through phagocytosis.  The neutrophils then kill the 
bacteria using reactive oxygen species and proteolytic enzymes.  After a few days, 
neutrophil activity begins to decrease and it is at this point, approximately 48-72 
hours post injury, that the late phase commences (Velnar et al., 2009).  Monocytes, 
which transform into macrophages at the wound site, play a major role in the late 
phase.  The same chemo-attractants as for neutrophils attract the macrophages along 
with additional growth factors, such as platelet-derived growth factor (PDGF), 
transforming growth factor-α (TGF-α), IGF-1 and VEGF (Werner & Grose, 2003).  
Macrophages continue the removal of debris and apoptotic neutrophils by 
phagocytosis to allow the healing to progress into later stages of inflammation and 
onto the proliferation phase.  Macrophages carry out further cleaning of the wound 
site via synthesis and secretion of enzymes known as matrix metalloproteinases 
(MMP), in particular MMP-1, 3, 9, 10 and 12 out of the 23 MMP known to be 
present in humans (Nagase et al., 2006).  MMP break down components of the 
extracellular matrix and are regulated by naturally occurring tissue inhibitors of 
metalloproteinases (TIMP) in order to prevent damage to surrounding healthy tissue.  
Macrophages also synthesize and secrete a serine proteinase urokinase plasminogen 
activator (uPA), which converts plasminogen to the active enzyme plasmin.  Plasmin 
is crucial for the digestion of the fibrin clot formed in the initial haemostasis stage to 
allow for the deposition of granulation tissue as the wound begins to enter the 
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proliferation phase (Vassalli et al., 1991).  Macrophages also stimulate angiogenesis 
and promote re-epithelialisation through the secretion of several growth factors, such 
as FGF-2, TGF-β and IGF-1 (Baum & Arpey, 2005).  These growth factors activate 
the recruitment of keratinocytes, fibroblast and endothelial cells and promote re-
epithelialisation (Baum & Arpey, 2005). 
 
1.2.3 Proliferation Phase 
On the third day, post wounding the proliferation phase begins, overlapping with the 
late inflammatory stage.  Macrophages are present in the wound for two or more 
weeks at the start of the proliferation phase.  Fibroblasts are stimulated to migrate 
into the wound by factors, such as TGF-β and PDGF, which are released by platelets 
and other inflammatory cells (Velnar et al., 2009).  In the wound, fibroblast cells 
proliferate abundantly and produce fibronectin, hyaluronan, proteoglycans and 
collagen.  These new proteins help to construct a new extracellular matrix, replacing 
the old matrix composed of fibrin.  The new matrix provides an ideal scaffold to 
support cell migration and is a reservoir for cytokines, growth factors, and facilitates 
wound contraction (Li et al., 2007).  On completion of proliferation and secretion of 
the matrix proteins, fibroblast cells undergo a phenotype change to myofibroblasts.  
Myofibroblasts contain thick bundles of actin, which extend out in a phenomenon 
known as pseudopodia.  These cytoplasmic projections attach specifically to 
fibronectin and collagen in the extracellular matrix.  Once attached, the 
myofibroblasts begin to retract, causing wound closure by approximating the wound 
edges. (Velnar et al., 2009).  This process is also known as the granulation phase due 
to the presence of granulation tissue.  Granulation tissue is soft, granular and pink in 
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appearance and characterised histologically by the presence of proliferating 
fibroblast and capillaries in the loose extracellular matrix (Enoch & Leaper, 2008).  
Epithelialisation is controlled by keratinocyte growth factor (KGF) (Werner, 1998), 
fibroblast growth factor (FGF) (Werner, 1998) and epidermal growth factor (EGF) 
(Jorissen et al., 2003). KGF is secreted predominately from fibroblast cells and is 
approximately 26–28 kDa in size. It is not fully understood how it initiates mitogenic 
activity in keratinocyte cells, but it is thought to be in a paracrine manner (Werner, 
1998). EGF will be discussed in greater detail in section 1.4.2. However, upon 
binding to the EFG transmembrane receptor it causes activation of multiple 
interlinked pathways, such as Ras/ mitogen-activated protein kinases (MAPK), Src, 
janus tyrosine kinase-signal transducers and activators of transcription (JAK-STAT), 
phosphoionositide 3-kinase (PI3K), AKT (Jorissen et al., 2003)  In order for 
complete re-epithelialisation to occur bacterial control needs to have been 
accomplished, appropriate nutrition available and the wound environment moist.  
The aim of the re-epithelialisation phase is to restore a fully intact epidermis layer 
(Li et al., 2007).  Keratinocytes begin preparing for migration as early as twelve 
hours post wounding.  Within each cell, there are numerous processes that occur, to 
prepare for migration, such as flattening and elongation, cytoplasmic projections, 
loss of cell to matrix contact and decreased cell-to-cell interaction (Li et al., 2007).   
Keratinocytes migrate over the granulation tissue, with the leading edge of migrating 
cells having their ability to proliferative temporarily inhibited.  The leading edge of 
migrating cells leaves behind a close knit layer of proliferating keratinocytes (Baum 
& Arpey, 2005).  The migrating cells use integrin surface receptors to bind to 
fibronectin in the newly formed ECM in the wound bed to steer the migration edge in 
the correct direction.  MMP are responsible for dissociation of this integrin 
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fibronectin interaction to allow the edge to continue moving forward.  Another 
source of keratinocytes is thought to be hair bulges that are near to the wound site.  
These keratinocyte stem cells are thought to migrate into the wound upon injury and 
contribute to the re-epithelialisation process (Baum & Arpey, 2005).  Once the 
leading edges of the keratinocytes meet, their migration stops.  This is known as 
contact inhibition.  The cells then attach to the substratum and begin to develop and 
form the basement membrane, which separates the epidermis and the underlying 
dermis. 
 
1.2.4 Remodeling Phase  
This phase is characterised by the formation of scar tissue which is constantly being 
re-organised through degradation and re-synthesis of the extracellular matrix.  The 
aim of the remodeling phase, also known as the maturation phase, is to try and regain 
normal tissue structure with the maximum tensile strength possible (de Oliveira 
Gonzalez et al., 2016).  Remodeling of the matrix continues up to 1 year or in certain 
cases longer after re-epithelisation has occurred (Witte & Barbul, 2005).  When scar 
tissue first becomes evident, it is red-pink in colour due to the increased capillary 
network that was present to aid in the initial stages of the wound healing process.  
However, as time progresses, the scar begins to change in pigmentation as the 
capillaries begin to dissipate and there is an increase in collagen fibers (Sorg et al., 
2017).  Collagen type III is degraded and replaced with newly synthesised collagen 
type I. Collagen type I becomes thicker and arranges in parallel to one and other 
forming a dense network (de Oliveira Gonzalez et al., 2016)  Another typical 
characteristic of scar tissue is the absences of sebaceous glands and hair follicles if 
the wound is deeper than the level of the hair bulbs in the dermis (Martin, 1997).  
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 Chronic wound healing 
A chronic wound can be defined as one that does not progress through the normal 
stages of wound healing in an efficient and timely manner.  Guo and DiPietro (2010) 
state that it is well documented that most chronic wounds present as ulcers, which 
can be categorised into three main types; diabetic foot ulcers, venous leg ulcers and 
pressure ulcers.  Table 1.1 shows the annual incidence and economic burden these 
chronic ulcers had on the NHS in a one year period alone.  As well as being a huge 
financial burden on the health service, they often have a detrimental impact on the 
individual’s quality of life.  In the USA, chronic wounds pose a similar problem with 
3–6 million people estimated to be affected by these wounds, of which 85 % are ≥ 65 
years of age.  This has led to an extortionate amount of expenditure on health care, 
estimated to be greater than $3 billion per year (Menke et al., 2007).  
 
Table 1.1Chronic wound treatment cost to the NHS (Posnett & Franks, 2008) 
 
 Annual incidence Cost per patient 
Annual NHS cost 
(2005-2006) 
Pressure ulcer 410,000 £4,300–6,400 £1.8–2.6 billion 
Venous leg ulcer 108,600 £1,500–1,800 £168–198 million 
Diabetic foot ulcer 57,000 £5,200 £300 million 
Total 575,600 £4,000–5,400* £2.3–3.1 billion* 
*
Values estimated averages 
There are many factors, both local (characteristics of the wound itself) and systemic 
(overall health of the individual), that can affect the repair of a wound at one or more 
stages of the healing process (Guo & DiPietro, 2010).  Systemic factors that can 
impair wound healing are as follows; age, co-morbidities, obesity, alcoholism, 
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smoking, poor diet, stress and medications, such as glucocorticoid steroids, non-
steroidal anti-inflammatories and chemotherapy.  
One problematic local factor is the presence of bacteria or bacterial biofilms, 
which are a common feature of most chronic wounds.  It has been established that a 
level of ≥ 106 micro-organisms per gram of tissue, regardless of what strain or type 
of bacteria are present, causes impaired healing of an open wound (Robson & 
Heggers, 1969; Robson, 1997).  Once the bacterial load increases to the critical 
colonisation level, the body’s host immune response is no longer able to fight the 
infection and the biofilm formation begins (Wysocki, 2002).  These biofilms are 
colonies of bacteria surrounded by a protective layer made of poly(saccharides), 
which make the bacteria more resistant to antibiotics (Falanga, 2004).  Biofilms 
usually cause erythema, swelling and produce a purulent malodorous exudate.  These 
biofilms consist of a wide range of micro-organisms, such as Pseudomonas 
aeruginosa, Staphylococcus aureus, Streptococci and Enterobacter (Dowd et al., 
2008; Toy & Macera, 2011). 
It is well known that for acute wounds to heal it is important that the wound 
remains moist in order to facilitate re-epithelisation.  However, Falanga (2004) states 
that there is a distinct difference between the wound fluid of an acute and chronic 
wound.  Samples of fluid taken from an acute wound caused an increase in 
proliferation in vitro of fibroblast, keratinocyte and endothelial cells, whereas fluid 
from chronic wounds caused inhibition of proliferation and angiogenesis (Bucalo, 
1993; Drinkwater et al., 2002).  In chronic wound fluid, there is also higher than 
normal concentrations of MMP (Yager et al., 1996) with no increase in TIMP to 
control the spike in MMP level.  As mentioned previously, MMP play a vital role in 
the proliferation phase, but when they are present in excessive amounts, in particular 
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MMP 2 and 9, they begin to prevent wound healing by excessive degradation of vital 
extracellular matrix proteins, such as fibronectin, and prevent keratinocyte migration 
(Bullen et al., 1995).  
Other local factors that have been documented to prevent normal wound 
healing are impaired blood flow (Falanga, 2004), prolonged hypoxia (Falanga, 2004) 
and phenotypic changes to wound cells (Stephens et al., 2003).  These changes 
reduce the ability of cells to respond to growth factors and, therefore, proliferate.  A 
phenomena known as fibrin cuff trapping, which will be discussed in section 1.3.2, is 
also thought to play a role in impairing normal wound healing (Stadelmann et al., 
1998). 
 
1.3.1 Diabetic foot ulceration 
It is estimated that the 4-10 % of patients diagnosed with diabetes mellitus will 
experience a foot ulcer at some point in their lifetime (Wu et al., 2007).  It is 
estimated that within the UK there are approximately 64,000 individuals at any one 
time with an active diabetic foot ulcer (Posnett & Franks, 2008), with 2,600 patients 
requiring lower limb amputation each year as a result of ulceration (Gordois et al., 
2003).  As seen in Table 1.1, this is estimated to cost the NHS £300 million per year 
with this cost most certainly increasing every year.  
Diabetes mellitus is a disease in which the body is unable to regulate its blood 
glucose levels sufficiently, causing hyperglycaemia.  It is divided into two main 
types; Type 1 or Type 2.  In patients suffering from Type 1 diabetes, hyperglycaemia 
is a result of their pancreatic islet cells producing no insulin to lower the blood 
glucose level.  In Type 2 diabetes, hyperglycaemia is due to a combination of factors, 
such as insulin resistance and impaired insulin production, as well as life style and 
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genetic factors (Reiber et al., 1998).  Diabetic foot ulcers present as a complication in 
patients who have diabetes mellitus.  The complex nature of diabetes results in the 
patient being at a higher risk of secondary conditions, such as neuropathy and 
peripheral vascular disease (PVD).  These secondary conditions are what results in 
the formation of foot ulcers through a chain of events.  
Neuropathy is the dysfunction of the peripheral nerves affecting the sensory 
and motor nerve fibers.  Sensory neuropathy results in the patient having a 
diminished or complete loss of the perception of pain, heat and pressure (Reiber et 
al., 1998).  Therefore, the patient does not feel repetitive minor injury, or in some 
cases, major injury to their foot.  Motor neuropathy affects the muscles in the foot 
causing them to weaken and experience partial paralysis.  This causes changes in the 
balance of the intrinsic muscles within the foot, resulting in restricted podiatric 
movement when walking, leading to deformities such as, claw toe, hammer toe and 
Charcot foot (Reiber et al., 1998; Jeffcoate & Harding, 2003).  Another side effect of 
neuropathy is the skin on the feet becoming dry and brittle.  As a result of the muscle 
deformities, the dry brittle skin becomes stretched, making it easier to puncture as it 
has reduced tensile strength (Shaw & Boulton, 1997).  A combination of these 
neuropathic factors results in the formation of skin calluses, which if left untreated, 
become ulcerated. 
PVD is when blood vessels begin to narrow and block, particularly in the 
lower extremities, reducing blood flow to that particular area of the body.  PVD has 
an active role in causing ulceration, gangrene and impaired healing (Pecoraro et al., 
1990; Shaw & Boulton, 1997).  The incidence of PVD in a diabetic patient is four 
times greater than a non-diabetic person, with the incidence increasing with duration 
of diabetes and the age of the patient (Pecoraro et al., 1990).  Pecoraro et al. (1990) 
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also documented that 62 % of non-healing foot ulcers are in patients who have PVD, 
of which, 46 % end up needing amputation.  PVD causes arteriolar-venular shunting, 
leading to ischaemia at the site of ulceration.  As a result of ischaemia, there is a 
reduced delivery of oxygen, nutrients, cytokines and growth factors, impairing 
wound healing (Jeffcoate & Harding, 2003).  
A typical diabetic foot ulcer can be seen in Figure 1.2. A neuropathic ulcer 
will usually present on the underside of the foot, often at the metatarsal heads.  An 
ulcer arising from PVD or ischaemia can, however, present anywhere on the foot or 
ankle.  Diabetic foot ulcers were first classified using a grading system developed by 
Wagner, which only took into account the depth of the ulcer (Wagner, 1981).  The 
Wagner classification was developed further with addition of a Wound Severity 
Scoring System.  The scoring system takes into account factors such as, ulcer 
duration, pulses, oedema, neuropathy, ischaemia and infection.  The scoring system 
also accounts for the presence or absence of necrotic tissue and granulation tissue.  
There are now many variations of this system, all of which give a more detailed 
description of the ulcer compared to Wagner’s initial scoring system making choice 
of treatment easier for a multidiscipline clinical team (Table 1.2). 
 
Table 1.2 Example of a diabetic foot ulcer grading system (Edmonds, 2006) 
 
Grade Classification Description 
1 
Normal foot No risk factors present 
2 
At risk foot 
One or more risk factors present 
(neuropathy, ischaemia, deformity, callus, oedema). 
3 
Ulcerated foot 
Neuropathic ulcer present on plantar surface and/or 
neuroischaemic ulcer on margins of foot. 
4 
Infected foot Ulcer infected, cellulitis, lymphangitis, osteomyelitis. 
5 
Necrotic foot 
Wet necrosis in neuropathic foot; dry necrosis in 




Figure 1.2 A photograph taking of a typical neuropathic diabetic foot ulcer presenting on the 
underside of the foot close to the metatarsal head surround by callus skin (Jeffcoate & Harding, 2003). 
 
Clinical studies show that early treatment with insulin and administration of vitamin 
A decreased the healing time and increased the strength of the healed wound (Laing, 
1994).  Laing (1994) also found in a study that on average it took two weeks longer 
for neuropathic ulcers in the plantar region of the foot to heal in the diabetic patient 
group compared to the non-diabetic group.  However, the difference was not 
statistically significant.  The best resolution to diabetic foot ulcers is to prevent 
occurrence, rather having to treat them.  Screening of diabetic patients annually for 
risk factors and treating any early signs that can lead to ulceration can significantly 
reduce the burden a ulcer will have on the patient’s life style as well has the 
economic cost of lengthy hospital stays and surgery needed for late stage ulcers.   
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1.3.2 Venous leg ulceration  
Venous leg ulceration is estimated to cost the NHS in the UK £400 million per 
annum (Simon et al., 2004) and account for 80% of all leg ulcers (Kolluri, 2014). 
Treatment of one individual ulcer alone costs the NHS approximately £1,298–£1,526 
per year based on costings in 2001 (Iglesias et al., 2010).  The prevalence of chronic 
leg ulceration is approximately 0.1–0.3% (Nelzen et al., 1994), with an estimated 1% 
of the UK population suffering from a leg ulcer at some point in their life time 
(Callam, 1992). 
Venous leg ulcers are most commonly found in the area between the mid-calf 
to the ankle, known as the gaiter region.  A typical venous ulcer will present as 
irregular in shape, generally shallow in depth and rarely extending to the muscle or 
bone.  There may be red granulation tissue or a yellow coloured exudate present in 
the wound bed.  Necrotic black tissue is rarely seen in venous ulcers (Etufugh & 
Phillips 2007).  A typical venous ulcer can be seen in Figure 1.3. 
 
Figure 1.3 A picture of a typical venous leg ulcer in the gaiter region. The ulcer has the typical 
characteristics of a venous leg ulcer shallow in depth, irregular in shape, with granulation tissue 




Blood flow within the lower leg is controlled by the venous system, which is 
made up of three types of veins; the superficial veins, perforator veins and deep veins 
(Etufugh & Phillips, 2007).  These veins all contain venous valves, which project 
from the wall of the vein and prevent the backflow of blood.  The calf muscle within 
the lower leg acts as a mechanical pump.  On contraction of the muscle, there is a 
slight increase in pressure within the deep veins causing the values to shut, 
preventing retrograde blood flow and the blood is pumped to the heart.  On 
relaxation of the calf muscle, the pressure drops and the valves re-open.  This allows 
the de-oxygenated blood to drain from the superficial veins at the skin surface back 
into the deep veins situated in the calf muscle via the perforating veins (Figure 1.4) 
(Etufugh & Phillips 2007).  
 
 
Figure 1.4 Schematic anatomy of the venous system of the lower leg. (a) Normal venous system 





When this process does not occur as it should, it causes venous hypertension, which 
leads to a condition known as chronic venous insufficiency (CVI) or chronic venous 
disease (CVD) (Raffetto, 2009).  CVI is the inability of the veins in the lower 
extremities to return blood towards the heart.  The term CVI covers a range of 
pathological abnormalities, ranging from leg oedema, varicose veins, to the more 
serious venous leg ulcer.  There are numerous risk factors for CVI, such as family 
history, advanced age, previous or current deep vein thrombosis (DVT), pregnancy, 
obesity, leg trauma and occupations that require prolonged periods of standing 
(Etufugh & Phillips 2007). 
The exact pathophysiology that results in venous hypertension, leading to 
ulceration, is still unknown.  However, over the past several decades, numerous 
theories have been proposed.  Burnard et al. (1982) put forward the first theory, 
known as the fibrin cuff theory.  The fibrin cuff theory proposes that raised venous 
pressure causes expansion of the endothelial pores, leading to molecules, such as 
fibrinogen, being able to pass from the capillary blood into the interstitial fluid.  The 
fibrinogen forms an insoluble cuff of fibrin around the dermal capillaries.  It was 
proposed that the fibrin cuff inhibited sufficient oxygen and nutrient diffusion from 
the blood capillaries into the interstitial fluid, resulting in cell death, tissue 
degradation and formation of the chronic venous ulcer (Burnand et al., 1982).  
Another theory proposed is the inflammatory trap theory (Liu et al., 2011).  This is 
an extension to the fibrin cuff theory and stipulates that inflammatory cells, such as 
leukocytes, become trapped in the fibrin cuff (Coleridge Smith et al., 1988).  The 
trapped leukocytes then release free radicals and proteolytic enzymes, which cause 
further damage to the endothelial cells and capillaries.  This causes an increase in 
their permeability to macromolecules, further exacerbating the fibrinogen depositing 
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and inflammatory state.  This leads to a hypoxic environment, resulting in cell death 
and ulceration (Abbade & Lastoria, 2005).  More recent studies have extended this 
theory by stating that there is an imbalance in both the wound bed and wound 
exudate of numerous key cytokines, growth factors and enzymes.  The most 
frequently studied are neutrophil elastase, MMP, transforming growth factor-beta 
(TGF-β), tumour necrosis factor-alpha (TNF-α) and α2-macroglobulin (Abbade & 
Lastoria, 2005; Liu et al., 2011). 
 
1.3.3 Pressure ulceration  
Despite having NICE clinical guidelines available for the treatment and management 
of pressure ulcers, as well as advanced medical devices and technology readily 
available, the occurrence of pressure ulcers is still increasing.  Cox (2011) reported 
that from 1993 to 2006, there was an 80 % increase in the occurrence of pressure 
ulcers in hospitalised patients. It was also found that the prevalence rates (14–42 %) 
were highest in ICU patients, with 1 in 5 hospital patients estimated to have a 
pressure ulcer (Posnett & Franks, 2008; Cox, 2011).  As seen in Table 1.1, 
approximately 410,000 people develop a pressure ulcer annually in the UK, costing 
the NHS an estimated £1.8–2.6 billion from 2005–2006.  
Hippocrates in 400 BC was the first to document a pressure ulcer in his 
clinical lecture on bedsores saying “at times they erupt from under intact skin” 
(Black et al., 2007).  The European Pressure Ulcer Advisory Panel (EPUAP) defines 
a pressure ulcer as an area of localised damage to the skin and underlying tissue 
caused by pressure, friction or shear forces or a combination of these (Grey et al., 
2006).  Pressure ulcers occur as a result of long-term repetitive compression of soft 
tissue, most commonly between an external surface and a boney prominence.  
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Approximately two thirds of pressure ulcers develop around the pelvis region, with 
the other third being primarily in on the lower limbs, in particular the heel.  A typical 
pressure ulcer can be seen in Figure 1.5, with the elderly being the most susceptible 




Figure 1.5 A picture of a typical pressure ulcer in the pelvic region cover by eschar, which can inhibit 
accurate grading of the ulcer (McSwiggan, 2011). 
 
There is no exact understanding of what triggers the breakdown of soft tissue in 
response to the forces mentioned above.  The following theories are thought to play a 
role in pressure related tissue degradation; impaired interstitial fluid flow (Reddy et 
al., 1981) and lymphatic drainage (Miller & Seale, 1981), ischaemia of the 
surrounding area (Daniel et al., 1981), sustained deformation of localised cells 
(Bouten et al., 2003) and reperfusion injury (Peirce et al., 2000).  Grey et al. (2006) 
document that sustained high pressure on a specific area causes closure of blood and 
lymphatic vessels leading to localised tissue ischaemia.  Once ischaemic conditions 
are established, necrosis of the multiple layers of skin, subcutaneous tissue and 
muscle begins, leading to the onset of ulceration. 
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It has been calculated that an external pressure of 50 mm Hg, if applied over 
a boney prominence, can cause an actual pressure of 200 mm Hg on that area of 
tissue (Grey et al., 2006).  Shear forces are the result of the movement of bone and 
subcutaneous tissue, but not the skin, which is held in a stationary position by 
frictional forces.  Frictional forces can also result from poor fitting prosthetic limbs 
or shoes, for example.  These frictional forces lead to epidermal blistering and 
increased erosion of the skin surface, which lead to ulcer formation.  Grey et al. 
(2006) have reported that the effects of friction is five times more damaging on areas 
of high pressure if moisture is present.  Moisture at the area of high pressure can 
result from perspiration, incontinence or excessive wound exudate.  Moisture also 
causes skin maceration over a prolonged period of time, which further intensifies the 
effect of the aforementioned forces. 
Over several decades, there has been numerous systems developed for 
grading pressure ulcers into different stages.  The first one to be developed was by 
Guttmann in 1955 (Black et al., 2007).  But the first system using a numeric 
classification based on the pathology of the ulcer was developed by Shea (1975).  In 
1989, the National Pressure Ulcers Advisory Panel (NPUAP) developed a 4 stage 
grading system, which was used widely for the following 20 years, with regular 
updates and revisions taking place as more knowledge about the pathogenesis of 
pressure ulcers emerged with advances in medical technology (National Pressure 
Ulcer Advisory Panel, 1989; Black et al., 2007).  The European Pressure Ulcer 
Advisory Panel (EPUAP) also developed a 4 stage grading system similar to the 
NPUAP in 1998, which also undergoes regular reviews and updates.  A summarised 
version of the EPUAP grading system can be seen in Table 1.3 (Grey et al., 2006; 
Black et al., 2007).   
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Table 1.3 European Pressure Ulcer Advisory Panel grading system 
 
Grade Description of ulcer 
1 Non-blanching redness if intact skin, warmth, increase in firmness of 
the skin may also be used in people with dark coloured skin as an 
indicator. 
2 Partial thickness skin loss involving epidermis or dermis or both. 
Ulcer presents on the skin surface as a blister or abrasion. 
3 Full thickness skin loss with damage to or necrosis of the 
subcutaneous tissue. 
4 Extensive damage, tissue necrosis evident, damage to muscle, bone or 
supporting structures with or without full thickness skin loss. 
 
As with diabetic foot ulcers and venous leg ulcers, prevention of risk factors for 
pressure ulcers is key to reducing the long-term impact on the patient’s life style and 
economic burden on the health system.  NICE guidance for the prevention and 
management of pressure ulcers document the following as risk factors for pressure 
ulcers; acute illness, age, level of consciousness, limited mobility or immobility, 
sensory impairment, chronic or terminal diseases, malnutrition or dehydration and 
past history of pressure damage (National Institute for Health and Care Excellence, 
2014).  
 
1.3.4 Arterial ulceration 
Arterial ulceration is a common complication in patients who have peripheral arterial 
disease (PAD).  PAD is estimated to affect 8–12 million Americans, of which 20 % 
are ≥ 65 years of age (Weitz et al., 1996).  The prevalence of arterial ulcers are 0.12–
1.8 % amongst the American population (Sieggreen & Kline, 2004).  Amputation is 
highly probable (50–60 %) in arterial ulceration, with 10 % of those amputations 
being above the knee (Hafner et al., 2000) 
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 Arterial ulcers commonly present on, or around, the toes, over boney 
prominences, or on the heel of the foot.  The ulcer has a characteristic punched out 
look giving the wound well defined edges (Figure 1.6a).  The skin surrounding the 
wound is usually pale, thin, taut, shiny and cool to touch, provided there is no 
infection present (Grey et al., 2006).  There is usually no oedema present with an 
arterial ulcer compared to a venous ulcer, with wound exudate low or non-existent.  
In early stage ulceration, the wound has a low volume of slough present and a 
yellow-like film on the bed, as seen in Figure 1.6a.  As ischaemic conditions 
increase, the tissue quickly becomes gangrenous, particularly if the ulcer is present 
on a toe, as seen in Figure 1.6b. 
 
Figure 1.6 Photographs of typical arterial ulceration of the foot.  a) Shows an arterial ulcer over the 
boney prominence at the base of the great toe.  It can be seen to display the characteristic feature of an 
arterial ulcer, punched out look with well-defined edges and a yellow film present in the wound bed 
(Vascular Society of Great Britain and Ireland, 2017).  b) Shows an arterial ulcer of the great toe in 





Early-stage chronic arterial peripheral disease in the lower extremities causes 
the patient to experience a cramping sensation in the calf muscle on walking, known 
as claudication.  Claudication has also been reported in the thigh, buttock and foot of 
PAD patients (Sieggreen & Kline, 2004).  The pain experienced by the patient will 
shift from claudication on walking, which is eased by resting, to pain when resting as 
the ulcer progresses. This pain, also called rest pain, is most common at night, often 
waking the individual from their sleep (Sieggreen & Kline, 2004). Rest pain can be 
relieved by either of the following methods; sleeping upright in a chair, hanging the 
affected leg down over the edge of the bed, or taking brief walks.  Pain experienced 
with an arterial ulcer is said to be an intense burning sensation, whereas, pain with a 
venous ulcer is dull, unless excessive exudate or infection are present (Grey et al., 
2006). 
Blood leaving the heart descends through the descending aorta into a complex 
network of arteries.  Eventually the blood ends up in the anterior tibial artery (Figure 
1.7) in the lower leg, which becomes the dorsalis pedis artery at the ankle (Martini & 
Nath, 2009).  The dorsalis pedis artery divides into the medial and lateral pedis 
arteries, which supply the plantar surface of the foot with oxygenated blood.  The 
medial and lateral pedis arteries form two loops called the dorsal and plantar arches 
(Martini & Nath, 2009), as seen in Figure 1.7.  The dorsal and plantar arches have 
numerous smaller arteries branching out from them that supplies the furthest away 




Figure 1.7 A schematic diagram showing the arterial network of the lower limb, in which oxygenated 
blood travels through (Martini & Nath, 2009). 
 
Arterial ulcers develop as a result of poor arterial blood flow, causing ischaemic 
tissue, leading to necrotic tissue and ulceration. The most common cause or arterial 
ulceration is atherosclerosis of the medium and large arteries (Schroeder et al., 
2006).  Atherosclerosis is the buildup of fatty material, known as atheroma, on the 
endothelial lining of the arteries (Falk, 2006).  Atheroma causes the artery to narrow, 
therefore, naturally reducing the blood flow.  When part of an atheroma plaque 
breaks away from the arterial wall, it travels downstream to a smaller artery, where it 
becomes lodged causing complete, or partial, occlusion of the vessel  This can cause 
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a number of life threating events depending where the atheroma becomes lodged, 
such as a heart attack, stroke or PAD (British Heart Foundation, 2016).  
 A Doppler ultrasound can be used to determine the extent of the arterial 
disease.  The Doppler ultrasound detects changes in arterial blood flow, with three 
distinct phases being seen on the trace in normal arterial function.  The first phase 
above the baseline is the forward flow of the blood.  The second phase below the 
baseline is the relaxation of the artery and some retrograde blood flow.  The third 
phase is thought to be the aortic valve bulging during diastole (Sieggreen & Kline, 
2004).  In early onset PAD, the third phase starts to diminish and as the PAD 
progresses, the first phase wave becomes dampened and broadened (Sieggreen & 
Kline, 2004).  
 The ankle-brachial index (ABI), also known as the ankle-arm index, is 
another standard test to evaluate PAD.  The ABI is defined as the ratio of the systolic 
blood pressure at the ankle to the systolic blood pressure at the brachial artery in the 
arm (Aboyans et al., 2012).  The ABI is measured using a Doppler ultrasound and 
blood pressure cuff (Aboyans et al., 2012).  The Doppler ultrasound is used in this 
scenario to determine when to stop inflating the cuff, once the signal disappears, and 
when to take the pressure reading, once the signal reappears on deflation of the cuff 
(Schroeder et al., 2006; Aboyans et al., 2012).  A summary of the ABI and its 
descriptors can be seen in Table 1.4.  
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Table 1.4 Summary of the ankle-brachial index (Sieggreen & Kline, 2004) 
 
Ankle-brachial index value 
Classification 
1.0–0.9 Normal, asymptomatic 
0.71–0.89 Mild disease, claudication present 
0.41–0.70 Moderate disease, claudication present 
≤ 0.40 Severe disease, rest pain, ulceration 
 
 Growth factors 
Growth factors, cytokines and low molecular weight compounds found in the serum 
play a vital role, instantly after injury and throughout the wound repair process.  
Immediately after injury, degranulation of α-granules in the platelet cells occurs.  
The α-granules are the main source of growth factors needed at the initial stage.  The 
blood clot acts as a reservoir for growth factors needed in the latter stages of the 
wound healing process (Werner & Grose, 2003).  Throughout the inflammatory 
phase, and into the proliferative phase of the healing process, various inflammatory 
cells, such as macrophages, neutrophils and eosinophils also secrete specific growth 
factors.  These growth factors stimulate various skin cells, such as fibroblasts and 
keratinocytes.  
The exact function and role of many endogenous growth factors is still not 
fully understood.  However, over the last decade, with advances in experimental and 
clinical studies, some light has been shed on the role of endogenous growth factors in 
wound healing.  Many of the growth factors are believed to have multifunctional 
roles, in the complex, highly orchestrated, cell signalling network.  In this section, 
several of the main growth factors will be discussed in detail, in relation to wound 
healing and treatment of chronic wounds. 
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1.4.1 Platelet-derived growth factor (PDGF) 
Platelet-derived growth factor (PDGF) is thought to have several functions in wound 
healing.  PDGF causes chemotaxis of macrophages and neutrophils to the wound 
site.  PDGF also upregulates the production of various components of the 
extracellular matrix, such as collagen, proteoglycans, fibronectin and hyaluronic acid 
(Pierce et al., 1991; Heldin et al., 2002).  PDGF stimulates fibroblast proliferation, 
and triggers the phenotype change of fibroblasts to myofibroblasts at the end of the 
proliferation phase in the wound healing (Werner & Grose, 2003). 
PDGF consists of a family of homodimer and heterodimer growth factors.  The 
PDGFs comprise A and B disulfide bonded poly(peptide) chains.  Each of the chains 
are approximately 100 amino acid residues in length (Heldin & Westermark, 1999).  
The A and B chains are synthesised as precursor molecules, which are then subject to 
proteolytic cleavage, leading to the formation of three isoforms, PDGF-AA, PDGF-
BB or PDGF-AB.  The main source of PDGF is from platelet α-granules (Ross et al., 
1974).  However, numerous types of cells, such as fibroblasts, keratinocytes, 
macrophages and smooth muscle cells can also synthesise PDGF, in response to 
external stimuli (Heldin & Westermark, 1999).  The majority of these cells can 
synthesise both chains, suggesting that isoform formation is random.  Although these 
cells are able to produce both poly(peptide) chains, synthesis of each chain is 
independently controlled at transcriptional and posttranscriptional level (Dirks & 
Bloemers, 1996).  Recently, two new homodimer isoforms of PDGF have been 
discovered PDGF-CC and DD.  The C and D chains have the same motif consisting 
of eight cysteine amino acids as the A and B chains, but have an extra three residues 
within the motif (Li et al., 2000; LaRochelle et al., 2001).  The mechanism of 
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activation for PDGF-CC and DD in vivo is still unclear, but both can be activated in 
vitro by addition of plasmin (Heldin et al., 2002). 
PDGF receptors are α and β transdermal membrane tyrosine kinase receptors, 
located across the cytoplasmic membrane of target cells.  As the isoforms are 
dimeric, they bind two receptors at the same time causing dimerisation of the 
receptors (Heldin & Westermark, 1999). An example of one such PDGF isoform 
receptor binding combination can be seen in Figure 1.8.  The receptor specificity for 
each PDGF isoform is summarised in Table 1.5.  
 
Table 1.5 Summary of receptors specificity for PDGF isoforms 
PDGF isoform Tyrosine kinase receptor 
AA αα 
AB αα, αβ 
BB αα, αβ, ββ 
CC αα, αβ* 
DD ββ, αβ* 
* Some authors document that PDGF- CC and DD can also induce αβ receptor complexes (Gilbertson 






Figure 1.8 Shows the ribbon model complex of PDGF-BB binding to PDGFR-ββ, causing 
dimerisation.  PDGF-BB is represented by the blue and green ribbons, one PDGFR-β represented by 
orange ribbons, and the other purple ribbons (Shim et al., 2010). 
 
On binding of PDGF to either receptor, it causes the transduction of 
mitogenic signals causing the cell to start cell division (mitosis).  However, each 
receptor causes a different effect on the actin filaments of the cell (Eriksson et al., 
1992).  Another difference is β-receptor activation, causing chemotaxis, whereas, α-
receptor activation prevents chemotaxis of certain cells, such as smooth muscle and 
fibroblast cells (Heldin & Westermark, 1999).  
 Greenhalgh et al. (1990) delivered topically recombinant human platelet-
derived growth factor (rhPDGF) (1 or 10 μg) in a 5 % poly(ethylene glycol) delivery 
vehicle, to full-thickness skin wounds, in genetically modified diabetic mice.  They 
found that wounds treated with rhPDGF had a significantly greater rate of wound 
closure, at day 21, compared to the control (Greenhalgh et al., 1990).  Likewise, Sun 
et al. (2007) showed that addition of a short collagen-binding domain (CBD) to 




at the wound site.  On testing the CBD-PDGF-BB system in a rabbit dermal ischemic 
ulcer model, they found that this form of topically delivered PDGF-BB promoted 
ulcer healing.  On histological examination of the tissue, they documented increased 
re-epithelisation, formation of capillary lumens-and increased collagen deposition 
(Sun et al., 2007).  
 Regranex® gel is a FDA approved gel containing 0.01 % becaplermin 
manufactured by Smith & Nephew.  Regranex® is licensed for use in USA for the 
treatment of lower extremity diabetic neuropathic ulcers that extend into the 
subcutaneous tissue, or further, and have a sufficient blood supply (Rees et al., 1999; 
Smith & Nephew, 2015).  Becaplermin is a recombinant version of the naturally 
occurring homodimeric PDGF-BB isoform.  Becaplermin is produced using 
recombinant DNA technology, by inserting the coding gene for the B chain into 
yeast (Saccharomyces cerevisiae) (Nagai & Embil, 2002).  A phase two randomised, 
double-blind, placebo-controlled study using becalpermin gel to treat pressure ulcers 
was found to have positive results (Rees et al., 1999).  Rees et al. (1999) concluded 
that once daily application of becalpermin gel (100 or 300 μg g-1) to chronic pressure 
ulcers, resulted in a significant increase in the number of completely healed, and ≥ 90 
% healed chronic pressure ulcers, compared to the control gel.  Interestingly, they 
found that the 300 μg g-1 gel did not show any significantly greater rate of healing 
than the 100 μg g-1 gel (Rees et al., 1999). 
 
1.4.2 Epidermal growth factor (EGF) 
Epidermal growth factor (EGF) is another important growth factor contributing to the 
wound healing process.  It has been documented that EGF is up regulated after acute 
injury causing accelerated re-epithelisation, through increased migration of the 
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keratinocytes (Barrientos et al., 2008).  EGF also promotes re-epithelisation through 
stimulation of angiogenesis, fibronectin synthesis, collagenase activity and 
fibroplasia (Hardwicke et al., 2008). 
EGF was first isolated in 1962 by Stanley Cohen, from a mouse submaxillary 
gland.  This formed part of Cohen’s Nobel Prize winning work in relation to growth 
factors (Cohen, 1962; Cohen, 1986).  The EGFs are a family of proteins, all of which 
have mitogenic activity.  The members of the family are EGF, transforming growth 
factor-α (TGF-α), heparin-binding EGF (HB-EGF), amphiregulin, epiregulin, 
betacellulin, epigen and neurglins 1–4 (Werner & Grose, 2003; Barrientos et al., 
2008).  EGF itself is a 53 amino acid single-chain poly(peptide), which includes six 
cysteine residues, forming three disulfide bonds, as seen in Figure 1.9.  
 
Figure 1.9 The primary 53 amino acid sequence of human EGF.  The 6 cysteine amino acids can be 
seen highlighted, which form the 3 disulfide bonds, folding the primary chain (Schultz et al., 1991). 
 
EGF ligands are released from macrophage (Barrientos et al., 2008), fibroblast and 
platelet cells (Shiraha et al., 1999; Barrientos et al., 2008), with their primary 
function being to initiate re-epithelisation.  Keratinocytes surrounding the edge of the 
wound and hair follicle epithelial cells release TGF-α (Werner & Grose, 2003).  
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TGF-α causes increased keratinocyte proliferation and migration, via upregulation of 
keratin-6 and 16 production (Jiang et al., 1993).  Post-wounding HB-EGF is 
upregulated, with increased secretion from keratinocytes, promoting early stage re-
epithelisation (Barrientos et al., 2008).  As with PDGF, there is more than one 
receptor for EGF ligands to bind to.  The EGF ligands bind to each of the following 
receptors; EGFR, human epidermal growth factor receptor 2 (HER2), HER3 and 
HER4, with different degrees of affinity (Werner & Grose, 2003).  These receptors 
are also referred to as ErbB1–4, and EGFR is also called HER1 (Werner & Grose, 
2003).   
EGFR is first synthesised as a precursor poly(peptide) with a total of 1210 
amino acid residues (Jorissen et al., 2003).  The precursor poly(peptide) then 
undergoes proteolytic cleavage, yielding the active EGFR receptor, which has 1186 
amino acid residues.  The active EGFR is then inserted into the cell membrane, of 
which 622 amino acids make up the extracellular binding region for the EGF ligands 
(Ogiso et al., 2002).  Ogiso et al. (2002) documented that amino acids, tryosine13, 
isoleucine23, arginine41 and leucine47 are especially important for the binding of 
EGF to the receptor.  Table 1.6 summarises the specificity of the EGF ligands for the 
four receptors. 
 
Table 1.6 Summary of the EGF family ligands and their corresponding receptors 
 
Receptor Ligand  
EGFR/HER1/ErB1 EGF, TGF-α, epigen, amphiregulin, HB-EGF, 
betacellulin, epigregulin  
HER2/ErbB2 None 
HER3/ErbB3 Epigregulin, neuregulin-1, neuregulin-2 
HER4/ErbB4 Betacellulin, HB-EGF, epigregulin, 
neuregulin-3, neuregulin-4  
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All four receptors are present in the membrane of target cells as monomers, known 
as, transmembrane tyrosine kinase receptors.  On binding of an appropriate ligand to 
a receptor, dimerisation occurs (Rubin & Yarden, 2001).  Receptors can pair up with 
a receptor of the same type, forming a homodimer (e.g. HER3-HER3), or a receptor 
of a different type, forming a heterodimer (e.g. HER3-HER4). Dimerisation is 
thought to occur as a result of the complex formed between a ligand and two 
receptors being more stable than a ligand and one receptor (Rubin & Yarden, 2001).  
None of the ligands of the EGF family can bind directly to HER2, nor is there any 
known ligand to exist (Rubin & Yarden, 2001).  However, HER2 can be activated 
when recruited as a second receptor in the dimerisation process, forming a 
heterodimer.  Therefore, HER2 still plays a vital role in normal wound repair.  It is 
well documented that overexpression of HER2 plays a causative part in 
tumorigenesis (Werner & Grose, 2003), in particular breast cancer (Rauser et al., 
2010; Mitri et al., 2012); but also, non-small-cell lung cancer (Cappuzzo et al., 
2005), ovarian cancer (Moasser, 2007), and gastrointestinal tract cancers (Rubin & 
Yarden, 2001).  
 Upon binding of any ligand to the appropriate tyrosine kinase receptor, 
autophosphorylation occurs.  This results in the simultaneous switching on of 
multiple cellular pathways.  Binding of the EGF ligand is thought to activate the Ras 
proto-oncogene, Grb2 adaptor protein, Shc, PLCγ protein, MAPK, PI3-K, JAKs and 
STATs signal pathways (Jorissen et al., 2003).  This activation can be both direct and 
indirect, due to the complex interlinking between pathways (Jorissen et al., 2003).  
Neuregulins bind to HER3 and HER4 causing mitogenic activity within the target 
cell through activation of the MAPK signaling pathway (Pinkas-Kramarski et al., 
1998).  EGF promotes both migration and proliferation, but via different pathways.  
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Chen et al. (1994a) found that the PLCγ proteins activation of signaling pathways is 
necessary for cell motility, with cell movement halting on inhibition of PLCγ.  They 
documented that activation of MAPK on its own was not sufficient to cause cell 
motility, but concluded that it plays a role in cell movement through regulating 
integrin adhesion (Chen et al., 1994a; Chen et al., 1994b). 
 Choi et al. (1994) produced biodegradable electro-spun nanofiber polymers, 
to which recombinant human EGF (rhEGF) was conjugated to, for the treatment of 
diabetic ulcers.  The new delivery system was tested in diabetic mice, which had full-
thickness dorsal wounds.  It was found that the topically applied nanofiber mesh 
conjugated with rhEGF showed accelerated wound closure, compared to the control 
groups (Choi et al., 2008).  Choi et al. (2008) also demonstrated that human 
keratinocyte cells cultured on top of rhEGF nanofibers showed a significantly greater 
increase in gene expression of keratin-1 and loricrin, compared to the control groups.  
Keratin-1 and loricrin are both essential proteins needed for proliferation and 
differentiation of keratinocytes (Choi et al., 2008). 
 A gelatin based wound dressing, loaded with either free EGF or microspheres 
loaded with EGF, was formulated by Ulubayram et al. (2001).  Two dose of EGF (1 
or 15 μg cm-2) were loaded into the dressings and applied to full-thickness wounds 
on rabbits.  They found that both the free EGF and microsphere loaded EGF, at 1 μg 
cm-2, closed the wounds faster than the control groups.  However, there was no 
difference, in the rate of wound closure, between the free and microsphere 
encapsulated EGF dressings.  Interestingly, on increasing the concentration in the 
dressings to 15 μg/cm2, the EFG-loaded microspheres exhibited faster wound closure 
than the free EGF and the control groups (Ulubayram et al., 2001).  
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 An Indian biotechnology company, Bharat Biotech, have developed and 
manufactured a topical gel containing rhEFG called Regen-D™ 150 for treatment of 
diabetic foot ulcers (Mohan, 2007).  They also have a lower strength gel, Regen-D™ 
60 for use in bed sores and burns (Bharat Biotech, 2015).  Mohan documents that 
Regen-D™ 150 was found to increase the quantity of healthy granulation tissue 
present, promoting epithelisation and faster wound healing.  
 
1.4.3 Transforming growth factor-β (TGF-β)  
Transforming growth factor-β2 (TGF-β2) and TGF-β3 are both involved in the 
recruitment of fibroblast and inflammatory cells to the wound site, post injury.  TGF-
β2 and TGF-β3 play vital roles in angiogenesis and neovascularisation, respectively 
in wound healing (Roberts et al., 1986; Pepper, 1997).  TGF-β2 is also implicated in 
the laying down of type I and type II collagen in the extracellular matrix and scar 
formation.  TGF-β3 is thought to be an important stop signal for differentiation in 
tissue (Tyrone et al., 2000) and play a part in keratinocyte migration (Barrientos et 
al., 2008).  Unlike the TGF-β1 and 2 isoforms, TGF-β3 promotes collagen re-
organisation and suppresses scar formation, indicating the healing process is coming 
to an end. 
TGF-β is a family of proteins consisting of TGF-β1, TGF-β2, TGF-β3, bone 
morphogenic proteins (BMP), Mullerian inhibiting substance, nodals, inhibins and 
activins (Werner & Grose, 2003).  TGF-β1 is made up of two identical 112 amino 
acid chains, which are linked by disulfide bonds (Massague, 1990).  Each of the two 
chains are initially synthesised as precursor poly(peptides) (390 amino acid residues), 
which undergo proteolytic cleavage yielding the two chains to form the active 
dimeric ligand (Massague, 1990).  TGF-β isoforms 1–3 are found in mammals, and 
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although they are structurally similar, 60–80 % homology, they have different 
biological functions (Penn et al., 2012).  TGF-β1–3 are secreted by several cells 
found in the wound site, such as platelets, macrophages, keratinocytes and fibroblasts 
(Barrientos et al., 2008). 
 The three isoforms of TGF-β bind to two receptors simultaneously in the cell 
membrane, known as type I (TGF-βRI) and type II (TGFR-βII) (Werner & Grose, 
2003).  There is a third TGF-β receptor (TGF-βIII), which all three isoforms bind to 
with high affinity.  However, the type III receptor is a non-signaling receptor, the 
main purpose of which is to present the TGF-β isoforms in the correct orientation to 
the type II receptor for binding (Roberts, 1998).  Upon binding of a TGF-β ligand to 
the type II receptor, it becomes phosphorylated. The phosphorylated type II receptor 
attracts, binds and phosphorylates the type I receptor, forming a heterodimer 
complex.  Once the receptor-ligand complex is formed, it results in the activation of 
the Smad intracellular signaling pathway (Penn et al., 2012). 
The Smad signal transduction begins through phosphorylation of the Smad-2 
and Smad-3 receptors, which then bind to Smad-4 (Figure 1.10).  On binding to 
Smad-4, they move across the nuclear membrane into the nucleus, where they cause 
up-regulation of specific genes (Werner & Grose, 2003; Mazzieri et al., 2005).  It has 
also been documented that TGF-β1 activates other intracellular signaling pathways, 
such as, MAPK, extracellular signal-regulated kinases (ERK) and c-Jun N-terminal 




Figure 1.10 Schematic diagram depicting the activation of the Smad intracellular signaling pathway, 
activated by a TGF-β ligand.  The TGF-β ligand can be seen being presented to the type II receptor in 
the correct orientation by the type III receptor, which then recruits the type I receptor.  This forms the 
heterodimer ligand-receptor complex, activating the Smad pathway and upregulation of target genes 
(Werner & Grose, 2003).  
 
 Upon injury, TGF-β1 is secreted from platelets and acts as a chemo-attractant 
for fibroblasts, macrophages and neutrophils.  This initial release of TGF-β1 is 
important for the initiation of the inflammatory phase.  Once these inflammatory 
cells are in situ they begin to produce, and release, TGF-β1 further increasing the 
TGF-β1 levels within the wound (Barrientos et al., 2008).  It is also thought that 
TGF-β1 inhibits the production of superoxides by macrophages, thus preparing the 
wound for granulation tissue formation, by protecting surrounding healthy tissue 
(Mitra & Khar, 2004).   
In vitro studies using TGF-β1 have shown an up-regulation of the genes 
required for the formation of several extracellular matrix components.  These 
components are fibronectin, collagen (Goldberg et al., 2007), tissue inhibitors of 
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metalloproteinases (TIMP) (Zeng et al., 1996), MMP (White et al., 2000) and 
fibronectin receptors (Barrientos et al., 2008).  Several studies and review articles 
(Barrientos et al., 2008; Werner & Grose, 2003), however, have documented the 
effect of TGF-β1 in relation to keratinocyte re-epithelisation to be paradoxical.  
Some authors concluded that addition of TGF-β1, in vivo and in vitro, resulted in 
decreased keratinocyte proliferation (Coffey et al., 1988; Sellheyer et al., 1993; 
Amendt et al., 1998).  It was also demonstrated that Smad3-null mice had increased 
wound healing compared to the wild-type mice (Ashcroft et al., 1999). This result 
further complements the conclusions drawn by the previous authors.  Conversely, 
over expression of TGF-β1 was found to aid in the facilitation of the phenotypic 
change of the keratinocytes.  In particular, in the later stages of healing, to a more 
proliferative type (Bottinger et al., 1997).  Also, addition of TGF-β1 to wounds on 
pigs was found to stimulate the expression of integrins needed for keratinocyte 
migration (Gailit et al., 1994). Interestingly, prolonged overexpression of TGF-β1 is 
thought to play a role in fibrosis, leading to the formation of keloid scars (Rudolph & 
Vande Berg, 2005). 
Werner & Grose (2003) document in their review that a significant amount of 
research has been conducted to try and understand why foetuses, in the early stages 
of gestation, do not scar.  Again, there has been a lot of conflicting data published on 
this area, most likely due to the conflicting data on the role of TGF-β1 in wound 
healing.  But one logical theory that is thought to play a part, is the reduction in the 
expression of TGF-β1 in the foetus, along with the reduced length of time the TGF-
β1 is present in the wound site (Yates et al., 2012).  This is thought to result in 
reduced expression of extracellular matrix components, leading to reduced scarring.  
However, this is not thought to be the sole factor contributing to reduce scarring in a 
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foetus, as there are many differences in the wound healing process between a foetus 
and an adult.  Some of these other different factors documented by Yates et al. 
(2012) are, no acute inflammatory phase, reduced secretions of PDGF and EGF.  
 TGF-β2, purified from bovine bone, was used topically to treat venous 
ulceration (Robson et al., 1995).  The treatment regime was three times per day for 
up to 6 weeks, using a lyophilised collagen vehicle as the delivery system.  On 
clinical evaluation, it was concluded that the quantity and quality of the granulation 
tissue was healthier, in the treated group compared to the control group (Robson et 
al., 1995).  Results from the two trials both showed an increase in the rate of wound 
closure.  However, only in one trial was the difference between the control group and 
treated group significant. 
 
1.4.4 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) has an important role in the 
inflammatory phase of the wound healing process.  At the inflammatory stage VEGF 
facilitates wound repair by increasing the vascular permeability at the site of injury, 
which provides the necessary access for inflammatory cells and growth factors.  
VEGF is also though to play a part in angiogenesis, lymphangiogenesis and re-
epithelisation at the wound site (Bauters et al., 1994; Takeshita et al., 1994; Bauters 
et al., 1995; Walder et al., 1996).  
VEGF was first discovered in the 1980s, by Harold Dvorak and Napeleone 
Ferrara.  VEGF is also referred to as vascular permeability factor (VPF), due to its 
ability to induce vascular leakage (Claesson-Welsh, 2016).  VEGF is essential for 
vascular development and angiogenesis.  The VEGF family consists of five 
structurally similar mammalian poly(peptides); VEGF-A, VEGF-B, VEGF-C, 
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VEGF-D and placenta growth factor (PlGF).  There are other members of the VEGF 
family, such as a sheep parapoxvirus VEGF-E (Lyttle et al., 1994) and a 
poly(peptide) derived from snake venom, known as VEGF-F (Koch & Claesson-
Welsh, 2012).  The mammalian factor VEGF-A is further subdivided into several 
isoforms, identified by the number of amino acids in their sequences.  The four 
isoforms are VEGF-A121, VEGF-A165, VEGF-A189 and VEGF-A206.  These isoforms 
are produced due to alternative splicing of the eight exons in the messenger 
ribonucleic acid (mRNA) sequence, which encodes the VEGF poly(peptide) (Cross 
et al., 2003).  In humans, the most prevalent isoform is VEGF-A165, which does not 
contain exons 6a and 6b, as seen in Figure 1.11. 
 
 
Figure 1.11 Schematic diagram showing the mRNA exon splicing variations for VEGF-A.  Each of 
the four isoforms vary in the total number of amino acids in the poly(peptide).  VEGF-A165 is the most 
common isoform found in humans (Cross et al., 2003).  
 
VEGF-A121 is an acidic poly(peptide), which does not contain exons 6 and 7, as seen 
in Figure 1.11.  As a result of the exclusion of exons 6 and 7 VEGF-A121 does not 
have the ability to bind to heparin (Ferrara et al., 2003).  VEGF-A165 also has exon 6 
missing, but still can bind to heparin.  This would suggest that heparin binding is 
more dependent on exon 7, rather than exon 6.  It is thought that the absence of the 
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heparin binding domain results in a significant decrease in mitogenic activity of the 
VEGF-A121 isoform (Keyt et al., 1996).  Native VEGF is a 45 kDa homodimeric 
glycoprotein, to which VEGF-A165 is functionally similar to (Ferrara & Henzel, 
1989).  VEGF-A189 and VEGF-A206 are strongly basic, do contain exons 6 and 7 and, 
therefore, can bind to heparin (Figure 1.11).  VEGF-A189 and VEGF-A206 are isolated 
mainly to the EMC, being released on proteolytic degradation of the EMC 
components (Ferrara et al., 2003). 
 There are several factors responsible for the regulation of VEGF gene 
expression.  Major growth factors, such as EGF, TGF-β, TGF-α, FGF, IGF, PDGF, 
keratinocyte growth factor and cytokines interleukin-1α (IL-1α) and IL-6, upregulate 
the mRNA expression for VEGF (Ferrara et al., 2003).  In a hypoxic environment, 
such as a wound site, hypoxia-inducible factor is released by in situ cells.  Hypoxia-
inducible factor binds to a VEGF-A promoter, stimulating the production and 
secretion of VEGF-A (Ferrara et al., 2003).  Therefore, there is a concentration 
gradient of both oxygen and VEGF-A present between normal and hypoxic tissue.  
In a hypoxic micro-environment, the oxygen tension is low and the VEGF-A 
concentration is high, with the opposite occurring in normal tissue.  The VEGF-A 
stimulates angiogenesis, reinstates tissue perfusion and increases the oxygen tension 
in the micro-environment (Barrientos et al., 2008).  However, a minimum amount of 
VEGF-A must remain in the micro-environment to prevent apoptosis of the 
endothelial cells (Neufeld et al., 1999; Matsumoto & Claesson-Welsh, 2001).  
Barrientos et al. (2008) document that in acute wounds the expression of VEGF-A 
by endothelial cells, fibroblasts, monocytes, keratinocytes and myocytes is 
intensified in response to the hypoxic conditions.  
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 VEGF-B is found to be expressed in abundance in embryotic heart tissue in 
early stage gestation.  In adults, it is expressed to certain degree in nearly all tissue, 
but expression is found to be more pronounced in the spinal cord, brown fat and 
heart tissue.  The VEGF-C isoform has also been detected in several embryonic and 
adult tissues (Matsumoto & Claesson-Welsh, 2001).  VEGF-C mRNA is strongly 
expressed in areas of tissue where lymphatic vessels are produced, playing a 
fundamental role in lymphangiogenesis (Matsumoto & Claesson-Welsh, 2001).   
 The five VEGF ligands and the four VEGF-A isoforms bind to three, 
homodimeric, tyrosine kinase transmembrane receptors, denoted as VEGFR-1, 
VEGFR-2 and VEGFR-3 (Claesson-Welsh, 2016).  There is a fourth receptor known 
as soluble VEGFR-1 (sVEGFR-1).  The sVEGFR-1 is not dimeric and has no 
transmembrane or intracellular domains.  The sVEGFR-1 is believed to play a 
negative regulatory role, whereby, it binds with strong affinity free VEGF-A, 
preventing it from binding to the functional VEGFRs (Cross et al., 2003).  VEGF 
also interacts with neuropilin membrane co-receptors (Ferrara et al., 2003).  
Neuropilin-1 is thought to present VEGF-A165 to the VEGFR-2 in such a way that it 
enhances the signal transduction upon activation of VEGFR-2 (Soker et al., 1998). 
 VEGFR-1, also denoted as Flt-1, is a 180 kDa receptor found to be expressed 
on the surface of vascular endothelial cells, macrophages, monocytes and 
haematopoietic stem cells (Cross et al., 2003).  VEGFR-1 binds to VEGF-A, VEGF-
B and PIGF ligands, with high affinity.  VEGFR-1 structure is made up of an 
extracellular domain consisting of seven immunoglobulin-like domains, a 
transmembrane region and an intracellular tyrosine kinase sequence, which contains 
a kinase-insert domain (Ferrara et al., 2003).  Cross et al. (2003) document that 
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VEGFR-1 binds VEGFA with an affinity of Kd 10 pM, but only gives a weak 
twofold increase in kinase activity. 
 VEGFR-2, also denoted as Flk-1 or KDR, is a 200–230 kDa receptor found to 
be expressed in lymphatic and vascular endothelial cells.  VEGFR-2 has a strong 
affinity for VEGF-A, VEGF-C, VEGF-D and VEGF-E ligands (Cross et al., 2003).  
VEGF-A is thought to bind to the second and third immunoglobulin-like domains in 
the extracellular part of VEGFR-2.  In particular, amino acids Arg(82), Lys(84) and 
His(86) in these immunoglobulin-like domains are thought to facilitate the binding of 
the ligand (Neufeld et al., 1999).  VEGF-A has a lower affinity for VEGFR-2 (Kd 
75-125 pM) compared to VEGFR-1, even though both receptors are structurally 
similar. (Cross et al., 2003).  
 VEGFR-3 is a 195 kDa receptor also known as Flt-4, with an affinity for 
VEGF-C and VEGF-D.  VEGFR-3 undergoes cleavage during synthesis, in the fifth 
extracellular immunoglobulin-like domain (Pajusola et al., 1994).  VEGFR-3 is 
mainly expressed on lymphatic endothelial cells, which, when activated, initiates 
migration, proliferation and survival of the lymphatic cells (Cross et al., 2003).  A 
summary of specific VEGF ligand-receptor binding, and the cells, which primarily 




Figure 1.12 Schematic diagram showing VEGF ligands and their corresponding receptors.  VEGFR-1 
is yellow and its corresponding ligands are also yellow.  VEGFR-2 is blue with its corresponding 
ligands shaded blue.  VEGFR-3 is green with its corresponding ligands shaded green.  VEGF ligands 
which contain two colours, indicates that they bind to more than one ligand.  It can also be seen which 
types of cells or tissues expresses specific ligands (Cross et al., 2003).  
 
 Upon binding of a VEGF ligand to a receptor, several of the tyrosine residues 
within the intracellular domains undergo autophosphorylation.  Three intracellular 
proteins, VEGFR-associated protein (VRAP), Sck and PLC-γ, bind to the activated 
tyrosine residues through their Src homology-2 (SH2) domain.  This causes 
activation of the membrane bound phosphatidylinositol 4,5-bisphosphate (PIP2), 
which through a series of event leads to the activation of protein kinase-C (PKC) 
transduction protein (Ferrara et al., 2003; Claesson-Welsh, 2016).  PKC activates 
several other downstream signal transducers, Raf, MEK, ERK, with the end result 
being cell proliferation (Figure 1.13).  PI3K and P38MAPK signal transduction 
pathways are activated directly by autophosphorylation of the intracellular domains 
of the VEGFR, leading to cell migration (Koch & Claesson-Welsh, 2012), as seen in 
Figure 1.13.  Other signal transducers and pathways are activated indirectly as a 
result of VEGFR activation, such as Rac, Akt/protein kinase-B (PKB) and Ras 
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(Cross et al., 2003).  Numerous downstream signal transduction molecules are 
activated in a cascade of events leading to cellular functions, such as, endothelial 
permeability, proliferation and migration.   
 It is documented that activation of the Akt/PKB pathway, activates an 
enzyme called endothelial nitric oxide synthase (eNOS) (Fulton et al., 1999).  This 
enzyme generates nitric oxide, which causes an increase in vascular permeability 
(Dimmeler et al., 1999). 
 
Figure 1.13 A schematic diagram representing the intracellular signal transduction, which takes place 
upon binding of a VEGF ligand to VEGFR-2.  Upon binding to the VEGFR-2 numerous tyrosine 
residue undergo autophosphorylation, leading to activation of several intracellular proteins and signal 
transduction cascades, resulting in vascular permeability, migrations and proliferation (Cross et al., 
2003).  
 
 Several studies treating ischemic wounds in hind legs of rabbits with VEGF-
A have been carried out (Bauters et al., 1994; Takeshita et al., 1994; Bauters et al., 
1995; Walder et al., 1996).  In these studies, VEGF-A was delivered either 
intramuscularly or intravenously, with various dosing regimens (3 mg kg-1 of VEGF 
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only or in combination with heparin).  As a result of these studies, it was found that 
administration of VEGF-A increased and restored angiogenesis, and initiated re-
epithelisation (Bauters et al., 1994; Takeshita et al., 1994; Bauters et al., 1995; 
Walder et al., 1996).  Galiano et al. (2004) topically treated full-thickness dorsal 
wounds in diabetic mice with 20 μg of rhVEGF165, on alternate days, for a total of 
five doses.  Results showed that the wounds treated with rhVEGF165 demonstrated 
decreased wound closure time (12 days), compared to the control group (25 days) 
(Galiano et al., 2004).  Saaristo et al. (2006) administered, via injection, an 
adenoviral vector encoding human VEGF-C to full-thickness dorsal wounds in 
diabetic mice.  They found that there was an up-regulation in VEGF-C expression, 
leading to a noted increase in lymphangiogenesis and angiogenesis.  This resulted in 
significant, accelerated wound healing, compared to the control group (Saaristo et 
al., 2006). 
 
1.4.5 Fibroblast growth factor (FGF) 
In adults fibroblast growth factors (FGFs) have been identified to play a role in 
wound healing, internal tissue repair and control of the nervous system.  FGF-2, 
FGF-7 and FGF-10 are thought to be the most influential members of the FGF family 
with regards to wound healing (Barrientos et al., 2008).  FGF-7 is also known as 
keratinocyte growth factor-1 (KGF-1) and FGF-10 as keratinocyte growth factor-2 
(KGF-2). 
The family of FGFs consists of 22 growth factors in total.  These 22 FGFs 
range in size from 17–34 kDa (Ornitz & Itoh, 2001).  Each growth factor consists of 
a section of 120 amino acid that shows up to 65 % homology.  FGFs control several 
cellular functions during embryo development, such as cell migration, proliferation 
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and differentiation.  FGF has also been implicated in the development and 
progression of tumour angiogenesis (Eswarakumar et al., 2005).  As with all the 
previously discussed growth factors, FGFs also bind to transmembrane tyrosine 
kinase receptors.  There are four FGF receptors, denoted FGFR-1–4, consisting of an 
intracellular cytoplasmic domain, a single transmembrane domain and an 
extracellular ligand-binding domain.  The extracellular domain, consists of three 
immunoglobulin-like domains, D1–D3 (Schlessinger, 2000).  Within the 
extracellular domain there is a linker known as the acid box.  The acid box is a short 
sequence of acidic residues linking the D1 and D2 domains.  The D2 domain 
contains a positive charged region for the binding of heparin (Schlessinger et al., 
2000).  FGFR-1–3 undergo exon splicing, in a similar manner as the previously 
mentioned VEGF ligands.  The splicing occurs in the D3 domain of the extracellular 
component in FGFR-1–3, but not FGFR-4 (Werner & Grose, 2003).  Eswarakumar et 
al. (2005) have documented in their review that exon 7 encodes the N-terminal half 
(denoted as a) of the D3 domain of FGFR-2 while exons 8 and 9, which can be 
alternatively spliced, encode the C-terminal half of D3.  Exons 8 and 9 are denoted as 
b and c, respectively.  A summary of the FGFR isoforms and their known specific 
ligand binding can be seen in Table 1.7, modified from (Eswarakumar et al., 2005). 
 
Table 1.7 FGFR isoforms specific ligand binding (Eswarakumar et al., 2005) 
 
FGFR isoform FGF ligand specificity 
1b 1, 2, 3, 10 
1c 1, 2, 4, 5, 6 
2b 1, 3, 7, 10, 22 
2c 1, 2, 4, 6, 9, 17, 18 
3b 1, 9 
3c 1, 2, 4, 8, 9, 17, 18 




FGFs also bind to heparin and heparan sulphate proteoglycans (HSPG), but with a 
lower affinity, compared to the FGFRs.  Heparin and heparan sulphate are found on 
the cell surface and also in the extracellular matrix.  They do not themselves transmit 
a signal within the cell, but play a vital role in the regulation and bind to the FGFRs.  
Heparan sulphate is synthesised and distributed by a wide range of tissues and 
organs, binding to core proteins forming the heparan sulphate proteoglycans (Nugent 
& Iozzo, 2000), whereas, heparin is only synthesised by mast cells found in 
connective tissue and involved in the inflammatory response.  Binding of FGFs to 
these molecules, stabilises FGFs through protection from heat denaturation, acid 
denaturation and proteolytic cleavage (Nugent & Iozzo, 2000).  Binding of one of 
these molecules to the FGFR, along with an appropriate ligand, leads to the 
formation of a FGF-FGFR-HSPG or heparin dimer (ratio 2:2:2) complex (Zhang et 
al., 2006), as seen in Figure 1.14.  Therefore, heparin and HSPGs are a necessity for 
stable binding of FGF to the receptor and subsequent activation. 
 
Figure 1.14. Shows the ribbon diagram of the FGF-2-FGFR-1-heparin dimeric complex.  The 
extracellular binding domains D2 and D3 of FGFR-1 are in green and blue, FGF-2 is yellow and 
heparin red (Eswarakumar et al., 2005). 
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As seen in Table 1.7, FGF-1 binds to all the FGFR isoforms, whereas FGF-7 binds 
only to FGFR-2b.  The FGFR isoforms not only exhibit different ligand binding, but 
also specific expression by certain cell types (Zhang et al., 2006).  Epithelial cells are 
thought to express only the FGFR-2b isoform (Orrurtreger et al., 1993), with 
mesenchymal cells expressing only the FGFR-2c isoform (Ornitz & Itoh, 2001; 
Eswarakumar et al., 2005).  It is this specific expression of these receptors by 
different cell types that allows the directional communication, between the two 
different tissue layers, during development (Ornitz & Itoh, 2001).  For example, 
FGFR-2b (expressed in the epithelial layer) is activated by FGF-7 and FGF-10, 
which are synthesised and secreted from the mesenchymal layer (Igarashi et al., 
1998), whereas FGFR (expressed in the mesenchymal layer) is activated by FGF-8 
synthesised and secreted by the epithelial layer (MacArthur et al., 1995).  Therefore, 
none of the FGFs activates the receptors found in the layer, which they are produced 
in, but in different tissue layer.  This facilitates the communication between the 
different tissue layers.  
Once an appropriate ligand-receptor complex has formed, the tyrosine 
residues present in the intracellular domains undergo autophosphorylation.  This then 
follows a similar process as discussed previously for the other growth factors.  FGF 
are thought to activate several intracellular signal pathways.  On activation of the 
receptor, the FRS2α and FRS2β docking proteins undergo phosphorylation.  This 
leads to the recruitments of Grb2 and Sos protein complexes (Kouhara et al., 1997).  
As a result of the recruitment of these proteins, the Ras, Raf and MAPK pathways 
are activated, in a downstream signaling cascade (Kouhara et al., 1997).  Grb2, once 
recruited, causes phosphorylation of Gab1 adaptor protein, which consequently leads 
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to the downstream recruitment of PI3K and activation of the Akt anti-apoptotic 
pathway (Eswarakumar et al., 2005). 
In chronic wounds, a number of growth factors, including FGF-2, are found 
to exist in the wound at a reduced concentration in comparison to a normal acute 
wound (Robson, 1997).  This led to a significant amount of research being carried 
out, using exogenous FGF as a potential treatment for chronic wounds.  A 
randomised, blinded, placebo-controlled clinical trial was conducted using a 
recombinant version of basic fibroblast growth factor, which is another name for 
FGF-2, to treat chronic pressure ulcers (Robson et al., 1992).  Patients received a 
placebo treatment or recombinant human FGF-2 (rhFGF-2), at three different 
concentrations (100, 500 or 1000 μg mL-1).  This was done in accordance with a 
dosing schedule, dependent on the tier of the study, for up to 22 days (Robson et al., 
1992).  Robson et al. (2008), found from their study that when all the subgroups 
were combined, that those treated with rhFGF-2 showed a significant decrease 
(p<0.05) in pressure ulcer volume, in comparison to the placebo treated group.  This 
was further reinforced when histological sections taken from treated patients showed 
an increase in fibroblast numbers and capillaries, compared to sections taken from 
the placebo group (Robson et al., 1992).  Similarly, in a randomised double-blind, 
parallel-group, placebo controlled, multicenter (15) study, repifermin was used to 
treat chronic venous ulcers, in 94 patients (Robson et al., 2001).  Repifermin is a 
shortened recombinant form of FGF-10, which shares 57 % homology with FGF-
7.(Robson et al., 2001).  Patients received either placebo or repifermin twice weekly 
for 12 weeks, along with compression therapy.  Repifermin (20 or 60 μg cm-2) and 
the placebo were delivered topically via a spray held at 2–3 inches from the wound.  
Robson et al. (2001) concluded from this study that repifermin showed accelerated 
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wound healing, with significantly more patients accomplishing 75 % wound closure, 
compared to the placebo group.  Interestingly, they noted that the repifermin showed 
a greater effect in a subgroup of patients whose wounds were ≤ 18 months old and ≤ 
15 cm2.  
 
1.4.6 Insulin-like growth factor (IGF) 
Due to IGF-1’s ability to cause an increase in cell migration, proliferation and, 
therefore, tissue growth, research has been conducted to determine the effects of 
exogenous IGF-1 to promote and initiate wound healing (Tsuboi et al., 1995; 
Koshizuka et al., 1997; Nagano et al., 2003; Emmerson et al., 2012; Nunes Achar et 
al., 2014).  The insulin-like growth factor family consists of 3 peptide ligands (IGF-
1, IGF-2 and insulin), six binding proteins (IGFBP-1–6) and two receptors (IGF-1R 
and IGF-2R).  IGF was first discovered by Salmon and Daughday in 1957, who 
initially called IGF sulphation factor.  This was due to its ability to incorporate 
sulphate into cartilage tissue (Salmon & Daughaday W., 1957).  In 1963, it was 
discovered that sulphation factor was similar to proinsulin; however, the biological 
actions of sulphation factor could not be inhibited by anti-insulin antibodies. As a 
result of this finding, sulphation factor was given the term non-suppressible insulin-
like activity (NSILA) factor (Frosech et al., 1963).  In the early 1970s, the terms 
sulphation factor and NSILA were replaced by somatomedin, due to its function as 
the mediator of effects of somatotropin, more commonly known as growth hormone 
(GH) (Jones & Clemmons, 1995).  Rinderknecht and Humbel, in 1976, isolated two 
active molecules from human serum, which upon sequencing were found to share 
approximately 50 % homology with proinsulin.  These two active molecules were 
thought to be the sulphation factor initially discovered by Salmon and Daughday and 
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further worked on by Frosech et al. (1963).  The first molecule was named insulin-
like growth factor-1 (IGF-1), due to the similarity of its amino acid sequence to that 
of proinsulin (Rinderknecht & Humbel, 1976).  The second molecule was named 
insulin-like growth factor-2 (IGF-2), due its structure being similar to IGF-1, but not 
identical (Rinderknecht & Humbel, 1976).  IGF-1 is still referred to as somatomedin 
C and IGF-2 as somatomedin A.  
 IGF-1 is a 7.6 kDa poly(peptide) consisting of 70 amino acids, with an A and 
B chain linked by disulphide bonds, in a similar manner as insulin (Laron, 2001).  
GH secreted from the anterior pituitary gland stimulates the synthesis of IGF-1 in 
most tissues.  However, the liver is the major source of IGF-1 circulating in the 
bloodstream (Dercole et al., 1984).  The main function of IGF-1 is to control the 
differentiation and, therefore, growth of body tissue.  Interestingly, this physiological 
function of increasing growth of body tissue, in particular, the increase in muscle 
protein synthesis and glycogen storage, has led to its misuse and abuse by 
bodybuilders (Guha et al., 2013).  Guha et al. (2013) have documented that its use is 
openly discussed on amateur bodybuilding internet forums.  Although to date, there 
has been no confirmed cases in professional sport, there is no test currently in place 
to detect IGF-1 misuse (Guha et al., 2013).  The performance-enhancing benefits, 
such as increased strength, muscle size, energy, endurance, bone density and benefits 
to the immune system, make it very appealing for illicit use by athletes (Guha et al., 
2013).  This has led to IGF-1 being added to the World Anti-Doping Agency’s 
Prohibited Substances List (WADA, 2017). 
A large portion (approx. 80 %) of circulating IGF-1 is bound with high 
affinity to the 46–53 kDa IGFBP-3.  In addition to the binary complex of IGF-1 and 
IGFBP-3, a 88 kDa molecule, known as an acid labile subunit (ALS), binds to the 
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already existing complex, forming a ternary complex (Laron, 2001).  ALS is a 
glycoprotein, also synthesised by the liver and regulated by GH, which prevents the 
passage of the ternary complex through the capillary endothelia layer to activate 
receptors.  The formation of the ternary complex serves to extend the half-life of 
IGF-1, by protecting it from proteolytic degradation and controls the IGF-1 IGF-1R 
interaction (Laviola et al., 2007).  It is estimated that the half-life of circulating 
unbound IGF-1 is only a few minutes (Rosenfeld et al., 1999).  Whereas, the 
formation of the binary complex of IGFBP and IGF-1, increases the half-life to 30 
minutes, which increases to 12 to 15 hours on formation of the ternary complex 
(Rosenfeld et al., 1999).  IGFBP-3 is thought to be mainly regulated by GH and to a 
lesser extent by IGF-1 (Kanety et al., 1993; Laron, 2001).  As IGFBPs and IGFRs 
both bind IGF ligands, it can be said there is localised competition between IGFBP 
and IGFR for the ligands.  This provides evidence that IGFBPs also play an 
inhibition/regulatory role on IGF signaling.   
 Both IGF-1 and IGF-2 bind with high affinity to two cell surface tyrosine 
kinase transmembrane receptors.  The IGF-1R binding domain has similar homology 
to the insulin receptors binding domain and can, therefore, bind insulin, but with a 
much lower affinity (Laviola et al., 2007).  The IGF-1R can also bind IGF-2, but 
with a 100-fold lower affinity than IGF-1 (Laviola et al., 2007).  The IGF-2R binds 
IGF-2 with the highest affinity and IGF-1 with a much lower affinity, but, it cannot 
bind insulin (Laviola et al., 2007).  At higher than normal concentrations, IGF-1 can 
bind to the insulin receptor with a low affinity of 1–5 % compared to the affinity of 
insulin (Guler et al., 1987). 
IGF-1R consists of an extracellular α-subunit (706 amino acids) and a 
transmembrane β-subunit (620 amino acids) (Jones & Clemmons, 1995).  The two 
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subunits are linked via disulphide bonds, resulting in the formation of one half of the 
receptor.  This half receptor binds to another identical half receptor through 
disulphide binding between the α-subunits to give the complete hetero-tetrameric 
receptor (Jones & Clemmons, 1995; Laviola et al., 2007).  On binding of an 
appropriate ligand to the IGF-1R, it is thought to activate several intracellular 
signaling pathways.  IGF-1R has been documented to prevent programmed cell death 
(apoptosis) via the activation of the Akt pathway (Vincent & Feldman, 2002).  PI3K 
is activated by binding to insulin receptor substrate-1 (IRS-1) via its SH2 domain.  
This results in an increase in PIP3 activity, which directly, and indirectly (via 
activation of phosphoinositide-dependent protein kinase-1 (PDK-1)) activates the 
Akt/PKB pathway (Figure 1.15).  The Akt/PKB causes a downstream signaling 
cascade, which results in the increase levels of anti-apoptotic factors, such as nuclear 
factor-Kβ (NF-Kβ), Bcl2 and BclX, as seen in Figure 1.15 (Vincent & Feldman, 
2002). 
 
Figure 1.15 A schematic diagram showing how the activation of the IGF-1R, prevents apoptosis via 
activation of the Akt/PKB signaling pathway (Vincent & Feldman, 2002). 
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Other pathways, which are activated by IGF-1R are the Ras/Raf/MAPK and 
ERK pathways.  Once the IGF-1R is activated by autophosphorylation, the Shc 
protein is activated at the tyrosine residues on the intracellular domain of the receptor 
(Vincent & Feldman, 2002).  The activated Shc binds to Grb2 leading to the 
upregulation of the Ras G-protein and upregulation of the Raf and ERK.  This 
pathway has been linked to cell migration and differentiation (Vincent & Feldman, 
2002).  
There are two commercially available recombinant preparations of IGF-1 for 
clinical use.  The first is Increlex™ (mecasermin) manufactured by Ipsen 
Biopharmaceuticals (New Jersey, USA) and the other is iPLEX™ (mescasermin 
rinfabate) manufactured by Insmed (Virginia, USA) (Rosenbloom, 2009).  The drug 
iPLEX™ is a combination of equimolar quantities of rhIGF-1 and rhIGFBP-3 
(Williams et al., 2008).  The advantage of having a combination product is that the 
binding protein is readily available to form the binary and then ternary complex, 
therefore, prolonging its half-life and maintain an adequate concentration of rhIGF-1 
in circulation.  Increlex™ is indicated for treatment of growth failure in children, aged 
2-17 years, with severe primary IGF-1 deficiency (BNF, 2017).  The dosing regime 
is initially 40 μg kg-1 twice daily for one week, increasing in 40 μg kg-1 steps to a 
maximum dose of 120 μg kg-1 twice daily.  Increlex™ is given by subcutaneous 
injection and is to be discontinued after one year if no response is evident (BNF, 
2017).  However, iPLEX™ is no longer available for growth therapy treatment 
(Rosenbloom, 2009). 
Creams containing 1 % and 3 % IGF-1 were applied topically to wounds in 
diabetic and non-diabetic rats, to evaluate the effect on wound healing (Nunes Achar 
et al., 2014).  As a result of this study, Nunes Acher et al. (2014) found that both 
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creams increased the rate of re-epithelisation in both, diabetic and non-diabetic rats, 
compared to the control groups.  There was also a significant increase in the 
expression of myofibroblast cells in the diabetic rats treated with the 3 % cream, 
compared to untreated diabetic rats.  Nunes Acher et al. (2014) also noted that there 
was an increased expression of myofibroblasts in the non-diabetic treated groups, 
compared to the diabetic treated groups.  This led to the suggestion that there may be 
a decrease in IGF receptor expression in diabetic animals (Nunes Achar et al., 2014).  
They concluded from the study that topically applied 1 and 3 % IGF-1 creams to 
wounds increased the re-epithelisation rate by increased myofibroblast expression in 
rats (Nunes Achar et al., 2014).  Likewise, Provenzano et al. (2007) concluded that 
systemic administration of IGF-1, via subcutaneous injection, resulted in increased 
healing of ligament wounds in the hind legs of rats, compared to the control group 
and GH administered group.  It was found that in the ambulatory groups that IGF-1, 
although not achieving full repair, after three weeks, did improve the tissue strength 
by approximately 60 % in comparison to the control group (Provenzano et al., 2007).  
This was an interesting finding that suggests IGF-1 could be used to increase tissue 
strength in the healing of limbs that are disused due to patient immobilisation.  
Emmerson et al. (2012) showed that the re-epithelisation by IGF-1 is 
mediated through binding to the IGF-1R, while certain anti-inflammatory effects 
were mediated through cross talk between the IGF-1R and estrogen receptor-α (ERα) 
in mice.  This was demonstrated using ERα null mice, which showed reduced 
healing and increased inflammation, on administration of IGF-1, compared to the 





Due to advances in molecular biology several growth factor based drugs have been 
widely studied for the treatment of chronic wounds, as discussed in the previous 
section.  Hydrogels offer an efficient and effective way to topically administer a 
sustained release of these growth factors to the wound site, promoting and enhancing 
wound repair.   
By definition, hydrogels are cross-linked 3D polymer networks, which have 
the ability to absorb and retain large volumes of water.  It has been documented that 
some hydrogels can absorb up to 20 times their own weight in water or biological 
fluid (Kim et al., 1992).  Hydrogels can be formulated by several methods, which are 
split into two main categories, chemical and physical cross-linking.  However, in 
some cases more than one of these cross-linking methods is used.  As a result of the 
wide range of formulation methods available, using many different polymers, 
hydrogels can be produced with the exact physical and chemical properties needed 
for their intended use.  This has led to the application of hydrogels in a vast range of 
disciplines, such as, the food industry (Shewan & Stokes, 2013), pharmaceutical 
industry (Peppas et al., 2000), oil industry (Abidin et al., 2012) and art industry 
(Carretti et al., 2009). 
 
1.5.1 Chemical cross-linking  
Chemically cross-linked hydrogels display greater mechanical strength in 
comparison to physically crossed-linked hydrogels.  As a result they are more 
resistant to degradation and complete dissolution in an aqueous environment 
(Hennink & van Nostrum, 2012).  However, if the hydrogel needs to be 
biodegradable over a period of time, labile bonds can be added to the network to 
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facilitate this process.  Labile bonds can be in the cross-links themselves or on the 
backbone of the polymer.  They can be broken by various methods in situ, such as 
chemically or enzymatically, but the most common is by hydrolysis (Hennink & van 
Nostrum, 2012).  Chemical cross-linking involves the formation of covalent bonds 
and includes chemical process, such as free radical polymerisation (Matyjaszewski et 
al., 1998), chemical reactions of complementary groups (Draye et al., 1998), high 
energy irradiation (Jabbari & Nozari, 2000), UV polymerisation (Ward & Peppas, 
2001), or by enzymes (Sperinde & Griffith, 2000). 
 
1.5.2 Physical cross-linking 
The main interest behind physically cross-linked hydrogels are that it avoids the use 
of cross-linking agents and initiators.  These compounds usually have to be extracted 
from the chemically cross-linked hydrogel before they can be used in a biological 
system.  This is because they are often toxic substances that can cause harm and kill 
living organisms and have negative effects on the active components loaded into the 
hydrogel network (Hennink & van Nostrum, 2012).  Physical cross-linking utilises 
non-covalent interactions, such as, ionic interactions (Hossain et al., 2001), stereo-
complexation (de Jong et al., 2001), crystallisation (Peppas & Scott, 1992) and 
hydrogen bonding (Bell & Peppas, 1996). 
 
1.5.3 Poly(vinyl alcohol) 
Several synthetic polymers, such as poly(methyl methacrylate), (PMMA) poly(N-
vinylpyrrolidone) (PVP), poly(ethylene glycol) (PEG) and poly(vinyl alcohol) (PVA) 
have been used by the pharmaceutical industry to manufacture hydrogels for drug 
delivery systems.  PVA is synthetic polymer that is odourless, white to cream in 
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colour, and used for a wide range of applications.  One of its most common and well 
known uses is as an adhesive.  Other uses are in the textile industry as sizing and 
coating agent (Reddy et al., 2014), a thickening agent in latex paint, in the 
manufacturing of paper, in gypsum based cements, in the food industry (DeMerlis & 
Schoneker, 2003) and pharmaceutical industry (Kadajji & Betageri, 2011).  PVA is 
soluble in hydrophilic solvents, such as water, ethylene glycol and dimethyl 
sulfoxide (DMSO) (Kadajji & Betageri, 2011).  A fully hydrolysed monomer of 
PVA has the molecular formula of CH2CH(OH), as seen in Figure 1.16.  However, 
the vinyl alcohol monomer cannot exist as a stable form and, therefore, PVA 
polymers are synthesised through a two-step process (Hassan & Peppas, 2000).  
First, the vinyl acetate, which does exit in a stable monomer, undergoes free radical 
polymerisation giving poly(vinyl acetate) (PVAc).  PVAc is then hydrolysed to yield 
PVA (Hassan & Peppas, 2000).  The hydrolysis of PVAc never reaches completion, 
yielding PVA with different degrees of hydrolysis and acetate groups.  Therefore, 
PVA actually exists as a co-polymer of PVAc and PVA.  Different grades of PVA 
are available commercially with a range of degrees of hydrolysis (80–99 %) (Sigma-
Aldrich, 2017). 
Figure 1.16 Skeletal formula of a) fully hydrolysed PVA, and b) a representation of partial hydrolysis 
of the PVAc poly(vinyl alcohol-co-vinyl acetate). 
 
Briscoe et al. (2000) express the degree of hydrolysis as a percentage using Equation 
1.1, where x and y represent the molar fractions of the hydroxyl and acetate groups, 
respectively. 
















 Degree of hydrolysis =  
𝑥
𝑥+𝑦
 x 100 %  
 
Both the degree of hydrolysis and amount of acetate groups present affect the 
solubility and crystallisation of the PVA variant (Kadajji & Betageri, 2011).  Another 
factor, which is influenced by the degree of hydrolysis, and is thought to play a part 
in the solubility of PVA, is the presence of intra- and inter-chain hydrogen bonding, 
between the hydroxyl groups (Briscoe et al., 2000).  Therefore, it is expected that 
both the hydroxyl–solvent hydrogen bonding and the intra- and inter-chain hydrogen 
bonding play a part in determining the viscosity of a polymer solution, as a direct 
result of effecting the solubility.  It can be seen in Figure 1.17, the degree of 
hydrolysis increases as solubility of the PVA decreases.  It can also be seen that on 




Figure 1.17 shows a solubility curve for PVA of average molecular weight 77,000 g mol-1 and varying 






As mentioned previously, PVA is synthesised by free radical polymerisation 
of PVAc followed by hydrolysis.  This process results in the production of PVA of 
different molecular weights.  Hassan & Peppas (2000) document that a 
polydispersity index (PDI) value of 2.0–2.5 is common in most commercial grade 
PVA and incidences of a PDI of 5 are not uncommon.  The molecular weight of the 
PVA effects both its physical and chemical properties, such as adhesion, diffusivity, 
crystallisation and mechanical strength (Hassan & Peppas, 2000).  As with degree of 
hydrolysis, similarly, there are many different grades of PVA available 
commercially, with varying ranges of molecular weight.  For example, molecular 
weight ranges can fall between, 31,000–186,000 g mol-1 (Sigma-Aldrich, 2017).  El-
Kader et al. (2002) found from their study, that as the molecular weight of the PVA 
was increased (5000, 17,000, 72,000 and 125,000 gm mol-1), the mechanical 
properties of PVA films, such as Young’s modulus and the tensile strength at the 
break decreased.  This resulted in the PVA films becoming more flexible, with an 
increase in PVA molecular weight (El-Kader et al., 2002).  
 
1.5.4 Sodium tetraborate decahydrate (borate) 
Sodium tetraborate decahydrate (borate) is one substance that can be used to cross-
link polymer chains to form a hydrogel network.  Borate is of particular interest for 
cross-linking PVA hydrogels, due to its relatively low toxicity.  In comparison, 
vanadate cross-linked polymers exhibit high toxicity towards living tissue, and, 
therefore, are not favourable for drug delivery (Loughlin et al., 2008). 
Boron is a naturally occurring solid state element, with an atomic number of 
5 and relative atomic mass of 10.81 g mol-1.  Boron is present in large deposits 
throughout the world as mineral salts, such as sodium metaborate and borax.  The 
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average soil concentration is 10–20 ppm and in boron mineral rich soil, it can be as 
high as 100 ppm (Woods, 1994).  Large deposits have been exploited in Turkey, as 
early as 1865, closely followed by several deposits in California and Nevada in the 
USA.  Borates have many uses, such as manufacturing of glass, fiberglass insulation, 
enamels, glazes, detergents, bleaches, alloys metals, agriculture and gold mining 
(Woods, 1994). 
 Sodium tetraborate decahydrate dissociates in water to yield equimolar 
quantities of borate ions and boric acid (Lin et al., 2003), as summarised in Equation 
1.2.  Borate anions can exist in different structural forms as the boron atom can 
coordinate in the trigonal or tetrahedral forms (Goel et al., 2013). 
 
Na2B4O7:10H2O   2B(OH)3 + 2B(OH)4
- + 2Na+  
 
1.5.5 Poly(vinyl alcohol) borate hydrogels 
PVA hydrogels have gained interest within the pharmaceutical industry as drug 
delivery systems.  This is because PVA hydrogels are biocompatible, non-toxic, non-
carcinogenic and inexpensive to manufacture, on a large scale (Han et al., 2014).  In 
particular, PVA-borate hydrogels have shown to exhibit the required viscoelastic 
properties necessary, for topical drug delivery to wounds (McCarron et al., 2011).  
PVA-borate is the preferred polymer-ion complex as it is the most biocompatible 
(Loughlin et al., 2008).  PVA can complex with other metal ions and charged 
secondary diazo dyes, such as Congo Red, cupric and vanadate ions (Loughlin et al., 
2008).  However, polymer-vanadate complexes exhibit high toxicity towards living 
tissue, and, therefore, are not favourable for drug delivery (Loughlin et al., 2008).  




linking.  First, there is complexation between the hydroxyl groups of the PVA 
polymer and the B(OH)4
- anion.  Second, there is thought to be a certain degree of 
intra and inter chain cross-linking.  This cross-linking is thought to be a combination 
of both polymer chain entanglement, as well as intra- and inter-chain hydrogen 
bonding, of the hydroxyl groups of the PVA (Briscoe et al., 2000).   
The complexation process between PVA and borate has been studied using 
13C and 11B nuclear magnetic resonance (NMR) (Dawber & Green, 1986; Sinton, 
1987; Bowcher & Dawber, 1989).  It has been eluded that the complexation is a two-
step process, whereby a mono-diol complex is initially produced, resulting in a 
poly(electrolyte), as seen in Figure 1.18a.  As a result of the poly(electrolyte) 
formation there is electrostatic repulsion between the similar charged mono-diol 
complexes.  This repulsion causes expansion of the polymer chains, leading to a 
sterically viable environment for the second step to proceed.  The second reaction 
results in the formation of the di-diol complex, as seen in Figure 1.18b.  Once an 
adequate amount of di-diol complexes have been formed the network forms a gel-
like system (Loughlin et al., 2008).  As seen in Equation 1.2, the dissociation of 
sodium tetraborate decahydrate yields Na+ cations.  These Na+ cations are though to 
also play a role in the overall shape of the polymer chains by exerting a shielding 
effect on the charged complexes (Lin et al., 2005).  Lin et al. (2005) state that the 
overall shape of the polymer chains in the hydrogel is due to a balance between the 
excluded volume of the polymer, electrostatic repulsion and the shielding effect of 





Figure 1.18 Shows the two-step complexation reaction between PVA and borate anions to form a 
hydrogel network.  (a) Shows the first step of the reaction resulting in the formation of the mono-diol 
complex.  (b) shows the second step of the reaction between the mono-diol complex and PVA, leading 
to the formation of the di-diol complex and thus the hydrogel network (Loughlin et al., 2008). 
 
The PVA-borate cross-link is reversible in nature, giving the PVA-borate hydrogels 
unique, self-healing and viscoelastic flow properties.  These viscoelastic properties 
are advantageous for topical drug delivery in wound management and repair.  The 
viscoelastic properties allow the PVA-borate hydrogel to flow into the wound 
crevasse, providing maximum wound-hydrogel contact, for drug delivery.  However, 
the cross-linking present provides enough cohesive integrity to allow for complete 
intact removal from the wound.  Another advantageous property of PVA hydrogels, 
which the PVA-borate hydrogels also possesses, is the ability to absorb excessive 
wound exudate, due to their ability to swell (Kim et al., 2003; Holloway et al., 2011).  
Chemically cross-linked gels possess good elasticity and cohesive integrity to remain 
intact in situ and be removed intact (Murphy et al., 2012).  However, they lack the 
sufficient fluid-like nature to flow into the wound itself.  This results in a reduced 
gel-wound contact area, and therefore, reduced drug delivery.  In contrast, physically 
cross-linked gels display good flow properties, but often lack the cohesive integrity 
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to be removed completely intact, needing to be physically washed and clean from the 
wound (Murphy et al., 2012).  
 The reversible nature of the PVA-borate cross-link was studied using light 
scattering techniques by Lin et al. (2005).  They observed that the cross-links had 
finite life-time (tlife), with the length of the observation determining the type of 
response.  During short observations (high frequency) (Figure 1.19a) the cross-links 
do not have time to dissociate and, therefore, the system behaves like an elastic solid 
(t < tlife and G’ > G”).  G” in rheological terms represents the loss modulus, or liquid-
like response of the network system.  While, G’ represents the storage modulus, or 
elastic/solid-like response of the network system.  During a long observation (low 
frequency) (Figure 1.19b) the cross-links have adequate time to dissociate and the 
system behaves overall like a viscous liquid (t > tlife and G” > G’) (Lin et al., 2005; 
Murphy et al., 2012).  
 
Figure 1.19 Photographs of samples of PVA-borate hydrogel (PVA 6 % w/w borate 2.0 % w/w) 
exhibiting its viscoelastic properties.  a) The hydrogel sample was subject to high frequency, short 
observations by manually rolling it into a ball between two flat surfaces before being placed inside the 
red circle.  This demonstrates the elastic solid-like response of the hydrogel system (G’ > G”).  b) On 
leaving the hydrogel sample to rest it experiences a low frequency, long observations.  Thus the cross-
linking has time to dissociate and the gel system flows like a viscous liquid down, out over the red 












Chapter 2  
2 Formulation and characterisation of PVA-borate hydrogels 
 Introduction  
Oscillating rheometry has been used to study several novel drug delivery 
formulations, including cross linked polymer semi-solids (Jones, 1999; Woolfson et 
al., 2000; Jones et al., 2001). In this study, oscillating rheometry was used to 
characterise physically the viscoelastic properties of the PVA-borate hydrogels.  The 
word rheology is derived from two Greek words, rheos meaning stream current (e.g. 
flowing) and logos meaning study of.  However, the modern day scientific definition 
of rheology can be defined as the study of flow and deformation of a material.  It is 
important to ascertain accurately the rheological (mechanical) properties of 
pharmaceutical preparations, as these rheological properties allow for optimisation 
and quality control (Jones, 1999). 
 Hooke’s Law defines the rheological behaviour of an ideal elastic solid.  The 
law states that the applied stress to a sample is directly proportional to the strain of 
the sample, provided the specific elastic limit for the material is not exceeded.  The 
resulting proportionality constant is known as Young’s Modulus (E) (Equation 2.1). 
 





This elastic solid-like behaviour can be illustrated using a spring with an 
applied loaded, as seen in Figure 2.1.  On applying a load (stress) to the spring, it is 
extended (strain) instantaneously, and is independent of time.  Therefore, according 





proportional to the spring’s extension (Jones et al., 2012).  Once the load has been 
removed the spring returns instantaneously to its original length, by using the stored 
elastic energy from the extension process.  
 
 
Figure 2.1 A schematic diagram representing Hooke’s Law.  It can be seen that on applying a load to 
the spring extension occurs.  The elastic limit has not been exceed and on removal of the load the 
spring returns to its original length.  The white box represents no load and the dashed box represents a 
load. 
 
Newton proposed that for ideal liquids the applied stress is directly 
proportional to the rate of deformation (shear rate), with the proportionality constant 
known as viscosity (Equation 2.2) (Jones, 1999).  Therefore, the viscosity of a 
Newtonian liquid is not dependent on the rate shear and will remain constant 
throughout a range of shear rates (Figure 2.2). 
 





When liquids deviate from the ideal (Newtonian) behaviour, the relationship 
between the stress and shear rate is no longer directly proportional.  These liquids are 
known as non-Newtonian liquids or fluids, which can either exhibit shear-thinning 







Figure 2.2 Typical schematic rheograms showing Newtonian and non-Newtonian flow behaviour, in 
relation to change in viscosity, when subject to an increasing shear rate. 
 
Polymeric materials that are used for the production of biomedical and 
pharmaceutical products display viscoelastic properties.  Viscoelastic materials 
exhibit both solid and liquid properties.  The elastic component behaves in 
accordance with Hooke’s law, while the viscous component behaves in accordance 
with Newton’s law.   
Materials can be further characterised by phase angle (δ) as a viscoelastic 
solid or viscoelastic liquid.  An ideal liquid has a phase angle of 90° because the 
input strain and measured sinusoidal stress signal are one quarter of a cycle out of 
phase.  Whereas, an ideal elastic material has a phase angle of zero as the input strain 
and output stress are in phase, as seen in Figure 2.3.  A viscoelastic material will 
exhibit a phase angle between 0° and 90° with 45° being the boundary between the 
elastic solid-like and viscous liquid-like behaviour.  If the elastic solid-like 
component is dominant over the viscous liquid-like component, the phase angle will 
be < 45° and the material will act like an elastic solid.  But, if the viscous liquid-like 
component is dominant over the elastic solid-like component, the phase angle will be 




Figure 2.3 Schematic diagram showing the stress response of an ideal liquid, ideal solid and 
viscoelastic material on application of an input sinusoidal strain (Jones et al., 2012). 
  
 Viscoelastic liquid behaviour can be illustrated using Maxwell’s model.  
Maxwell’s model consists of a spring and dashpot connected in series, in which both 
can be deflected independently (Mezger, 2014).  Before loading, both the spring and 
dashpot show no deformation (Figure 2.4a).  On loading with a constant force the 
spring deforms instantly, until it reaches a constant deflection, which is directly 
proportional to the loading force (Mezger, 2014), as seen in Figure 2.4b.  After a 
short period of time, while the constant loading force is still being applied to the 
system, the piston of the dashpot beings to deform continuously.  Both components 
of the system are now displaying deformation, as seen in Figure 2.4c.  On removal of 
the loading force the spring instantly recoils, fully, to its original shape and length.  
However, the piston of the dashpot remains unchanged, demonstrating that 
viscoelastic liquid materials can remain partially deformed after a loading cycle is 
complete, as seen in Figure 2.4d (Mezger, 2014).  This is because the reformation of 
the original shape is never totally complete, even after a prolonged period of rest, as 
these materials usually change shape to completely fill the space they occupy 
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(Mezger, 2014).  Therefore, these types of materials essentially behave like a liquid, 




Figure 2.4 Schematic diagram representing the deformation of a viscoelastic liquid using Maxwell’s 
model.  a) No loading force applied.  b) The spring representing the elastic component is deformed on 
application of a constant loading force.  c) The piston of the dashpot has now been deformed after a 
short period of time, as the loading force is still being applied.  d) The loading force has now been 
removed and the spring has recoiled.  But the piston remains unchanged indicating partial irreversible 
deformation. 
 
Viscoelastic solid behaviour can be illustrated using the Kelvin and Voigt’s 
model.  In a similar manner to the Maxwell model, the Kelvin and Voigt model uses 
a spring and dashpot to represent the elastic and viscous components, respectively.  
In this model, however, the spring and dashpot are connected in parallel by a rigid 
frame (Mezger, 2014).  In Figure 2.5a both components exhibit no deformation.  On 
application of a constant loading force, both the spring and the piston of the dashpot 
are deformed simultaneously, to the same extent (Mezger, 2014), as seen in Figure 
2.5b.  As the two components are rigidly connected, the spring cannot deform 
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instantaneously, due to the dashpot slowing the deformation process.  Upon removal 
of the loading force, the spring begins to recoil in a non-instantaneous, time-
dependent manner. This again is because the dashpot slows down the reformation 
process in a similar manner to the deformation process.  However, due to the rigid 
connection between the two components, they both return to their original position 
and there is no partial permanent deformation (Mezger, 2014), as seen in Figure 2.4c.  
 
 
Figure 2.5 Schematic diagram representing the deformation of a viscoelastic solid using Kelvin and 
Voigt’s model.  a) No loading force applied.  b) On application of a constant loading force the spring 
and piston of the dashpot are both deformed simultaneously, to the same extent and in a time-
dependant manner.  c) The piston and spring reform completely in a time-dependent manner with no 
permanent deformation of the system.  
 
PVA-borate hydrogels have shown to exhibit the required viscoelastic 
properties necessary for topical drug delivery to wounds (McCarron et al., 2011).  
The liquid-like behaviour of the PVA-borate hydrogels allows the hydrogel to flow 
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into the wound, completely filling the wound cavity.  This provides maximum 
surface area for drug delivery from the PVA-borate hydrogel to the wound.  
However, the solid-like behaviour that occurs over short time periods allows the 
hydrogel to be removed completely intact from the wound cavity.  This makes the 
PVA-borate hydrogel an ideal candidate for an advanced topical drug delivery 
system for wound management and repair. 
 
  Aims and objectives  
The aim of work in this chapter is to formulate a range of PVA-borate hydrogels and 
characterise physically their viscoelastic properties. 
 
Objectives;  
 formulate a range of hydrogels of varying PVA and borate concentration, 
 characterise the viscoelastic properties of the PVA-borate hydrogels using 
oscillatory rheometry,  
 determine the swelling ability of the PVA-borate hydrogels, 
 evaluate the effect of temperature on the viscoelastic properties of the 
hydrogels, 
 evaluate the effect of varying concentrations of PVA and borate on the pH of 
the hydrogel formulation, 
 determine the hydrogel stability over 24 months using oscillating rheometry.  
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 Materials  
Chemicals and reagents 
Poly(vinyl alcohol) (PVA) (Mw = 31–50 kDa, 98–99 % hydrolysed), sodium 
tetraborate decahydrate (ACS reagent ≥ 99.5 %) and dialysis tubing cellulose 
membrane (Mw cut off 14 kDa, average flat width 43 mm) were purchased from 
Sigma-Aldrich Ltd. (Gillingham, Dorset, UK). 
All reagents were of appropriate laboratory standard and used without further 
purification. 
Deionised water (R ≥ 18 MΩ cm) was obtained from a Purelab Ultra, purification 
system, Egla (Marlow, UK)  
 
Apparatus  
Kinexus Pro rheometer, Malvern instruments (Malvern, Worcestershire, UK). 
 
 Methods 
2.4.1 Formulation of PVA-borate hydrogels 
A PVA stock solution (24 % w/w) was prepared by placing PVA (120 g) into a 500 
mL Duran® bottle at 25 °C.  Deionised water was added to bring the total weight to 
500 g.  The sealed bottle containing the PVA and deionised water was placed in a 
pre-heated water bath at 80 °C, swirling periodically until complete dissolution 
occurred.  The Duran® bottle was then reweighed and adjusted to the required weight 
with deionised water.  A borax stock solution (5 % w/w) was prepared by placing 
sodium tetrahydroxyborate decahydrate (10 g) into a 250 mL Duran® bottle at 25 °C.  
Deionised water was added to bring the total weight to 200 g.  The sealed bottle was 
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then placed on a heated magnetic stirring mantle (50 °C, 30 rpm) until complete 
dissolution had occurred. 
A range of PVA-borate semi-solid hydrogels were prepared by mixing 
various weights of PVA stock solution (24 % w/w), borax stock solution (5% w/w) 
and deionised water, to give hydrogels of final concentrations of PVA (6.0, 8.0, 10.0, 
12.0 % w/w) and borax (1.0, 1.5, 2.0, 2.5 % w/w).  A homogenous fluid-like gel was 
formed upon heating to 80 °C for approximately three hours, with periodic stirring.  
Hydrogels were weighed before and after heating and any weight loss was 
replenished with deionised water to achieve the desired total weight.  The fluid-like 
gel was then transferred to poly(propylene) storage containers and left for 48 hours at 
room temperature and pressure (RTP) to allow complete gelation to occur before 
characterisation took place.  Final formulations were clear and homogenous in 
appearance with no air bubbles present. 
 
2.4.2 Physical characterisation of viscoelastic properties 
Analysis of the viscoelastic properties was carried out using a Kinexus Pro rheometer 
(Malvern Instruments Ltd., Worcestershire, UK) on all hydrogel formulations.  All 
tests were carried out at 25 °C ± 0.2 °C, using 20 mm diameter stainless steel parallel 
plate geometry and a working gap of 1-2 mm (Figure 2.6a).  The linear viscoelastic 
region (LVR) of the PVA-borate hydrogel was determined by an amplitude sweep 
(0.01–100 % strain at a frequency of 1.0 Hz). All tests, thereafter, were performed 
within the LVR.  Three replicates were performed for each formulation (n=3).  A 
sample of the hydrogel was loaded onto the lower plate (Figure 2.6b.) as per the 




Figure 2.6  Shows photographs of the parallel plate geometry (20 mm) on the Kinexus Pro rheometer.  
a) Shows the 1 mm working gap width b) Shows a small sample of hydrogel loaded onto lower plate 
prior to compression by top plate. 
 
A strain (1.0 %) controlled frequency sweep (0.1–10 Hz) was carried out, from 
which the crossover modulus (Gc) and relaxation time (tr) were determined.  The 
relaxation time was calculated from the crossover angular frequency using Equation 
2.3 (Woolfson et al., 2000), where tr = relaxation time (s), ω = angular frequency 
(rad s-1)  and ν = frequency (Hz). 








The cross model for oscillation data (Equation 2.4) was applied to the 
frequency sweep using the rSpace© software producing a plot of complex viscosity 
against angular frequency (ω).  From the cross model, zero shear viscosity (η0) and 
the correlation coefficient were derived.  
 









In Equation 2.4 η* = complex viscosity (Pas), η∞ = infinite viscosity (Pas), η0 = Zero 
shear viscosity (Pas), ω = angular frequency (rad s-1), k is inversely proportional to 
the onset of shear thinning and n is the shear thinning index. 
 
2.4.3 Working gap width test 
To obtain accurate reproducible crossover modulus readings for the more rigid 
formulations, the working gap width of the parallel plate geometries was increased 
from 1.0 mm to 1.5 mm and 2.0 mm.  To ascertain if changing the working gap 
width altered the magnitude of the crossover value and, therefore, skew the data, four 
hydrogel formulations were selected (PVA 8 % w/w borate 1.0, 1.5, 2.0, 2.5 % w/w) 
and a frequency sweep was ran on each, as detailed in section 2.4.2, at each of the 
three working gap widths.  Statistical analysis was used to determine any significant 
changes in the crossover modulus of each formulation by applying two-way analysis 
of the variance (ANOVA) to the data. 
 
2.4.4 Yield stress analysis 
Yield stress (σ) was determined by stress growth carried out using a Kinexus Pro 
rheometer (Malvern Instruments Ltd., Worcestershire, UK) on all hydrogel 
formulations.  Shear rate was kept constant (0.01 s-1) and stress build up was 
monitored over a 5 minute period with a sampling interval of 1 second.  Peak stress 
was analysed and recorded by the rSpace © software.  All tests were carried out at 25 
°C ± 0.2 °C, using 20 mm diameter stainless steel parallel plate geometry and a 





2.4.5 Adhesive analysis 
Adhesiveness of each hydrogel formulation was determined from the normal force 
profile as a function of time as the gap between the top and bottom parallel plate 
increased.  This was carried out using a Kinexus Pro rheometer (Malvern Instruments 
Ltd., Worcestershire, UK).  The top plate was submerged 2 mm into each sample 
(10.00 g) in a poly(propylene) container (Sarstedt diameter 43 mm depth 55 mm) 
with a contact time of 30 s before the pull-away test was triggered, as seen in Figure 
2.7.  Pull-away speed was 10.33 mm s-1 as used by Murphy et al. (2012).  The 
rSpace© software carried out peak normal force analysis which provided the pull 




Figure 2.7. Photograph showing the 20 mm upper plate submerged into a PVA borate hydrogel 
sample (10.00 g) prior to the triggering of the pull-away test, at room temperature. 
 
2.4.6 Temperature sweep 
The effect temperature had on complex viscosity of several PVA borate hydrogels 
was determined using a Kinexus Pro rheometer (Malvern Instruments Ltd., 
Worcestershire, UK).  A single frequency (2.0 Hz) shear strain (1.0%) controlled 
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temperature ramp was run on each hydrogel sample.  Samples were equilibrated to 
25 ± 0.2 °C before starting the temperature ramp.  The temperature ramp range was 
25–80 °C with the temperature increasing at a constant rate of 5 °C min-1 and a 
sampling interval of 2 seconds.  All tests were carried using 20 mm diameter 
stainless steel parallel plate geometry and a working gap of 1–2 mm. 
 
2.4.7 pH study  
The pH of each hydrogel formulation was measured using a Sensorex® spear tip pH 
probe for measuring the pH of semi-solid materials.  The probe was submerged into 
each hydrogel and the pH recorded once the reading remained constant for 10 s.  
Three replicates were performed for each formulation (n=3). 
 
2.4.8 Hydrogel swelling study  
The ability of each hydrogel formulation to swell was measured using a fluid uptake 
study.  A sample of hydrogel (10.00 g) was placed into cellulose membrane dialysis 
tubing with a 14 kDa molecular weight cut off.  The tubing was tied tightly at each 
end ensuring there were no air spaces between the tubing and the gel.  The tubing 
containing the hydrogel sample was weighed before being placed in beaker 
containing 100 mL phosphate buffer saline (pH 6.8) at 37 °C.  The hydrogel was 
removed at 30 minute intervals over a total time of 180 minutes.  The surface of the 
dialysis membrane was patted dry with tissue paper to remove any surface liquid and 
weighed before being placed back into the beaker.  The swelling ratio was calculated 
as a percentage using Equation 2.5 (Kim et al., 2003), where ws = weight of swollen 
sample and wd = weight of initial dry sample.  
  % Swelling ratio =  
(Ws−Wd)
Wd
 x 100 Equation 2.5 
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2.4.9 Hydrogel formulation stability study 
Stability of hydrogel formulations was monitored over 2 years by measuring the 
crossover modulus at 9, 12, 18 and 24 months.  Three replicates were performed for 
each formulation (n=3).  Statistical analysis was used to determine any significant 
changes in the crossover modulus of each formulation by applying two-way analysis 
of the variance (ANOVA) to the data. 
 
 Results 
A range of PVA-borate formulations were found to have sufficient complexation to 
produce hydrogels for topical drug delivery.  The concentrations of PVA and borate 
used to produce sixteen formulations were 6.0, 8.0, 10.0, 12.0 % w/w and 1.0, 1.5, 
2.0, 2.5 % w/w, respectively.  Each hydrogel formulation was clear and homogenous 
in appearance, once complete gelation had occurred, as seen in Figure 2.8.  The 
viscoelastic properties of each formulation were characterised physically using 
oscillating rheometry, as stated in section 2.4. 
 
Figure 2.8 Picture of a sample of a PVA (6.0 % w/w)–borate (2.0 % w/w) hydrogel at room 
temperature, manufactured as described in section 2.4.1. 
 
A typical plot of G` G`` and phase angle (δ) against frequency from a 
frequency sweep test of a PVA-borate hydrogel can be seen in Figure 2.9.  As seen in 
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Figure 2.9, the crossover point is the frequency at which the loss modulus (G’’) and 
the storage modulus (G’) crossover each other.  The corresponding shear force at this 
frequency is then documented as the crossover modulus value, which is unique to 
each formulation.  The crossover modulus allows for precise reproducibility of any 
formulation.  At low frequencies (long time scales) the PVA-borate hydrogel has a 
liquid-like behaviour as the viscous component G’’ is dominant over the elastic 
component G’ and the phase angle is greater than 45°.  At the point where the two 
components cross the hydrogel ceases to behave like a liquid and begins to behave 
like a solid.  Now the solid component G’ is dominant over the liquid component G’’ 
at higher frequencies (short time scales) and the phase angle is less than 45°, 




Figure 2.9 A typical PVA-borate hydrogel plot of G` G`` and phase angle (δ) against frequency, 
produced from a strain controlled frequency sweep (1.0–10 Hz) at 25 °C ± 0.2 °C.  The green line 
represents the phase angle (δ), the red line represents the elastic solid-like component of the hydrogel 
and the blue line the viscous liquid-like component.  
 
Figure 2.10 shows the results from strain controlled frequency sweeps with 
crossover point analysis carried out on each of the sixteen hydrogel formulations.  It 
can been seen from Figure 2.10 that increasing the PVA concentration from 6 to 12 
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% w/w increased the crossover modulus.  Increasing the borate concentration also 
caused the crossover modulus to increase.  A more pronounced increase in crossover 
modulus was seen when increasing the borate concentration from 1.0 to 2.5 % w/w 
for PVA concentrations 8.0, 10.0 and 12.0 % w/w.  However, the 6.0 % w/w PVA 
concentration only showed a marginal increase in crossover modulus on increasing 
the borate concentration.  It was observed that when increasing the PVA 
concentration from 10.0 to 12.0 % w/w, whilst keeping the borate concentration 
constant at 2.0 and 2.5 % w/w, the increase in crossover modulus was more 
pronounced than when increasing the PVA concentration from 6.0 % through to 10.0 
% w/w, for the same borate concentrations.  The largest crossover modulus was 
25037 ± 2625 Pa for PVA 12.0 % w/w borate 2.5 % w/w hydrogel and the lowest 
crossover modulus was 3678 ± 374 Pa for the PVA 6.0 % w/w borate 1.0 % w/w gel.  
Graph showing G' G'' crossover modulus against borate concentration
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Figure 2.10 Crossover modulus plotted against borate concentration.  Data was from a strain (1.0 %) 
controlled frequency sweep (0.1–10 Hz).  Data shown as mean ± standard deviation (n=3). All 
measurements carried out at 25°C ± 0.2°C. 
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To obtain crossover values for formulations PVA 12.0 % w/w borate 2.0 % 
w/w and PVA 12.0 % w/w borate 2.5 % w/w, the working gap width of the parallel 
plate geometry had to be increased from 1.0 mm to 1.5 mm and 2.0 mm, 
respectively.  The experimental study in section 2.4.3 was designed and carried out 
to determine if increasing the working gap width had any significant effect on the 
magnitude of the crossover modulus.  It can be seen from Figure 2.11 that there is 
only a small variance in the crossover modulus for each of the hydrogels tested on 
increasing the working gap width.  Two-way ANOVA statistical analysis on the data 
set further confirmed that there was no significant difference between the three 
crossover modulus values for each of the hydrogels. 
 
Graph showing the effect of changing working gap width has on
crossover modulus



























Figure 2.11 Graph showing the effect of changing working gap width on crossover modulus values of 
PVA 8.0 % w/w borate 1.0, 1.5, 2.0, 2.5 % w/w hydrogels.  Data shown as mean ± standard deviation 
(n=3).  All measurements carried out at 25°C ± 0.2°C. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
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Relaxation time was determined for each formulation and plotted against 
PVA concentration, as seen Figure 2.12.  For formulations containing 2.0 and 2.5 % 
w/w borate, it was observed that the relaxation time increased with an increase in 
PVA concentration.  The hydrogel formulation containing PVA 12.0 % w/w borate 
2.5 % w/w took the longest time, 0.369 ± 0.019 s, to recover from the applied strain 
with formulation PVA 12.0 % w/w borate 1.0 % w/w taking the shortest time (0.106 
± 0.002 s) to recover.  Another trend identified was the decrease in relaxation time 
for hydrogels containing 1.0 % w/w borate with an increase in PVA concentration 
from 6.0 to 12.0 % w/w.  The formulation PVA 6.0 % w/w borate 1.0 % w/w 
exhibited a relaxation time of 0.191 ± 0.004 s, which decreased to 0.106 ± 0.002 s on 
increasing the PVA concentration to 12.0 % w/w.  This trend was the opposite of that 
observed for the other three borate concentrations.  Hydrogels containing 1.5 % w/w 
borate showed little change in relaxation time on increasing the PVA concentration, 
when compared to the other borate concentrations.  Increasing the borate 
concentration increased the relaxation time for all the PVA concentrations.  The 
smallest increase in relaxation time overall on increasing the borate concentration 
was observed in hydrogels containing PVA 6.0 % w/w.  It could, therefore, be stated 
that the borate concentration has a greater effect on relaxation time than PVA 
concentration.  However, changes in either or both result in altered relaxation times.  
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Graph showing relaxation time against PVA concentration
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Figure 2.12 Relaxation time calculated from the crossover modulus data using Equation 2.3, plotted 
against PVA concentration.  Data shown as mean ± standard deviation (n=3). 
 
The zero shear viscosity was determined for each formulation by applying the 
cross model to the frequency sweep data.  The cross model takes into account the 
whole flow curve produced, which includes the zero shear viscosity region, power 
law region and infinite shear viscosity region.  The zero shear viscosity value is 
determined at the point where the viscosity plateaus, as the shear rate decreases and 
approaches zero.  Therefore, it represents the viscosity of a material at rest and is 
useful to predict stability of pharmaceutical preparations.  Figure 2.13 shows the zero 
shear viscosities for each of the hydrogel formulations.  It can be stated that as PVA 
and borate are increased, the zero shear viscosity of the hydrogel also increases.  One 
exception to this statement was seen for the PVA 8.0 % w/w borate 2.5 % w/w 
86 
 
hydrogel formulation.  On increasing the borate concentration of a hydrogel 
containing 8.0 % w/w PVA from 2.0 to 2.5 % w/w, the zero shear viscosity 
decreased from 18077 ± 819 to 13493 ± 178 Pas.  The increase in zero shear 
viscosity on increasing the borate concentration was minimal for hydrogels 
containing 6.0 % w/w PVA, compared to PVA 12.0 % w/w hydrogels, which 
displayed an increase in zero shear viscosity on increasing the borate concentration 
from 1.0 % w/w (3109 ± 148 Pas) to 2.5 % w/w (55150 ± 418 Pas), as seen in Figure 
2.13. 
 
Bar graph showing zero shear viscosity with varying PVA and borate concentration
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Figure 2.13 Zero shear viscosity calculated using cross model (Equation 2.4) fitted to crossover 




Yield stress analysis determines the stress required to reach the yield point.  
The yield point is the point up until which any deformation if elastic is non-
permanent, and on removal of the stress the material will return back to its original 
shape.  After the yield point any further deformation is permanent, and the material 
will not return to its original shape.  The trends seen in Figure 2.14 are similar to 
those seen in Figure 2.10 for the crossover analysis.  As PVA and borate 
concentrations were increased, so did the shear stress required to reach the yield 
point.  Hydrogels containing 6.0 % w/w PVA showed a minimal increase in shear 
stress with increasing borate concentration.  The largest increase was observed for 
the PVA 12.0 % w/w hydrogels when the borate concentration was increased from 
2.0 to 2.5 % w/w giving a pronounced increase in shear stress from 288.5 ±24.2 Pa to 




Graph showing yield stress against borate concentration
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Figure 2.14 Graph showing the effect varying PVA and borate concentrations had on yield point stress 
represented as shear stress (Pa) in the graph.  Data shown as mean ± standard deviation (n=3). 
 
A tackiness test was designed to run on the rheometer using a normal force 
pull-away sequence.  The test was designed to mimic the sequence of events and 
parameters that a texture analyzer uses to determine adhesive properties.  It was 
found that increasing both the PVA concentration and the borate concentration 
caused an increase in tackiness of the hydrogels.  The hydrogel formulation 
containing PVA 12.0 % w/w borate 2.5 % w/w was the tackiest, requiring a normal 
force of 9.60 ± 0.30 N to pull the submerged top parallel plate out of 10 g of 
hydrogel after a contact time of 30 sec.  The formulation PVA 6.0 % w/w borate 1.0 
% w/w was the least tacky requiring a normal force of 2.23 ± 0.25 N to pull the 
submerged top plate out of the hydrogel.  Increasing the borate concentration from 
89 
 
1.0 to 1.5 % w/w, while keeping the PVA concentration constant at 6.0 % w/w had 
no effect on tackiness of the formulations, as seen in Figure 2.15.  A similar trend 
was seen when increasing the borate concentration from 1.5 % to 2.0 % w/w, while 
keeping the PVA concentration constant at 8.0 % w/w, resulting in 4.04 ± 0.37 N and 
4.09 ± 0.76 N normal forces, respectively. 
Graph showing tackiness represented by normal force with varying
PVA and borate concentrations
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Figure 2.15 . Tackiness represented as normal force plotted against PVA concentration.  Contact time 
of 30 s and pull-away speed was 10.33 mm s-1.  Data shown as mean ± standard deviation (n=3). All 
measurements carried out at 25°C ± 0.2°C. 
 
Temperature sweeps were carried out on each formulation to determine how 
an increase in temperature affected the viscosity of the hydrogels.  Figure 2.16 shows 
the effect of temperature increase on the viscosity of hydrogels of a constant PVA 
concentration (8.0 % w/w), but varying borate concentration.  It can be seen from 
Figures 2.16 and 2.17 that as the temperature is increased from 25 to 80 °C the 
90 
 
viscosity of all the hydrogels decreases until the gel system is completely fluid like.  
It was expected that all four formulations on reaching 80 °C would be of similar 
viscosity.  This is because during the formulation process, as detailed in section 
2.4.1, the gels are heated to 80 °C for several hours to allow for complete fluidisation 
and homogeneity.  Figure 2.17 shows the same temperature sweep as Figure 2.16 but 
with a constant borate concentration (2.0 % w/w) and varying the PVA 
concentration.  The same trend was observed as in Figure 2.17 with the viscosity of 
all the hydrogels of varying PVA concentration decreasing with increasing 
temperature.  
Graph showing the effect of temperature on complex viscosity
with varying borate concentration
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Figure 2.16 Graph showing temperature sweep (25–80 °C) plotted against complex viscosity for four 
PVA borate hydrogels with varying borate concentration (1.0, 1.5, 2.0, 2.5 % w/w) and a constant 
PVA concentration of (8.0 % w/w). 
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Graph showing the effect of temperature on complex viscosity
with varying PVA concentration
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Figure 2.17 Graph showing temperature sweep (25–80 °C) plotted against complex viscosity for four 
PVA–borate hydrogels with varying PVA concentration (6.0, 8.0, 10.0, 12.0 % w/w) and a constant 
borate concentration of (2.0 % w/w). 
 
The pH was recorded for each of the sixteen formulations using a pH probe 
for semi-solid materials.  It was found that all the formulations fell within the pH 
range of 7.3–8.3.  Therefore, it can be concluded that hydrogels are neutral in pH 
with three formulations being slightly basic.  The basic formulations occur when 
high concentrations of borate are incorporated with low concentrations of PVA.  It 
can be seen from Figure 2.18 that the higher the borate concentration was in the 
formulation, regardless of the PVA concentration, the higher the pH was.  As a result 
of this finding it can be stated that the concentration of borate in the formulation has 
a greater effect on the pH than the PVA concentration.  However, it was also 
observed that the lower the PVA concentration was within the formulation the higher 
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the pH of the hydrogel.  The PVA 6.0 % w/w borate 2.5 % w/w hydrogel was found 
to have the highest pH of 8.3, with the PVA 12.0 % w/w borate 1.0 % w/w hydrogel 
having the lowest pH of 7.3. 
Graph showing the pH of each hydrogel formulation
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Figure 2.18 pH of sixteen formulations of PVA-borate hydrogels with varying concentrations of PVA 
and borate.  Data shown as mean ± standard deviation (n=3). 
 
It is important to understand the ability of the formulations to absorb fluid as 
part of their development because some wounds can have heavy exudate present.  
Swelling studies were conducted on all the formulations using a dialysis tubing-
based method, as described in section 2.4.8.  The percentage swelling was then 
calculated using Equation 2.5 and plotted against time.  Figure 2.19 shows that from 
90 to 120 minutes formulations containing the lowest borate concentration (1.0 % 
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w/w) had the greatest percentage swelling compared to the other three borate 
concentrations at these time points.  At the 30-minute time point, the 2.0 % w/w 
borate concentration showed the most swelling, whilst the 1.5 % w/w concentration 
showed the least.  At the 60-minute time point, the 2.5 % w/w borate concentration 
had the greatest swelling compared to the 1.5 % w/w borate concentration, which 
again showed the lowest percentage swelling.  It was found that the highest 
concentration of PVA (12.0 % w/w) exhibited the greatest swelling at all time points 
(30–180 minutes) when the borate concentration was kept constant at 1.5 % w/w, as 
seen in Figure 2.20.  At 150 and 180 minutes, all four concentrations followed the 
same trend of increased PVA concentration causing increased swelling.  However, 
the 10.0 % w/w PVA-borate 1.5 % w/w hydrogels consistently gave the lowest 
percentage swelling from 30 to 120, as seen in Figure 2.20.  The formulation that had 
swollen the least after 180 minutes was PVA 6.0 % w/w borate 1.5 % w/w hydrogel 
with 7.53 ± 0.09 % increase in mass.  The PVA 12.0 % w/w borate 1.5 % w/w had 
swollen the most after 180 minutes with an increase in mass of 8.90 ± 0.09 %, 
followed by the PVA 10.0 % w/w borate 1.5 % w/w formulation with a 8.28 ± 0.10 
%, increase in mass from time zero.  
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Graph showing the effect varying borate concentration has on
 percentage swelling
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Figure 2.19 Percentage swelling of PVA-borate hydrogels varying borate concentration and keeping 
PVA concentration constant at 8.0 % w/w.  A sample (10.00 g) of hydrogel contained within cellulose 
dialysis tubing was placed in 100 mL of phosphate buffer saline (pH 6.8) at 37 °C.  Data shown as 
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Figure 2.20 Percentage swelling of PVA-borate hydrogels varying PVA concentration and keeping 
borate concentration constant at 1.5 % w/w.  A sample (10.00 g) of hydrogel contained within 
cellulose dialysis tubing was placed in 100 mL of phosphate buffer saline (pH 6.8) at 37 °C.  Data 
shown as mean ± standard deviation (n=3). 
 
The stability of fourteen of the sixteen formulations was monitored over 24 
months, using the crossover modulus to determine any changes in viscoelastic 
properties.  The PVA 6.0 % w/w borate 2.5 % w/w and PVA 8.0 % w/w borate 1.0 % 
w/w hydrogels showed no statistically significant changes in the crossover modulus 
over the 24 months, as seen in Figure 2.21 and Table 2.1.  Therefore, this would 
suggest they are the most stable formulations and have a shelf-life of 18–24 months. 
The PVA 6.0 % w/w borate 2.0 % w/w formulation was stable for 12 months with a 
significant change in viscoelastic properties at 18 and 24 months.  The PVA 8.0 % 
w/w borate 2.0 % w/w and PVA 10.0 % w/w borate 1.0 % w/w formulations 
exhibited poor stability, both showing a highly significant change in viscoelastic 
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properties after 9 months.  Formulations containing PVA 10.0 % w/w borate 1.0 and 
2.0 % w/w, and PVA 12.0 % w/w borate 1.0 and 2.0 % w/w all exhibited significant 
changes in viscoelastic properties after 18 months.  
 
Table 2.1 Two-way ANOVA statistics for stability data seen in Figure 2.21 

















6.0/1.0 - - - * 
6.0/1.5 - *** *** *** 
6.0/2.0 - - *** *** 
6.0/2.5 - - - - 
8.0/1.0 - - - - 
8.0/1.5 - - - *** 
8.0/2.0 *** *** *** *** 
8.0/2.5 - - - * 
10.0/1.0 *** *** *** - 
10.0/1.5 - ** *** ** 
10.0/2.0 - *** *** - 
10.0/2.5 - - - *** 
12.0/1.0 - * ** - 




Figure 2.21 A graph showing the stability of fourteen of the hydrogel formulations over 24 months.  Crossover modulus was used to monitor changes in hydrogels viscoelastic 
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 Discussion  
PVA-borate hydrogels are of particular interest as a topical drug delivery system for 
wound management and repair, due to their novel viscoelastic properties.  In this 
chapter, sixteen PVA-borate hydrogel formulations of varying PVA and borate 
concentration were manufactured and characterised physically using oscillating 
rheometry. 
 The unique viscoelastic properties of PVA-borate hydrogels used in this work 
are due to the response of the cross-link interaction between the PVA and borate to 
an applied force, for a specific duration of time.  On rheological characterisation of 
the hydrogel formulations, it was found that at high frequencies (short time periods) 
the hydrogels exhibited elastic solid-like behaviour, due to the elastic component 
dominating the liquid viscous-like component (G’ > G”).  At high frequencies or 
high shear rates, the cross-links between the PVA polymer chains and the borate 
molecules do not have sufficient time to dissociate (t < tlife), therefore, the system 
behaves like an elastic solid (Loughlin et al., 2008).  When the PVA-borate system 
demonstrates this elastic solid-like behaviour, the gel is comparable in nature to the 
chemically cross-linked PVA-glutaraldehyde hydrogel, which has an infinite lifetime 
(tlife), showing no flow-like behaviour (Lin et al., 2005).  The solid-like behaviour 
displayed at high frequencies allows the hydrogel to be handled and manipulated into 
the shape of the wound prior to application.  It also allows for complete intact 
removal of the gel as one mass of material, post treatment, without any further 
trauma to the wound site (Loughlin et al., 2008; Murphy et al., 2012).  The low bio-
adhesiveness of the hydrogel also partly contributes to the reduced trauma at the 
wound site.  In comparison, it was found from the rheological analysis that at low 
frequencies (long time periods) the hydrogels exhibit viscous liquid-like behaviour, 
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as the viscous component dominates over the elastic solid-like component (G” > G’).  
This is because at low frequencies the cross-links have sufficient time to dissociate (t 
> tlife), relax and reorientation, allowing the gel system to flow like a viscous liquid 
(Lin et al., 2005).  This liquid-like behaviour is advantageous for a topical delivery 
system for wound treatment as it allows the hydrogel to flow into the wound, filling 
the cavity entirely.  This facilitates maximum contact between the wound surface and 
the hydrogel surface, maximising drug delivery. 
 The concentrations of both the PVA and borate present in the formulation 
were found to have an effect on the viscoelastic properties of the PVA-borate 
hydrogels.  Therefore, the viscoelastic properties of the hydrogel could be controlled 
by altering the quantity of PVA or borate present in the formulation, to achieve an 
optimum formulation.  On increasing the concentration of the PVA, or borate, or 
both in the formulation the rheological parameters measured, such as crossover 
modulus, yield stress, zero shear viscosity and relaxation time also increased.  The 
increase in these rheological parameters is thought to occur as a result of increased 
cross-linking between the PVA polymer chains and borate ions, but also an increase 
in hydrogen bonding of the hydroxyl groups of the polymer chains (Koike et al., 
1995; Lin et al., 2005; Murphy et al., 2012).  An increase in cross-linking leads to a 
denser gel network, which increases the viscosity of the gel, giving a larger elastic 
response at low frequencies (Murphy et al., 2012).  On increasing both the PVA and 
borate concentrations within the hydrogel formulation, the crossover modulus 
increased.  The crossover modulus is the frequency at which the elastic and liquid 
shear moduli are equal and, therefore, indicates the transition of the gel system 
behaving like a viscous liquid to an elastic solid, with increasing frequency.  Murphy 
et al., (2012) identified similar trends, stating that an increase in both the PVA and 
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borate concentration caused an increase in both the storage (elastic) and loss (liquid) 
moduli, hence also the crossover modulus.  The relaxation time for the hydrogel 
formulations containing borate 1.0 % w/w and PVA 6.0, 8.0, 10.0 and 12.0 % w/w 
did not increase on increasing PVA concentration, but instead decreased.  This could 
be the result of an insufficient amount of borate being present in the formulation to 
participate in further cross-linking on addition of increasing PVA.  Therefore, these 
non-cross-linked PVA polymer chains can relax and re-orientate much faster on 
removal of the applied stress, than those involved in cross-linking with borate (Lin et 
al., 2003).  Murphy et al. (2012) also observed a similar trend with regards to the 
crossover frequency. They suggested that by increasing the PVA concentration, 
whilst the borate concentration remains low, encourages the formation of the mono-
diol complex rather than the di-diol complex.  The formation of mono-diol 
poly(electrolyte) complex causes the polymer chains to expand due to the 
electrostatic repulsion.  This results in reduced polymer-polymer interactions, which 
is not sufficiently counteracted by PVA-borate interactions due to the low 
concentration of borate present.  This causes a reduced elastic solid-like response by 
the hydrogel and the overall gel system having a greater viscous liquid-like response. 
Determination of crossover moduli for hydrogel formulations containing 
PVA 12.0 % w/w, with 2.0 % and 2.5 % borate was not achievable using a 1.0 mm 
working gap width.  This problem was not encountered during determination on, the 
first fourteen formulations.  The traces displayed by the rheometer were showing a 
dog leg effect, indicating that a phenomena known as wall slip was occurring 
(Malvern Instruments, 2015).  Wall slip is the slipping of the material between the 
two parallel plates, which have smooth surfaces, due to a loss of friction.  The 
recommended method to overcome this, according to the manufacturer’s application 
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note on wall slip, is to use roughened of serrated plates (Malvern Instruments, 2015).  
However, this was not an available option during this work.  One disadvantage of 
using roughened or serrated plates is the interaction between the plate surface and the 
material has to be taken into consideration when interpreting data.  The working gap 
width is the distance between the two geometries of the rheometer.  It was thought 
that if the force applied to the hard solid-like hydrogel sample was reduced by a 
small amount it may be possible to overcome the wall slip, but maintain enough 
friction to achieve a crossover modulus value.  On increasing the working gap width 
to 1.5 mm for the PVA 12.0 %, borate 2.0 % w/w and 2.0 mm for the PVA 12.0 % 
w/w borate 2.5 % w/w it was possible to obtain crossover values for these two 
formulations.  Therefore, the experiment, as detailed in section 2.4.3, was then 
carried out to confirm that changing the working gap width had no statistically 
significant effect in the magnitude of the crossover modulus value and that they 
could be compared to the other fourteen values measured using the commonly used, 
standard 1.0 mm working gap width.  
 The tackiness study carried out using the rheometer was performed as 
detailed in section 2.4.5.  The results obtained show that as both the borate and PVA 
concentration increased the tackiness of the formulation also increased.  When the 
borate concentration is kept constant and the PVA concentration is increased, it 
would be expected that the formulation would become tackier in nature.  This is 
because there is a higher ratio of PVA to borate present resulting in less cross-
linking.  As a result of less cross-linking, a higher quantity of the PVA polymers are 
present in a viscous fluid-like formulation and it is known that solutions of PVA 
have adhesives properties (Park et al., 2011; Cakir et al., 2011).  Therefore, it is 
presumed that formulations with high PVA concentrations and low borate 
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concentrations will naturally be tackier.  Murphy et al. (2012) found that on 
increasing the borate concentration the adhesiveness of the PVA-borate formulation 
decreased, which is the opposite of the trend seen in this study.  A decrease in 
adhesive properties with an increase in borate concentration is what would be 
expected, due to an increase in cross-linking of the PVA polymers with the borate 
ions, resulting in fewer non-cross-linked PVA polymers contributing to the 
adhesiveness of the formulation.  Murphy et al. (2012) used a texture analyser in 
adhesive mode, an instrument purpose made for measuring adhesion, unlike the 
rheometer.  The rheometer measures normal force, which is the force required to pull 
the submerged top plate out of the hydrogel.  The expectation is that the tackier the 
formulation the larger the force required to pull the top plate out.  This is a method 
suggested and recommended by Malvern Instruments who manufacturer the 
rheometer and, therefore, was deemed a suitable way to measure tackiness and 
adhesiveness of the hydrogel formulations.  The texture analyser measures the force 
required to pull the top plate off the surface of the hydrogel (McCarron et al., 2011).  
Whereas, the rheometer measures the force required to pull a submerged probe or 
plate out of the hydrogel formulation.  It is this difference in the way the two 
instruments operate, which could have led to the difference in results.  As PVA and 
borate are increased in the formulation the resultant hydrogels becomes physically 
more rigid and solid-like, due to increased cross-linking density.  Therefore, the 
submerged plate of the rheometer will require a larger force to pull the plate out of 
the gel as the formulations increase in rigidity.  This is due to the hydrogel flowing 
over the outer edge of upper plate, as seen in Figure 2.22.  Therefore, not only must 
the adhesive force be overcome, but the structure of the gel matrix must also be 
disrupted.  This may explain the results obtained from this experiment and perhaps 
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Figure 2.22 Schematic diagram showing the upper plate of the rheometer submerged in a pot 
containing 10 g of PVA-borate hydrogel.  It can be seen that the hydrogel begins to flow over the edge 
of the upper plate as it is pushed against the gel surface with a constant force, before the pull-away test 
is triggered after 30 s contact time.  This shows that not only does the adhesive force of the gel have to 
be overcome when the upper plate is pulled out, but also the structure of the gel has to be disrupted. 
 
 It is important to assess the effect temperature has on the PVA-borate 
hydrogel as the temperature of wounds can vary, affecting the viscoelastic properties 
and the release of the drug from the hydrogel (Dini et al., 2015).  Temperature had a 
profound effect on the viscosity of all the hydrogels tested.  It was found that on 
increasing the temperature from 20 °C to 80 °C that the complex viscosity decreased 
for all hydrogel formulations.  The PVA-borate cross-link are thermos-reversible in 
nature and upon heating above a threshold temperature the cross-links dissociate and 
the gel behaves like a viscous liquid. Once the temperature drops below the threshold 
temperature the gel cross-linking network reforms.  As the temperature of the PVA-
borate hydrogel is increased, the di-diol complex formed and the hydrogen bonding 
between polymer chains begin to dissociate (Lin et al., 2003).  Lin et al. (2003) 







Therefore, as body temperature is 37 °C and the temperature range of wound beds 
are between 33–38 °C (Dini et al., 2015), the PVA-borate gel network will stay 
intact when applied to a wound.  Loughlin et al. (2008) found a similar effect 
occurring with the PVA-borate hydrogel on heating and that it also effected the 
release of lidocaine from the hydrogel, due to an increase in free borate ions 
concentration as a result of the di-diol complex dissociation.  
 The pH of the majority of the sixteen formulations were found to be neutral, 
with those that were not neutral being weakly basic.  The weakly basic hydrogel 
formulations were those that contained a high borate concentration and low PVA 
concentration.  This can be explained by the presence of excess free borate ions in 
the aqueous environment of the hydrogel, which are not participating in cross-linking 
interactions (Guan & Zhang, 2013).  These free borate ions are then driving the pH 
of the hydrogel up from neutral to basic.  Loughlin et al. (2008) found that on adding 
D-mannitol to the PVA-borate formulation it acted as a scavenger molecule, binding 
up the free borate ions.  The binding up of these free borate ion caused a decrease in 
pH of the hydrogel system, confirming that the free borate ions caused the increase in 
pH.  On increasing the PVA concentration of the hydrogel formulations containing 
high concentrations of borate (2.0 and 2.5 % w/w), in this study, caused the pH of the 
hydrogels to return to neutral.  It can be assumed that increasing the PVA 
concentration resulted in the excess free borate ions being used in cross-linking 
interactions and, therefore, were not available to drive up the pH of aqueous 
environment within the hydrogel.   
 By definition, hydrogels are 3D cross-linked structures, which can retain and 
accommodate large volumes of water (Hoffman, 2002).  This advantageous property 
of hydrogels makes them attractive for treatment of chronic wounds as they have the 
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ability to absorb excess exudate from the wound site, or donate water to the wound 
site.  Their ability to donate water to necrotic tissue allows it to soften and be 
removed in process known as autolytic debridement (Trudgian, 2000).  A study 
revealed that a typical pressure ulcer produced on average 6 mL day-1 of wound 
exudate, with other chronic wounds, such as diabetic foot ulcers producing on 
average 25–40 mLs day-1 (Iizaka et al., 2011).  Smith & Nephew (2009) in their 
clinical guidelines stated that the typical chronic wound can produce 20–50 mLs day-
1.  Iizaka et al. (2011) estimated, using their model that a 20 cm2 pressure ulcer 
classified with light exudate, would produce approximately 2.7 mL day-1 of exudate.   
Therefore, it can be predicted according to the swelling data that a sample (10.00 g) 
of PVA-borate hydrogel would be able to manage exudate in a wound classed with 
light exudate and not a heavy exudate wound, such as a diabetic ulcer.  Hydrogels 
can also be applied to viable tissue throughout the wound healing to promote the 
warm moist environment required for keratinocyte proliferation and tissue 
regeneration (Trudgian, 2000; Gantwerker & Hom, 2012).  Therefore, it is important 
to investigate the swelling characteristic of the PVA-borate hydrogel formulations to 
ascertain their ability to absorb and retain fluid.  The swelling kinetics of several 
chemically cross-linked hydrogels have been studied extensively, such as PVA-N-
isopropylacrylamide, PVA-diallyldimethylammonium chloride, PVA-methacrylic 
acid (Kim et al., 2003), poly(ethylene glycol)-poly(methyl vinyl ether-co-maleic 
acid) (Singh et al., 2009) and poly(acrylamide-co-methyl methacrylate)-NN’-methyl-
ene bis acrylamide (Begam et al., 2002).  As dry hydrogels begin to absorb water for 
the first time, the water molecules hydrate the most hydrophilic groups within the 
matrix first, known as primary bound water.   As the matrix begins to swell, there is 
exposure of hydrophobic groups, which interact with the water entering the matrix 
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and is known as secondary bound water.  The primary and secondary bound water 
together are called the total bound water (Hoffman, 2002).  Additional water is then 
absorbed into the hydrogel matrix by osmosis as the water soluble polymers aim for 
infinite dilution.  However, this is counteracted by chemical and physical cross-links.  
This extra water, which is thought to fill voids and pores between the cross-linked 
network chains is known as bulk or free water (Hoffman, 2002).  If the cross-links 
are labile to dissolution in aqueous solution then as the network continues to swell 
the hydrogel will begin to breakdown and dissolve.  The PVA-borate hydrogels are 
labile to complete dissolution when submerged in an aqueous solution.  Therefore, 
samples of the hydrogels were enclosed in cellulose dialysis tubing membrane to 
complete the swelling studies for this chapter.  The dialysis membrane allowed for 
diffusion of the water into the hydrogel while, maintaining the structural integrity of 
the hydrogel.  However, one limitation of this was after a prolonged period of time 
certain formulations did begin to disintegrate, despite having the dialysis tubing in 
place.  As the PVA-borate hydrogel disintegrates, free PVA and boron species are 
released.  Therefore, there is potential for the absorption of the hydrogel excipients 
on topical application to an open wound.  In this project the extent of the release of 
free PVA and boron species was not investigated.  However, Murphy et al. (2012) 
did detect and quantify the cumulative release of free PVA and boron species, 
measured as boric acid, in an in vitro release study, over a period of two hours.  It 
was found that as the concentration of borate in the formulation increased, so did the 
release of boron species from the formulation, in a non-linear fashion (Murphy et al., 
2012).  However, as the borate concentration is increased within the formulation the 
degree of cross-linking increases, which is thought to constrict the network and 
reduce the diffusion of both free PVA and boron species (Murphy et al., 2012).  
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Murphy et al. (2012) also suggest that above a borate concentration of 0.025 M 
(approximately 1.0 %) poly(borate) species form.  Poly(borate) species are though to 
display slower diffusion of free boron species, such as boric acid.  It was found that 
on increasing the PVA concentration within the formulation there was no clear trend 
shown on the release of boric acid.  This is thought to be because excess boron 
species are available from the boric acid-tetrahydroxyborate equilibrium to 
participate in di-diol cross-linking, assuming the concentration of cross-linking is 
small in comparison to the concentration boric acid (Murphy et al., 2012).  In this 
study the concentration of borate within the chosen optimum formulation was 2.0 % 
w/w, therefore, it can be assumed that poly(borate) species are formed, reducing the 
release of free boron species.  Murphy et al. (2012) found that PVA with a high 
degree of hydrolysis (28–99 %) exhibited a lower release of boron species and free 
PVA, compared to PVA of a similar molecular weight but lower degree of hydrolysis 
(26–88 %).  Higher degrees of hydrolysed PVA will result in denser network 
formation, through increased di-diol cross-linking, reducing PVA diffusivity.  In this 
study the PVA used was 98–99 % hydrolysed and, therefore, the release of free 
boron species can be assumed to be minimal.  McCarron et al. (2011) observed no 
adverse reactions, caused by application of a sample (4.0 g) of PVA-borate hydrogel 
loaded with lidocaine anesthetic for 30 minutes to lacerations.  
It was found that on increasing the PVA concentration within the hydrogel 
formulation the percentage swelling increased.  In comparison, as the borate 
concentration within the formulation was increased the percentage swelling 
decreased.  A similar trend has been reported for PVA-poly(vinylpyrrolidone) (PVP) 
hydrogels, produced by freeze-thaw cycling (Holloway et al., 2011).  On increasing 
the concentration of PVA in the formulation, while the concentration of PVP 
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remained constant the percentage swelling increased.  The PVA-borate hydrogel can 
be compared in relation to the swelling ability of the chemically cross-linked PVA-
glutaraldehyde hydrogel (Varshosaz & Koopaie, 2002).  Varshosaz & Koopaie, 
(2002) reported that on increasing the concentration of glutaraldehyde, while keeping 
the PVA concentration constant within the hydrogel film formulation the percentage 
swelling decreased.  A similar trend seen when increasing the cross-linker (borate) 
for the PVA-borate hydrogels in this chapter.  In both hydrogels the increase in the 
cross-linking agent, borate and glutaraldehyde, results in an increased cross-linking 
density within the hydrogel network, resulting in decreased network expansion and 
reduced uptake of fluid and swelling.  
 The stability of 14 of the sixteen hydrogel formulations where monitored over 
24 months by detecting changes in the crossover modulus value, for each 
formulation.  Several of the PVA-borate formulations showed statistically significant 
changes in the crossover modulus over 24 months, indicating instability.  The exact 
reason for this instability in certain formulations is unknown.  Further work 
involving repetition of this study and further analysis is needed to try and determine 
possible causes for this.  One possible explanation for the change in crossover 
modulus may be due to a shift in the PVA-borate cross-link equilibrium or boric 
acid-tetrahydroxyborate equilibrium.  Murphy et al. (2012) reported that release of 
boron species from the hydrogel as boric acid may occur over a prolonged period of 
time.  Therefore, based on this information, there may be diffusion of free boron 
species as boric acid over time through the aqueous environment within the hydrogel. 
This may lead to pockets throughout the hydrogel having varying degrees of cross-





The viscoelastic properties of the sixteen PVA-borate hydrogels formulated were 
investigated using oscillating rheometry.  It was concluded from the rheological 
characterisation of the hydrogels that the viscoelastic properties could be modified by 
varying the PVA and borate concentrations.  The hydrogel formulation, PVA 6.0 % 
w/w borate 2.0 % w/w was deemed to be the optimum formulation.  The optimum 
formulation was deemed to be a hydrogel that displayed the correct balance between 
elastic cohesiveness and liquid-like flow, while showing low adhesive properties.  
The optimum gel when physically manipulated must retain its shape for several 
seconds before flowing at an acceptable speed, for ease of application to the wound 
site.  These properties were determined and quantified using oscillating rheometry. 
The PVA-borate hydrogels demonstrate the ability to uptake and carry small 
volumes (10.00g approximately 1–2 mL) of deionised water, making them 
advantageous for wound management and potentially suitable for application to 
exuding wounds.  The work completed in this chapter, along with the results 
obtained, suggest that the PVA-borate hydrogels are a potentially suitable topical 












3 Formulation, characterisation, in vitro release and stability 
study of protein-loaded PVA-borate hydrogels. 
 
 Introduction 
The use of pharmaceutically active peptides and proteins has increased significantly 
since the introduction of the first therapeutic recombinant protein, human insulin, 
over 30 years ago (Vermonden et al., 2012).  Delivery of therapeutic proteins and 
peptides can be problematic due to their fragile 3D structures and poor stability.  Oral 
administration presents a significant challenge, as the proteins are highly susceptible 
to proteolytic degradation by gastrointestinal enzymes and chemical degradation due 
to the acidic environment of the stomach, resulting in the loss of biological activity 
(Li et al., 1998).  Another problem with oral administration is the large molecular 
weight and hydrophilic nature of many therapeutic proteins.  Several of the 
recombinant poly(peptide) growth factors, such as VEGF, FGF and IGF-1, used in 
wound healing are typically 5–50 kDa (Ferrara & Henzel, 1989; Ornitz & Itoh, 2001; 
Laron, 2001).  The high molecular weight and hydrophilic nature contributes to poor 
transdermal and biological membrane absorption, resulting in reduced bioavailability 
(Vermonden et al., 2012).  Therefore, the main route of administration currently is 
parentally, however, parental administration also has drawbacks.  One significant 
drawback is the need for frequent injections due to the short half-life of many 
proteins and peptides.  Growth factors involved in wound healing act locally as they 
possess short diffusional distances across the extracellular matrix because they 
degrade within a short period of time.  Platelet-derived growth factor, basic fibroblast 
growth factor and vascular endothelial growth factor after intravenous administration 
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have half-lives of 2, 3 and 30 minutes, respectively (Edelman et al., 1993; Lee, 2000; 
Eppler et al., 2002).  The high frequency of injections required to maintain a plasma 
protein-drug concentration within a defined therapeutic window will lead to reduced 
patient compliance and concordance (Li et al., 1998).  Therefore, there is a need for 
an alternative controlled release delivery system, which is capable of enhancing the 
pharmacodynamics and pharmacokinetic properties of the therapeutic protein or 
peptide being delivered.  
Polymeric hydrogels have been studied extensively as delivery systems for proteins 
and growth factors (Mellott et al., 2001; Murthy et al., 2002; Censi et al., 2012).  
Proteins can be loaded into hydrogel matrices in numerous ways, such as (i) being 
physically entrapped, (ii) being adsorbed to the matrix by interactions or (iii) 
participating in the formation of the gel structure through covalent or non-covalent 
binding (Vermonden et al., 2012).  By choosing specific hydrogel excipients and a 
particular method of incorporation, site-specific sustained release can be achieved, 
while maintaining protein stability and biological activity.  An important objective of 
pharmaceutical development is achieving a zero-order sustained release of the 
therapeutic drug (Huang et al., 2002).  Zero-order kinetics occurs when the rate of 
drug release, decomposition or dissolution is independent of the concentration of 
reactants, leading to a constant rate of release, decomposition or dissolution (Aulton, 
2007).  However, achieving zero-order sustained release kinetics for a complex 
delivery system is not an easy task as many factors influence the release of the 
loaded drug. 
The mechanism by which proteins are released from hydrogels is governed by both 
the protein and polymer network characteristics (Censi et al., 2012).  A general 
assumption is, if the pores between the polymers are larger than the hydrodynamic 
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radius of the protein, diffusion occurs.  The rate of diffusion is dependent on the size 
of the protein and the free-volume water content of the hydrogel (Amsden, 1998).  
However, if the hydrodynamic radius of the protein is larger than the hydrogel pores, 
generally, swelling and erosion or degradation are required for protein release (Censi 
et al., 2012).  Increasing the cross-linking density, decreasing the water content 
within the hydrogel or increasing the size of the protein all result in decreased drug 
release.  Equation 3.1, derived by Ritger and Peppas (1987), is applied widely to 
release data to determine the mechanism of drug release (Censi et al., 2012).  Mt is 
the amount of drug released at time t, M∞ is the total amount of drug present in the 
hydrogel, k is the release rate constant and n is the release coefficient used to 
determine the mechanism of release (Ritger & Peppas, 1987).  A summary of the 
release coefficient values and the corresponding mechanism of drug release can be 






Table 3.1 Summary of drug release mechanisms  
 
Release coefficient value n Mechanism of drug release 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous transport (non-Fickian diffusion) 
1.0 Case II transport 
n > 1.0 Super Case II transport 
 
Fickian diffusion (case I transport), and case II transport can both be defined by a 




Case I and II transport are delivery systems controlled solely by diffusion and 
polymer relaxation, respectively (Ritger & Peppas, 1987).  However, anomalous 
non-Fickian diffusion is governed by both diffusion and relaxation (Ritger & Peppas, 
1987).  Censi et al. (2012) suggest that case II transport and anomalous diffusion can 
be a result of erosion rather than polymer relaxation depending on the specific 
polymers used in the hydrogel formulation.  In some scenarios, the release 
coefficient value can exceed 1.0, indicating super case II transport, which is 
controlled by erosion (Holowka & Bhatia, 2014).  Deviations in the release 
mechanisms mentioned above can occur when the hydrogel is subject to specific 
external stimuli, such as temperature, pH, presence of certain molecules, presence of 
a magnetic or electric field. 
 The isoelectric point of proteins has implications on both the loading and 
release of proteins from hydrogels due to electrostatic interactions (Jensen et al., 
2002; Koetting & Peppas, 2014).  Therefore, in this chapter model payloads with 
different isoelectric points will be selected in order to determine the effect the 
isoelectric point has on the loading to, and release from the PVA-borate hydrogel.  
The isoelectric point is the pH at which a particular molecule carries no overall net 
charge (Righetti, 2004).  If the pH of the environment in which the molecule is 
situated deviates in either direction from the isoelectric point then the molecule will 
obtain either a positive of negative overall net charge (Denniston et al., 2008).  If the 
pH of the environment is lower than the isoelectric point the molecule will have a 
positive net charge.  Alternatively, if the pH of the environment is higher than the 
isoelectric point the molecule will be negatively charged. 
PVA-borate hydrogels have been extensively studied as potential drug 
delivery systems for wound management.  One drug that has been delivered topically 
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using the PVA-borate hydrogel is lidocaine anaesthetic, prior to the suturing of 
lacerations, in an emergency department setting (Loughlin et al., 2008; Jenkins et al., 
2014).  The PVA-borate hydrogel also demonstrated efficient and effective delivery 
of two photosensitiser drugs, methylene blue and meso-tetra (N-methyl-4-pyridyl) 
porphine tetra tosylate, for photodynamic antimicrobial chemotherapy, of heavily 
infected wounds (Donnelly et al., 2009). 
An important question to be answered in this chapter was to decide if a PVA-
borate hydrogel was capable of providing a sustained release of three model proteins.  
These model payloads would have different isoelectric points and different molecular 
weights.  The proteins used were bovine serum albumin (BSA), haemoglobin (Hb) 
and trypsin.  The release and stability of the three model peptides was confirmed 
first.  It was important to do this before, carrying out further experimental work with 




 Aims and objectives 
The aim of work in this chapter is to formulate, characterise and complete in vitro 
release studies for several PVA-borate hydrogels (PVA 6.0 % w/w borate 2.0 % 
w/w) loaded with bovine serum albumin (BSA), haemoglobin (Hb) and trypsin. 
 
Objectives; 
 formulate PVA-borate hydrogels loaded with varying concentrations BSA, 
Hb and trypsin, 
 determine a suitable non-destructive method for loading proteins and 
peptides into the PVA-borate hydrogels,  
 characterise the viscoelastic properties of the protein-loaded PVA-borate 
hydrogels using oscillatory rheometry, 
 determine a suitable compatible receiver phase for the release studies, 
 complete in vitro release studies of the three model proteins from the 
hydrogel using Franz diffusion cells, 
 detect and quantify the protein released from the hydrogels using a 
bicinchoninic acid (BCA) assay and UV-Vis spectroscopy, 
 determine any degradation of the released proteins from the hydrogel using 




Chemicals and reagents  
Poly(vinyl alcohol) (PVA) (Mw = 31–50 kDa, 98–99 % hydrolysed), sodium 
tetraborate decahydrate (ACS reagent ≥ 99.5 %), D-mannitol (ACS reagent), sodium 
chloride (BioXtra ≥ 99.5 %), potassium chloride (BioXtra ≥ 99.5 %), di-Sodium 
hydrogen phosphate, potassium di-hydrogen phosphate, haemoglobin from bovine 
blood, trypsin from porcine pancreas (BioReagent 1000-2000 BAEE units/mg solid), 
bovine serum albumin (lyophilised powder ≥ 96 %), Victoria Pure Blue dye and 
Transwell® tissue culture inserts (Poly(carbonate) membrane, pore size 8.0 µm) were 
purchased from Sigma-Aldrich Ltd. (Gillingham, Dorset, UK).  
A Pierce™ BCA Protein assay kit was purchased from Medical Supply Company. 
(Dublin, Ireland).  Phosphate-buffered saline tablets (Dulbecco A tablets) Oxoid 
were purchased from ThermoFisher scientific (Hampshire, UK). 
 NuPage® Bis-Tris gel 4–12 % (1.0 mm x 10 well) Novex®, NuPage® MOPS SDS 
running buffer (20x) Novex®, SeeBlue® Plus2 Prestained standard Novex® were 
purchased from Life Technologies Ltd. (Paisley, UK). 
Coomassie brilliant blue R-250 staining solution, Bio-rad laboratories Inc. 
(Hertfordshire, UK). 




Kinexus Pro rheometer, Malvern instruments (Malvern, Worcestershire, UK). 
Varian Cary 50 Scan UV-Vis spectrophotometer supplied by Manson Technology. 
(Dublin, Ireland); used with a 10 mm quartz cuvette.  
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FLUOstar® Omega microplate reader, BMG LABTECH Ltd. (Ortenburg, Germany).   
Franz diffusion cells, Perme-Gear diffusion cells & systems. (USA) and Techne TE 
10D Tempette® water bath & pump, Bibby scientific Ltd. Staffordshire. (UK) 
 
 Methods 
3.4.1 Peptide and protein loading method development 
Samples (4.00 g) of PVA 6 .0% w/w borate 2.0 % w/w hydrogel were weighed, 
placed in small glass jars and allowed to sit for 24 hours, until evenly distributed 
within the jar.  Victoria Pure Blue dye solution (500 μL) was then added to each 
hydrogel sample by two different processes.  One sample was injected into the centre 
of the hydrogel sample and another was placed on the surface of the hydrogel, prior 
to being mixed into the hydrogel sample mechanically using a stainless steel spatula.  
Each hydrogel sample was left for 72 hours at room temperature.  Photographs were 
taken at 3, 24 and 72 hours as a visual record of monitoring the diffusion of the dye 
throughout the gel.  After 72 hours, UV-Vis spectrometry was used to determine the 
homogeneity of the dye throughout the hydrogel.  Four samples (0.50 g) from each 
hydrogel and dissolved in 5 mL of deionised water in a glass beaker on a magnetic 
stirring mantle at room temperature.  Once fully dissolved, the absorbance of each 
solution was read at 619 nm, the average absorbance was calculated and Student’s t-
test statistical analysis was carried out on the data. 
 
3.4.2 Formulation of BSA, haemoglobin (Hb) and trypsin-loaded hydrogels 
An optimum hydrogel formulation of 6.0 % w/w PVA and 2.0 % w/w borate was 
selected from rheological studies in Chapter Two to be loaded with various quantities 
of bovine serum albumin (BSA), haemoglobin (Hb) and trypsin (0.05, 0.10, 0.20, % 
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w/w).  A sample (25 g) of this formulation was prepared by mixing 6.25 g of PVA 
stock solution (24 % w/w) and 10.00 g of borax stock solution (5.0 % w/w).  A 
homogenous fluid-like gel was formed upon heating to 80 °C for approximately three 
hours, with periodic stirring.  Hydrogels were weighed and any weight loss was 
replenished with deionised water.  The gels were then transferred to poly(propylene) 
storage containers and left for 48 hours at room temperature and pressure (RTP) to 
allow complete gelation.  To a desired quantity of hydrogel, the appropriate volume 
of protein stock solution (5 mg mL-1) was added to the hydrogel and mixed in using a 
stainless steel spatula.  The hydrogels were then stored in the fridge (2–8 °C) until 
used.  
 
3.4.3 Viscoelastic analysis of hydrogels loaded with peptides 
Viscoelastic analysis of the hydrogels, loaded with various concentrations of bovine 
serum albumin, haemoglobin (Hb), trypsin and D-mannitol, was carried out using a 
Kinexus Pro rheometer (Malvern Instruments Ltd., Worcestershire, UK) as described 
previously in sections 2.4.2.  Briefly, a strain (1.0 %) controlled frequency sweep 
(0.1–10 Hz) was completed from which, the crossover modulus (Gc) was determined.  
All tests were carried out at 25 °C ± 0.2 °C, using 20 mm diameter stainless steel 
parallel plate geometry and a working gap of 1 mm.  Three replicates were 
performed for each formulation (n=3).  Student’s t-test statistical analysis was carried 
out on the data.  
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3.4.4 Optimisation of in vitro receiver phase, study I 
Samples (2.00 g) of hydrogel (PVA 6.0 % w/w, borate 2.0% w/w) containing no 
protein were weighed and placed in 12-well hanging cell culture inserts (membrane 
PET pore size 8.0 µm).  The inserts were suspended in glass jars containing 25 mL of 
receiver phase (PBS or deionised water).  Cling film was placed over the top of the 
jars to prevent evaporation.  The experiment was run for 24 hours at room 
temperature, on magnetic stirring mantle at 100 rpm.  After 24 hours, the gels were 
removed from the inserts, reweighed and photographed to document any 
observations indicative of the formulation becoming de-stabilised. 
 
3.4.5 Optimisation of in vitro receiver phase - study II 
The experiment described in section 3.4.4 was repeated with the components of the 
PBS solution separated out and each made as a receiver phase solution, as seen in 
Table 3.2.  PBS and deionised water were used as positive and negative controls, 
respectively.  A photograph of each hydrogel sample was taken after 24 hours to 
document any visual observations indicative of the formulation becoming de-
stabilised. 
 
Table 3.2 Composition of receiver phases used in section 3.4.5 
 
Chemical name Concentration (mM) 
Sodium chloride 137 
Sodium chloride 154 
Potassium chloride 2 
di-sodium hydrogen phosphate 8 
Potassium di-hydrogen phosphate 1 
PBS – 




3.4.5.1 Optimisation of in vitro receiver phase, study III 
The experiment described in section 3.4.4 was repeated again, with the receiver 
phase kept constant (sodium chloride solution 154 mM).  A range of PVA borate 
hydrogels (PVA 6.0 % w/w) borate (2.0 % w/w) were formulated as described in 
section 2.4.1 with the addition of varying concentrations of D-mannitol (0.5, 1.0, 1.5, 
2.0 % w/w), which were added to the borate solution in the formulation process.  
After 24 hours, photographs were taking to document any observations indicative of 
the formulation becoming unstable. 
 
3.4.6 In vitro release studies 
Protein release studies were carried out using Franz diffusion cells (Perme-Gear cells 
& Systems, USA) and a Techne TE 10D Tempette® water bath & Pump (Bibby 
scientific Ltd. Staffordshire, UK), as seen in Figure 3.1.  All release studies were 
carried out at 37 °C using poly(carbonate) membranes cut to size (pore size 8.0 µm, 
Sigma Aldrich).  A sample (1.00 g) of protein-loaded hydrogel (PVA 6.0 % w/w, 
borate 2.0 % w/w) was placed in each of the donor chambers at time zero.  Samples 
(0.5 mL) were withdrawn at specified time intervals (0–8 hours) and replaced with 
0.5 mL of fresh receiver phase.  A blank PVA-borate hydrogel of the same 





Figure 3.1 a) Shows a schematic diagram of a single Franz diffusion cell setup.  b) A photograph of 
the actual Franz diffusion cell apparatus used in the laboratory for all the in vitro release studies.  
Parafilm can be seen placed over the end of the sampling port and the top of the donor chamber to 
prevent any evaporation. 
 
3.4.7 Detection and quantification of BSA, Hb and trypsin 
Samples were analysed for the presence of BSA and trypsin, and quantified, using a 
bicinchoninic acid (BCA) assay.  A calibration plot was produced using nine 
dilutions (20–2000 μg mL-1) from a stock solution (2 mg mL-1) of each protein.  
Samples (25 μL) of each dilution and samples from the in vitro release study were 
pipetted into a 96-well plate.  To each of these wells, 200 μL of BCA assay working 
reagent was added to obtain a sample to working reagent ratio of 1:8.  The 96-well 
plate was then placed on an orbital shaking incubator at 37 °C at 100 rpm for 30 
minutes.  The plate was then removed and allowed to cool to room temperature prior 
to the absorbance of each well being measured at 562 nm using a FLUOstar® Omega 
microplate reader, (BMG LABTECH Ltd. Ortenburg, Germany).  
Samples were analysed for the presence of haemoglobin using UV-Vis 
spectrometry.  Haemoglobin was found to have a λmax of 405 nm.  A calibration plot 
was produced using nine dilutions (0.00–0.16 mg mL-1) from a 0.50 mg mL-1 stock 




and rinsed with deionised water between each sample.  Three replicates were 
performed for each calibration plot dilution and each time point sample (n=3). 
 
3.4.8 Sodium dodecyl sulphate poly(acrylamide) gel electrophoresis 
Sodium dodecyl sulphate gel electrophoresis (SDS-PAGE) was carried out using an 
XCell SureLock™ Mini-Cell electrophoresis system (Invitrogen, Life Technologies 
Ltd, Paisley, UK).  Samples (20 µl) from the in vitro release study and protein 
standards dissolved in deionised water, were prepared under reducing conditions in 
laemmli buffer and loaded onto a Bis-Tris NuPAGE® 4–12 % resolving gel.  
Electrophoresis was run using NuPAGE® MOPS SDS running buffer (x1), in 
constant voltage mode (200 V) and a varied current of 100–125 mA and 60–80 mA 
during stacking and running, respectively.  After the electrophoresis had finished, the 
gel was removed from the cassette and placed in coomassie brilliant blue R-250 stain 
for 60 minutes on an orbital shaker (45 rpm), at room temperature.  The coomassie 
blue stain was removed and the gel was rinsed twice with deionised water for 5 
minutes each time.  The gel was then placed in de-staining solution, consisting of 
methanol, acetic acid and deionised water at the ratio of 50:10:40 % v/v for 30 
minutes on an orbital shaker (45 rpm) for 30 minutes, at room temperature.  After 30 
minutes, the de-staining solution was diluted to methanol 12.5 %, acetic acid 2.5 % 
using deionised water.  The gel was then left overnight on the orbital shaker at room 
temperature, after which it was imaged.  
 
 Results 
The experiment as stated in section 3.4.1 was completed to determine how long it 
would take a substance to reach a state of homogeneity throughout a completely 
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gelled hydrogel network.  After 72 hours, it was found that injecting Victoria blue 
dye into the centre of the gel was ineffective at achieving homogeneity of the dye 
throughout the gel. However, in comparison, the gel that had the dye physically and 
mechanically mixed in using a stainless steel spatula had achieved a homogenous 
mix of dye throughout the gel, within the same time period, as seen in Figure 3.2.  
 
Figure 3.2 Photographs showing the diffusion of Victoria blue dye through two hydrogel samples 
(PVA 6.0 % w/w borate 2.0 % w/w) over a 72-hour period at room temperature.  A) dye injected into 
hydrogel and B) dye mixed in physically using a spatula. 
 
On further investigation using UV-Vis spectrometry, it was quantitatively 
confirmed that there was a homogenous mix of dye throughout hydrogel sample B 








deemed that there was no significant difference in the absorbance values between the 
four samples taken from hydrogel B, as seen in Table 3.3.  It was concluded that this 
would be a suitable non-destructible method to use to achieve homogenous loading 
of proteins and peptides into the PVA-borate hydrogels.  
 
Table 3.3 Absorbance values for four random samples of hydrogel containing Victoria blue dye 




(Mean ± SD) 
Student’s t-test 
(P value ) 
1 0.3027 ± 0.0028 – 
2 0.3023 ± 0.0017 0.8421 
3 0.3015 ± 0.0002 0.5001 
4 0.3030 ± 0.0007 0.8659 
Blank gel (no dye) 0.0028 ± 0.0004 <0.0001 
P value > 0.05 = no significant difference, p < 0.001 = highly significant difference 
 
Upon addition of BSA and trypsin into the hydrogel formulation, the gels 
remained clear and homogenous in appearance with no air bubbles present.  
However, the haemoglobin hydrogels were a translucent brown colour once fully re-
congealed.  To aid protein stability hydrogels where stored in the fridge (2–8 °C). 
 Each protein-loaded hydrogel was subject to an oscillating rheometry 
frequency sweep test.  This was to determine what effect the concentration and 
molecular weight of the protein had on the viscoelastic properties of the hydrogel.  It 
can be seen from Figure 3.3 that upon incorporation of all three concentrations of 
BSA (0.05, 0.10 and 0.20 % w/w) into the hydrogel, there was a decrease in the 
crossover modulus compared to the blank hydrogel, containing no BSA.  The 0.10 % 
w/w BSA concentration showed a significant (p < 0.05) difference from the blank 
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hydrogel.  However, the 0.05 and 0.20 % w/w crossover modulus showed no 
significant change from the blank hydrogel (p>0.05).  The 0.05 % w/w had the 
lowest crossover modulus (2571 ± 426 Pa) of the three BSA concentrations followed 
by the 0.10 % w/w (2638 ± 175 Pa) in comparison to the blank hydrogel, which had 
a crossover modulus of 3384 ± 425 Pa. 
Graph showing the effect of increasing BSA concentration on the
 crossover modulus of a PVA 6 .0 % w/w borate 2.0 % w/w hydrogel























Figure 3.3 Graph showing the effect of incorporating three concentrations of BSA into a PVA (6.0 % 
w/w) borate (2.0 % w/w) hydrogel has on the crossover modulus, compared to a blank hydrogel, of 
the same formulation.  Data shown as the mean ± standard deviation (n=3).  All measurements carried 
out at 25°C ± 0.2°C. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
On incorporating three concentrations of trypsin (0.05, 0.10 and 0.20 % w/w) into the 
hydrogel all three concentrations caused a decreases in the crossover modulus, 
compared to the blank hydrogel.  The 0.05 % concentration showed the largest 
reduction in crossover modulus in comparison to the blank hydrogel, from 3100 ± 70 
Pa to 2517 ± 62 Pa, respectively.  A similar overall general trend can be seen for 
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trypsin and BSA in Figure 3.4 and Figure 3.3, respectively.  It can be seen from 
Figure 3.4 that as the concentration of trypsin increased the reduction of the 
crossover modulus became less significant.  Trypsin 0.20 % w/w showed the least 
significant reduction (p<0.05) of the three concentrations, when compared to the 0.05 
(p<0.001) and 0.10 % w/w gels (p<0.01). 
Graph showing the effect of increasing trypsin concentration on the
crossover modulus of a PVA 6.0 % w/w borate 2.0 % w/w hydrogel























Figure 3.4 Graph showing the effect of incorporating three concentrations of trypsin into a PVA (6 % 
w/w) borate (2.0 %) w/w hydrogel has on the crossover modulus, compared to a blank hydrogel, of 
the same formulation.  Data shown as the mean ± standard deviation (n=3).  All measurements carried 
out at 25°C ± 0.2°C. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
Conversely, haemoglobin had the opposite effect on the crossover modulus 
compared to BSA and trypsin.  Upon addition of 0.05 % w/w haemoglobin the 
crossover modulus for the blank hydrogel increased from 2990 ± 49 Pa to 3431 ± 
354 Pa.  However, on statistical analysis of the data this increase was not statistically 
significant (p = 0.0995).  Increasing the haemoglobin concentration further to 0.10 % 
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w/w caused the crossover modulus to increase to 3569 ± 150 Pa, which was a 
statistically significant (p < 0.01), when compared to the blank hydrogel.  The 0.20 
% w/w haemoglobin concentration gave the largest crossover modulus (3871 ± 6 Pa), 
which was a highly significant (p < 0.001) increase from the crossover modulus of 
the blank hydrogel.  Therefore, as the concentration of haemoglobin in the hydrogel 
increased, the crossover modulus also increased, as seen in Figure 3.5.  All three 
concentrations caused an increase in the crossover modulus compared to the blank 
gel, but only the 0.10 and 0.20 % w/w hydrogels were statistically significant. 
Graph showing the effect of increasing haemoglobin concentration on
the crossover modulus of a PVA 6.0 % w/w borate 2.0 % w/w hydrogel

























Figure 3.5 Graph showing the effect of incorporating three concentrations of haemoglobin into a PVA 
(6.0 % w/w) borate (2.0 % w/w) hydrogel has on the crossover modulus, compared to a blank 
hydrogel, of the same formulation.  Data shown as the mean ± standard deviation (n=3).  All 
measurements carried out at 25°C ± 0.2°C. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
Before commencing release studies using the Franz diffusion cell apparatus, a short 
investigation was conducted to determine an appropriate receiver phase.  After 24 
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hours in contact with the two receiver phases, deionised water and phosphate buffer 
saline (PBS), the hydrogel samples that were in contact with PBS receiver phase 
showed formation of a hard, white, dense layer, as seen in Figure 3.6.  In 
comparison, the hydrogel samples that were in contact with deionised water showed 
no formation of this dense white layer.  
 
 
Figure 3.6 A representative photograph of two samples (2.00 g) of PVA (6.0 % w/w) borate (2.0 % 
w/w) hydrogel in 12-well hanging cell culture inserts after 24 hours in contact with two different 
receiver phases, at room temperature.  A1 and A2 show a sample that was in contact with a PBS 
receiver phase.  B1 and B2 show a sample that was in contact with a deionised water receiver phase.  
Both samples had pictures taken side-on (A2 and B2) and from the bottom of the insert (A1 and B1). 
 
After 24 hours, each sample was reweighed.  It was found that the hydrogel samples 
that were in contact with the PBS receiver phase had lost an average weight of 0.18 ± 
0.06 g.  In comparison, the hydrogel samples that were exposed to the deionised 
water had lost 1.62 ± 0.07 g.  As seen in Table 3.4, the deionised water had caused an 







phase.  This would suggest that the white layer that forms in the gel when in contact 
with PBS is less permeable than the normal hydrogel matrix.  A visual representation 
of weight loss of the samples exposed to deionised water and PBS can be seen in the 
Figure 3.7. 
 
Table 3.4. Average weight loss of hydrogel samples exposed to two different receiver phases 
 
Weight Mean ± SD (g) PBS Deionised water 
Initial 2.00 ± 0.00 2.00 ± 0.00 
Final 1.82 ± 0.06 0.33 ± 0.07 
Weight Loss 0.18 ± 0.06 1.62 ± 0.07 
Percentage weight loss (%) 9.00 81.00 
 
 
Figure 3.7 Representative photographs showing hydrogel samples removed from the 12-well hanging 
culture insert after 24 hours in contact with two different receiver phases, at room temperature.  
Photograph A is the hydrogel sample exposed to PBS in which the white layer can be seen at the 
bottom of the hydrogel.  Photograph B is the hydrogel sample exposed to deionised water and the 
extent of reduction in the mass of the sample can be clearly seen in comparison to the sample in photo 
A. 
 
To determine if it was a specific component of the PBS buffer that was causing the 





made in separate solutions.  Samples of hydrogel were then exposed each of solution, 
as detailed in section 3.4.5.  It can be seen from Figure 3.8 that a 154 mM (sodium 
chloride) NaCl solution caused the formation of the dense white layer, more so than 
the PBS.  It can also be noted that the 137 mM NaCl concentration did not cause the 
formation of the white layer.  This suggests that the white layer formation may be 
dependent on the concentration of NaCl.  On further investigation it was found that 
both the concentration and volume of the salt solution played a crucial role in the 
formation of the white layer.  All the other components of the PBS tablet did not 
cause the white layer to form, as seen in Figure 3.8.  
 
Figure 3.8 A representative photograph showing several hydrogel samples that have been in contact 
with several different receiver solutions for 24 hours at room temperature.  A) deionised water, B) 
PBS, C) NaCl 137 mM, D) NaCl 154 mM, E) KCl 2 mM, F) Na2HPO4 8 mM, G) KH2PO4 1 mM. 
 
Loughlin et al. (2008) found that upon addition of D-mannitol to the hydrogel 
formulation it prevented the precipitation of lidocaine hydrochloride from the PVA-
borate hydrogel system.  They also saw that upon precipitation of the lidocaine, the 
hydrogel became dense, rigid and white, similar to what the findings are when the 
hydrogel was in contact with the PBS and NaCl.  Therefore, the experiment outlined 
in section 3.4.5.1 was carried out to identify if the de-mixing caused by the salts 
could be counteracted by addition of D-mannitol to the formulation.  Four 
concentrations of D-mannitol were incorporated into the formulation of a PVA 6.0 % 
w/w borate 2.0 % w/w hydrogel.  The changes in viscoelastic properties of the 
hydrogels on the addition of the D-mannitol were determined using oscillatory 
B A E D F C G 
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rheometry.  On adding 0.5 % w/w D-mannitol to the hydrogel, the crossover 
modulus decreased from 6411 ± 59 Pa to 4951 ± 106 Pa, which is a statistically 
significant difference, as seen in Figure 3.9.  On increasing the concentration of D-
mannitol further until a maximum concentration of 2.0 % w/w the crossover modulus 
continued to decrease to a minimum value of 1487 ± 32 Pa. 
 
Graph showing the effect D-mannitol has on the crossover modulus of a
PVA 6.0 % w/w borate 2.0 % w/w hydrogel






















Figure 3.9 Graph showing the effect several concentrations of D-mannitol has on the crossover 
modulus of a PVA 6.0 % w/w borate 2.0% w/w hydrogel.  Data shown as the mean ± standard 
deviation (n=3).  All measurements carried out at 25°C ± 0.2°C. p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***). 
 
Addition of D-mannitol to the hydrogel formulation also caused a decrease in the 
yield stress.  D-mannitol 0.5 % w/w caused a statistically significant decrease 
(p<0.001) to 25.03 ± 0.11 Pa from 38.27 ± 0.2 Pa, recorded for the hydrogel 
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containing no D-mannitol.  On increasing the concentration of D-mannitol the yield 
stress continued to decrease, as seen in Figure 3.10.  This is the same trend that was 
observed for the crossover modulus.  The 2.0 % w/w D-mannitol formulation had the 
lowest yield stress of 1.76 ± 0.45 Pa.  It can be seen from Figure 3.11 that addition of 
D-mannitol prevented the formation of the white de-mixed layer in the hydrogel at 
all concentrations.  
Graph showing the effect D-mannitol has on the yield stress of a PVA 6.0 % w/w
borate 2.0 % w/w hydrogel























Figure 3.10 Graph showing the effect several concentrations of D-mannitol has on the yield stress of a 
PVA 6.0 % w/w borate 2.0% w/w hydrogel.  Data shown as the mean ± standard deviation (n=3).  All 





Figure 3.11 A representative photograph showing how D-mannitol incorporated into a PVA (6.0 % 
w/w) borate (2.0 % w/w) hydrogel prevented the formation of a white layer when in contact with PBS 
solution for 24 hours at room temperature. D-mannitol concentrations A) 0.0, B) 0.5, C) 1.0, D) 1.5 
and E) 2.0 % w/w. 
 
To observe how the dense white layer formation affected the release of proteins from 
the hydrogel, a release experiment was carried out using PBS and deionised water 
receiver phases.  It was found that after 8 hours, there was 51 % less BSA released 
from the hydrogel, which was in contact with the PBS, compared to the hydrogel in 
contact with the deionised water.  After 8 hours, 47.03 ± 2.33 % of the BSA was 
released from the hydrogel into the PBS receiver phase.  In comparison, 98.75 ± 2.58 
% of the loaded BSA was released from the hydrogel into the deionised water 
receiver phase, as seen in Figure 3.12. 
A B D E C 
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Percentage cumulative release profile of BSA from a PVA borate hydrogel
into two different receiver phases



































Figure 3.12 A percentage cumulative release profiles for BSA-loaded PVA (6.0 % w/w) borate (2.0 % 
w/w) hydrogel over 8 hours into two different receiver phases, PBS and deionized water.  Release 
studies were carried out at 37 °C, using poly(carbonate) membranes with a pore size 8.0 µm on Franz 
diffusion cells.  Data shown as the mean ± SD (n=3). 
 
Protein release studies were carried out using a Franz diffusion cell apparatus.  
Deionised water was used as the receiver phase to avoid any complications with de-
mixing even though it was found to be inhibited by addition of D-mannitol.
 Figure 3.13 shows a typical BCA assay calibration plot that was used to 
determine the BSA concentration in each sample taken from the receiver phase.  A 
calibration plot was performed on each micro-plate of samples to account for day–to-
day and plate-to-plate optical variability.  As the r2 value is 0.99 it can be said that 






BSA BCA Assay calibration plot







y = 0.0011x + 0.06
r2=0.99
BSA concentration (g mL -1)
Absorbance
(a.u.)
Figure 3.13 BCA assay calibration plot produced using several dilutions of a BSA stock solution 2 mg 
mL-1.  BSA standard dilutions concentration range 20–2000 µg mL-1.  The λ = 562 nm and data are 
shown as the mean ± standard deviation (n=3). 
 
Figure 3.14 shows three concentration of BSA released from a hydrogel (PVA 6.0 % 
w/w borate 2.0 % w/w), over an 8-hour period.  It can be seen that the 0.10 % w/w 
concentration gave the highest percentage cumulative release at all time points over 
the 8 hours, compared to the 0.20 and 0.05 % w/w hydrogels.  The 0.05 % w/w 
concentration gave the lowest release up until 5 hours, with hour 8 giving a higher 
percentage cumulative release (52.22 ± 2.02 %) than that of the 0.10 % w/w BSA 
concentration.  The 0.10 % w/w loaded hydrogel had released 58.34 ± 1.17 % after 8 
hours.  At hour 6, the 0.05 and 0.10 % w/w had similar percentage cumulative 
release values of 45.98 ± 2.72 % and 45.82 ± 2.87 %, respectively.  Likewise at hour 
7, the 0.05 and 0.10 % BSA hydrogels again had the same percentage cumulative 
release values of 49.52 ± 3.88 % and 49.81 ± 2.96 %, respectively.  The BSA 0.20 % 
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w/w loaded hydrogel released the least amount of BSA (50.24 ± 2.60 %) at 8 hours 
compared to the two lower concentrations.  One general trend displayed by all three 
BSA-loaded hydrogel release profiles was, as time increased the quantity of BSA 
released increased.  All three release profiles began to plateau at approximately 6 
hours. 
Percentage cumulative release profiles of BSA from a PVA borate hydrogels































Figure 3.14 Percentage cumulative release profiles for three BSA-loaded PVA (6.0 % w/w) borate 
(2.0 % w/w) hydrogels of varying BSA concentration, over 8 hours.  Release studies were carried out 
at 37 °C using poly(carbonate) membranes with a pore size 8.0 µm, on Franz diffusion cells.  The data 
are shown as the mean ± standard deviation (n=3). 
 
A haemoglobin calibration plot was produced using nine dilutions (0.00–0.16 mg 
mL-1) of a 0.50 mg mL-1 stock solution dissolved in deionised water, as seen in 
Figure 3.15.  Each dilution was then analysed using UV-Vis spectrometry at a λ max 
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of 405 nm.  A calibration plot was carried out on each plate of samples to account for 
day–to-day and plate-to-plate optical variability.  As seen in Figure 3.15, the r2 value 
is 0.99.  Therefore, it can be said that the data are correlated and confidence can be 
had in calculated values using the line equation. 
Haemoglobin calibration plot
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Figure 3.15 A UV-Vis haemoglobin calibration plot produced using nine dilutions of a bovine 
haemoglobin stock solution (0.50 mg mL-1).  The nine standard dilutions were within the 
concentration range 0.00–0.16 mg mL-1.  The λ = 405 nm and the data are shown as the mean ± 
standard deviation (n=3). 
 
Figure 3.16 shows three percentage cumulative release profiles for hydrogels of the 
same formulation (PVA 6.0 % w/w borate 2.0 % w/w) loaded with varying 
concentrations of haemoglobin.  The 0.10 % w/w concentration of haemoglobin had 
the highest percentage release at all time points, except for the first time point (1 
hour).  The 0.10 % w/w haemoglobin hydrogel yielded the largest overall percentage 
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cumulative release (50.62 ± 1.52 %) at 8 hours, compared to the other two higher 
concentrations of haemoglobin.  At 1 hour, the 0.05 % w/w haemoglobin gel gave 
the highest percentage release of 16.27 ± 0.61 %, but, at 8 hours it had released the 
least amount of haemoglobin (34.10 ± 3.02 %), in comparison to the other two 
concentrations.  From zero to four hours, the 0.20 % w/w hydrogel gave the lowest 
percentage release of haemoglobin.  However, from 4 to 8 hours it gave a higher 
percentage release of haemoglobin than the 0.05 % w/w loaded gel.  Interestingly, as 
observed in Figure 3.14, for BSA the middle concentration (0.10 % w/w) gave the 
highest percentage release.  A general trend that is displayed by the three release 
profiles is as time increases the percentage of haemoglobin released also increases.  
Only the 0.05 and 0.20 % w/w profiles show signs of plateauing at approximately 6 
and 7 hours, receptively.  However, as seen Figure 3.16, it is feasible that the 0.10 % 
w/w release profile would plateau at approximately 60 % release had the experiment 
been permitted to run for a longer duration. 
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Percentage cumulative release profiles of haemoglobin loaded PVA borate hydrogels





























Figure 3.16 Percentage cumulative release profiles for three haemoglobin-loaded PVA (6.0 % w/w) 
borate (2.0 % w/w) hydrogels of varying haemoglobin concentration, over 8 hours.  Release studies 
were carried out at 37 °C using poly(carbonate) membranes with a pore size 8.0 µm, on Franz 
diffusion cells.  The data are shown as the mean ± standard deviation (n=3). 
 
A typical BCA assay calibration plot for trypsin can be seen in Figure 3.17.  The line 
equation of this plot was used to determine the trypsin concentration in each sample 
from the release study.  A calibration plot was carried out on each plate of samples to 
account for day–to-day and plate-to-plate optical variability.  As the r2 value is 0.99, 
therefore, it can be said that the data are correlated and confidence can be had in 




Trypsin BCA assay calibration plot







y = 0.0004x + 0.0002













Figure 3.17 BCA assay calibration curve produced using several dilutions of a trypsin stock solution 2 
mg mL-1.  The standard dilutions concentration range 20–2000 µg mL-1.  The λ = 562 nm and the data 
are shown as mean ± standard deviation (n=3). 
 
One observation from comparing the trypsin calibration plot to the haemoglobin and 
BSA calibration plots, is that the absorbance values for the trypsin standards are 
lower than those for BSA and haemoglobin of the same concentration.  This would 
suggest that the BCA assay may be less sensitive towards trypsin compared to BSA 
and haemoglobin.  
 The percentage cumulative release profiles for the three concentrations of 
trypsin-loaded into the PVA-borate hydrogels can be seen in Figures 3.18, 3.19 and 
3.20.  The hydrogel loaded with 0.05 % w/w trypsin gave the lowest percentage 
cumulative release (31.24 ± 11.92 %) at 8 hours, as seen in Figure 3.18.  The 0.05 % 
w/w loaded hydrogel released no detectable quantities of trypsin until the fourth 
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hour.  The release profile in general is erratic with large deviations in the mean 
values obtain for the 4 to 8 hour time points.   
Percentage cumulative release profile of trypsin from a PVA-borate hydrogel




























Figure 3.18 Percentage cumulative release profile for a PVA (6.0 % w/w) borate (2.0 % w/w) 
hydrogel loaded with 0.05 % w/w trypsin.  Release studies were carried out at 37 °C for 8 hours using 
poly(carbonate) membranes with a pore size 8.0 µm, on Franz diffusion cells.  The data shown as the 
mean ± standard deviation (n=3). 
 
The release profile for the 0.10 % w/w trypsin-loaded hydrogel can be seen in Figure 
3.19.  The maximum percentage cumulative release was found to be 51.14 ± 16.73 % 
at 8 hours.  Similar to the 0.05 % w/w loaded hydrogel the 0.10 % w/w trypsin-
loaded gel did not release any detectable quantities of trypsin until the fourth hour, at 
which point it had released 24.60 ± 3.15 %.  Again, this hydrogel showed erratic 
release of trypsin with large deviations in the mean values obtained for time points 5 




Percentage cumulative release profile of trypsin from a PVA borate hydrogel































Figure 3.19 Percentage cumulative release profile for a PVA (6.0 % w/w) borate (2.0 % w/w) 
hydrogel loaded with 0.10 % w/w trypsin.  Release studies were carried out at 37 °C for 8 hours using 
poly(carbonate) membranes with a pore size 8.0 µm, on Franz diffusion cells.  The data shown as the 
mean ± standard deviation (n=3). 
 
The 0.20 % w/w trypsin-loaded hydrogel gave the highest percentage cumulative 
release of trypsin at 8 hours (80.32 ± 18.37 %), as seen in Figure 3.20.  The 0.20 % 
w/w trypsin gel gave a more typical release profile shape, similar to the BSA and 
haemoglobin.  However, the standard deviation of the mean values were again large 
in comparison to those for BSA and haemoglobin.  Unlike the 0.05 and 0.10 % w/w 
trypsin-loaded hydrogels, the 0.20 % w/w hydrogel did release detectable quantities 
of trypsin before the fourth hour.  But, there was still no instant release seen, as the 
first detectable quantity of trypsin was at hour 2, as seen in Figure 3.20. 
 The 0.05 and 0.10 % w/w trypsin-loaded hydrogels did not show release 
profiles indicative of sustained release, in comparison to the release profiles for 
haemoglobin and BSA, as seen in Figures 3.14 and 3.16, respectively.  Also all the 
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mean percentage cumulative release values for all three trypsin concentrations 
showed large variation in the mean values, compared to the BSA and haemoglobin 
mean values. 
 
Percentage cumulative release profile of trypsin from a PVA borate hydrogel




























Figure 3.20 Percentage cumulative release profile for a PVA (6.0 % w/w) borate (2.0 % w/w) 
hydrogel loaded with 0.20 % w/w trypsin.  Release studies were carried out at 37 °C for 8 hours using 
poly(carbonate) membranes with a pore size 8.0 µm, on Franz diffusion cells.  The data shown as the 
mean ± standard deviation (n=3). 
 
Figure 3.21 shows the resultant SDS-PAGE gel for the molecular weight checks on 
the released haemoglobin, BSA and trypsin, compared to a standard of each protein.  
It can be seen from lanes 3 and 4 that the BSA released from the hydrogel was not 
subject to any degradation when compared to the standard BSA sample.  The BSA 
was also in proximity to the 62 kDa molecular marker, which in the SeeBlue® Plus2 
Prestained standard Novex® solution is BSA.  The haemoglobin did show 
degradation, however, it was degraded prior to being added to the hydrogel, as seen 
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in lane 6 of Figure 3.21.  Haemoglobin has a molecular weight of approximately 64 
kDa, however, it can be seen from lanes 6 that the haemoglobin had been degraded 
prior to being loaded into the hydrogel.  In lane 7, it can be seen that the hydrogel 
released haemoglobin without any sign of further degradation.  Lanes 9 and 10 show 
the trypsin standard and trypsin sample from the release study, respectively.  It can 
be seen that the trypsin released from the hydrogel was not subject to any further 
degradation upon release, than what had already occurred prior to incorporation 
within the hydrogel.  But, similarly to the haemoglobin it can be seen from lane 9 
that the trypsin standard had degraded prior to being added to the hydrogel.  The 
trypsin is in the proximity to the 14 kDa molecular marker and trypsin has a 
molecular weight of 23.3 kDa. 
 
  
Figure 3.21 Image of the SDS-PAGE NuPAGE® Bis–Tris 4-12 % resolving gel (1.0 mm x 10 well), 
stained with coomassie blue for the three proteins released from a hydrogel (PVA 6.0 %w/w Borate 
2.0 % w/w) and their standards.  Lane 1 molecular markers, lane 3 BSA standard, lane 4 BSA sample, 
lane 6 Hb standard, lane 7 Hb sample, lane 9 trypsin standard, lane 10 trypsin sample.  Lanes 2, 5 and 
8 were intentionally left blank.  














PVA-borate hydrogels have been extensively studied as potential drug delivery 
systems for wound management.  However, delivering a protein or peptide for 
wound management and repair using the PVA-borate hydrogel is a novel application.  
Therefore, no published literature is available to indicate if the PVA-borate hydrogel 
system is capable of delivering a therapeutic protein or peptide, which is still intact 
and biologically active.  With this in mind, it was deemed not financially viable to 
commence the work using the intended insulin-like growth factor-1 (IGF-1), but, 
instead use three model proteins first.  Therefore, in this chapter, a PVA 6.0 % w/w 
borate 2.0 % w/w hydrogel was used to deliver three model proteins of varying 
isoelectric points and molecular weights, summarised in Table 3.5, to determine the 
percentage release and stability.  
 
Table 3.5 Summary of model proteins properties 
 




Net charge in 
hydrogel 
Bovine serum albumin 66.0 4.2–5.4 Negative 
Bovine haemoglobin 64.5 6.8 Negative 
Trypsin 23.3 10.1–10.5 Positive 
 
 Lidocaine hydrochloride (Loughlin et al., 2008), methylene blue and meso-
tetra (N-methyl-4-pyridyl) porphine tetra tosylate (Donnelly et al., 2009) were all 
previously incorporated into the PVA-borate hydrogel system using a similar 
formulation process to that used in section 2.4.1 of this thesis.  However, these drugs 
remained stable on heating to 80 °C during the manufacturing process and it is 
known that proteins and peptides undergo degradation upon heating.  To prevent 
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denaturation of plasma proteins during a cardiopulmonary bypass the maximum 
temperature of the heat exchanger is maintained between 40–42 °C (Vazquez & 
Larson, 2013).  It was found that on increasing the temperature of the heat exchanger 
to between 43–45 °C degradation of the plasma proteins had begun, detected using 
SDS-PAGE (Vazquez & Larson, 2013).  Therefore, a new method for incorporating 
proteins and peptides into the PVA-borate hydrogel needed to be ascertained.  
Gehrke et al. (1998) formulated dextran-divinylsulfone cross-linked hydrogels for 
delivery of proteins.  They loaded both model proteins, ovalbumin and α-amylase, by 
soaking samples of the hydrogel in excess buffer solutions containing the dissolved 
proteins (Gehrke et al., 1998).  They concluded that the loading process involved 
both adsorption and absorption, known collectively as sorption.  Similarly, Jensen et 
al. (2001) loaded four model peptides into chondroitin 4-sulphate hydrogels using 
the same equilibrium swelling technique to avoid heating the proteins to 60 °C 
during the formulation process.  However, Jensen et al. (2001) found that the three 
positively charged model proteins were concentrated in the gel system, but, the 
negatively charged bovine serum albumin (BSA) was not.  They concluded that the 
positively charged proteins were involved in ionic interactions with the negative 
charged polymer backbone in the hydrogel, thus giving higher loading 
concentrations.  In comparison, the repulsion between the negatively charged BSA 
and the negative charges of the polymers, hindered the loading.  They suggest that 
BSA was loaded passively, by diffusing in the water phase of the gel, thus giving a 
lower loaded concentration in comparison to the other two proteins. 
It was decided for the purpose of this work that the most cost effective way to 
incorporate the model proteins was to add the desired volume of protein solution to 
the desired quantity of pre-made hydrogel and mix it in by hand, using a stainless 
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steel spatula, at room temperature.  On physically cutting up the hydrogel with the 
spatula, it created a larger surface area for uptake of the protein solution.  The 
hydrogel then self-healed upon resting at room temperature, providing a hydrogel 
with a homogenous mix of protein throughout its matrix.  One advantage of carrying 
out the loading process using this method was it kept protein wastage to a minimum, 
which will be extremely important in later work when loading the expensive 
bioactive growth factor.  Second, using the swelling equilibrium method showed 
poor uptake of opposite charged proteins, which required up to two weeks to achieve 
an acceptable amount of protein in the hydrogel (Jensen et al., 2002).  Whereas, the 
process used in this thesis resulted in loaded hydrogels ready to use within 12–24 
hours.  Appel et al. (2012) found that mixing solutions of BSA and lysozyme into 
preformed modified PVA hydroxyethyl cellulose hydrogel resulted in homogenously 
loaded gels. 
 BSA has been widely used as a model protein for novel delivery system 
release studies due to its high stability (Shalaby et al., 1993; Mellott et al., 2001; 
Khoury et al., 2003; Balasubramanian et al., 2010).  On loading three concentrations 
of BSA into the PVA-borate hydrogel, crossover moduli analysis was carried out 
using oscillating rheology.  This was used to determine if addition of the BSA had 
caused any changes in the viscoelastic properties of the hydrogel.  BSA was found to 
decrease the crossover modulus of the hydrogel in comparison to a hydrogel of the 
same formulation containing no BSA.  BSA when solubilised in deionised water and 
incorporated into the PVA-borate hydrogel system has an overall negative charge, 
due to having an isoelectric point in the range of 4.2–5.4 (Shalaby et al., 1993; 
Jensen et al., 2002; Khoury et al., 2003).  Jensen et al. (2002) observed what was 
thought to be repulsion between the negatively charged BSA and the negative 
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charged regions on the polymers, which hindered the loading.  A similar electrostatic 
repulsion may be occurring in the PVA-borate hydrogel.  Loughlin et al. (2008) state 
that the mono-diol complex formed during the first step, in the two step cross-linking 
reaction between the PVA and borate is a negatively charged poly(electrolyte).  
Therefore, it may be possible that not all of the polymers fully cross-link forming the 
di-diol complex, leading to some negatively charged regions on the polymeric 
backbone.  Negatively charged regions could also result temporarily from the 
reversible nature of the PVA-borate cross-link.  If this were the case, then there is the 
possibility of repulsion between the BSA and the negatively charged regions on the 
polymers, similar to what Jensen et al. (2002) observed.  As a result, the cross-
linking density may be reduced as the negatively charged BSA would push the PVA 
poly(electrolytes) further apart, reducing the cross-linking density and polymer 
entanglement.  Hence, reducing the hydrogel viscosity and crossover modulus.  Lin 
et al. (2005) also stated that the Na+ cation produced from the dissociation of sodium 
tetraborate decahydrate plays a part in the overall shape of the polymer chains and 
cross-linking process due to a shielding effect on the poly(electrolyte).  The shielding 
effect reduces the repulsion between the poly(electrolytes), increasing the cross-
linking and polymer entanglement by causing the polymer chains to re-orientate to 
reside closer together and interact.  Therefore, another possible explanation for the 
reduction in the crossover modulus on addition of BSA may be due to the negatively 
charged BSA interacting with the Na+ cation, reducing its ability to provide the 
necessary shielding effect.  As a result, the repulsion between the polymers is 




 On adding trypsin to the hydrogel, the crossover modulus decreased in 
comparison to the blank hydrogel formulation.  This is similar to the trend seen for 
the BSA and indicates that the hydrogel viscosity and viscoelastic properties have 
been reduced.  Trypsin has an isoelectric point between 10.0–10.5 (Tietze, 1953; 
Walsh, 1970), therefore, as the PVA 6.0 % w/w borate 2.0 % w/w hydrogel is pH 8.0 
the trypsin will have an overall positive charge when in the hydrogel.  The trypsin is 
the opposite charge to the BSA when loaded in the hydrogel, yet, also causes a 
decrease in crossover modulus.  Therefore, the proposed theory of what is occurring 
due to electrostatic repulsion between the BSA and negative regions of the polymers 
cannot be the cause of the decrease in crossover modulus caused by trypsin.  One 
possible reason for the reduced crossover modulus could be explained by a different 
interaction.  The positively charged trypsin molecules may interact with the 
negatively charged borate anion, resulting in decreased cross-linking with the PVA.  
If this is the case, decreased cross-linking will cause a reduction in the crossover 
modulus and, therefore, a low viscosity gel with a weak elastic response at low 
frequencies (Murphy et al., 2012). 
 Incorporation of haemoglobin into the hydrogel caused an increase in the 
crossover modulus value, despite being negatively charged in the hydrogel 
environment.  The increase in crossover modulus indicates that the haemoglobin is 
causing an increase in the cross-linking density of the hydrogel matrix.  The exact 
mechanism of how it is causing this increase in the crossover modulus within the 
PVA-borate hydrogel is uncertain.  However, Patton et al. (2006) demonstrated that 
it was possible to cross-link bovine haemoglobin to a poly(acrylamide) hydrogel 
matrix.  It was concluded that the haemoglobin-poly(acrylamide) cross-link was the 
result of a covalent attachment between specific amino acids in the large tetrameric 
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haemoglobin structure and the poly(electrolytes) (Patton & Palmer, 2006).  
Therefore, the bovine haemoglobin in this study may also be partaking in a cross-link 
reaction with the PVA polymer.  If this is the case, it would result in a hydrogel 
matrix with an increased cross-linking density, thus explaining the increase in the 
crossover modulus.  
 Prior to commencing the release studies, an appropriate receiver phase was 
selected.  The first choice was phosphate buffer saline as it is commonly used in 
biological research due to the osmolarity and ion concentration being similar to that 
of human blood.  However, on running a trial release experiment it was observed that 
a white, opaque, dense looking layer formed at the surface of the hydrogel, which 
was in contact with the PBS receiver phase.  On further investigation, it was found 
that the PBS was the cause of this white layer forming and that both the 
concentration and volume of the salt solution played a crucial role in the formation of 
the white layer.  A similar occurrence was seen by Loughlin et al. (2008) on addition 
of lidocaine hydrochloride to the PVA-borate hydrogel.  On addition of high 
concentrations of the lidocaine hydrochloride (≥ 3.0 % w/w), they documented an 
ionic induced gel network collapse and drug precipitation.  The network collapse, or 
de-mixing, is caused by an increase in the free ion concentration within the hydrogel.  
On increasing the free ion concentration within the formulation, the repulsion 
between the poly(electrolyte) network decreases due to an increased shielding effect 
by the exogenous free ions.  This alteration in the sensitive balance between the 
repulsive force and shielding effect leads to over shielding, increasing in the PVA-
borate cross-linking density to an extent that causes phase separation and de-mixing 
(Pezron et al., 1988a; Loughlin et al., 2008).  When the hydrogel comes in contact 
with the PBS solution, it begins to absorb the PBS due to its ability to uptake fluid 
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and swell.  As the PBS is absorbed it reaches a threshold free ion concentration 
within the hydrogel causing the ionic induced de-mixing and increased cross-linking 
density.  Loughlin et al. (2008) reported that the de-mixing only occurred when the 
lidocaine hydrochloride concentration within the hydrogel was ≥ 3.0 % w/w.  
Likewise, in the experiment completed in this chapter, it was found that the 
formation of the de-mixed, dense white layer only formed when the total salt 
concentration was ≥ 154 mM.   
Loughlin et al. (2008) found that by adding D-mannitol to the PVA-borate-
lidocaine formulation, the de-mixing caused by the high concentrations of lidocaine 
hydrochloride no longer occurred.  D-mannitol is a polyol sugar, which acts as a 
scavenger molecule for the free borate ions within the formulation.  Complexation 
between two different poly-functionalised alcohol sugars, D-mannitol and D-sorbitol, 
with borate was studied using matrix-assisted laser desorption/ionization Fourier-
transform mass spectrometry (Penn et al., 1997).  Penn et al. (1997) found that both 
polyol sugars form monoester and diesters with the borate ions, with the diester 
formation more energetically favourable.  Similarly, Pezron et al. (1988b) found that 
addition of D-mannitol also prevented the de-mixing of a galactomannan-borate 
cross-linked formulation in the presence of a 1 M NaCl solution.  Galactomannans 
are polyhydroxy compounds similar to PVA (Pezron et al., 1988b).  In a similar 
manner, it was found in the study completed in this chapter, that addition of D-
mannitol prevented the formation of the white de-mixed layer when a hydrogel 
sample came in contact with the PBS receiver phase.  This is due to the D-mannitol 
complexing with the free borate ions, therefore, preventing them from causing an 
increase in cross-linking density. 
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It was found that on addition of D-mannitol to the PVA 6.0 % w/w borate 2.0 
% w/w formulation, the viscoelastic properties of the hydrogel changed.  These 
changes were observed by changes in the crossover modulus and yield stress 
analysis.  As the concentration of D-mannitol increased both the crossover modulus 
and the yield stress values decreased.  As the D-mannitol binds with the free borate 
ions, they are no longer available to partake in the cross-linking reaction, thus, 
reducing the cross-linking density of the hydrogel.  As a result of reduced cross-
linking, the hydrogel has a low viscosity and becomes more fluid like.  D-mannitol 
has a greater affinity for the borate ions than the PVA polymer.  Consequently, the 
D-mannitol competes with the PVA polymer for the borate ions and can remove 
borate from the PVA-borate interaction, also causing the hydrogel system to fluidise 
(Loughlin. et al., 2008).  D-mannitol can also sequester the borate bound to the PVA, 
which results in the diol complex not forming, resulting in a more fluid-like hydrogel 
system.  Both Loughlin et al. (2008) and Pezron et al. (1988b) found that on adding 
D-mannitol to their borate cross-linked polymers, their formulations became more 
fluid-like.  Despite showing that the de-mixing can be prevented by the incorporation 
of D-mannitol into the PVA-borate formulation, it was decided that deionised water 
would be used as the receiver phase.  The reason for this was to avoid adding another 
variable component to the hydrogel formulation, which was found to affect the 
viscoelastic properties and had the potential to interact with the loaded proteins. 
 Release studies were carried out on Franz diffusion cell apparatus at 37 °C to 
mimic body temperature.  Protein release from polymeric hydrogels is governed by 
the characteristics of both the hydrogel matrix and protein itself.  Both the BSA and 
haemoglobin-loaded hydrogels gave sustained release profiles over 8 hours, for all 
three concentrations.  As previously discussed, BSA caused a reduction in the 
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crossover modulus, leading to a more fluid-like hydrogel network.  The reduction in 
hydrogel viscosity provides greater relaxation of the polymers, which allows greater 
swelling on contact with the receiver phase.  The combination of these effects and 
the repulsion between the protein and the polymer could explain why the 0.10 % w/w 
BSA-loaded hydrogel gave the highest release (58.34 ± 1.17 %) of all the protein-
loaded gels studied.  Mellot et al. (2001) demonstrated a sustained released of BSA 
from cross-linked poly(ethylene glycol) diacrylate hydrogels, which they believed to 
be relaxation-controlled diffusive release.   
Haemoglobin, although negatively charged in the hydrogel environment, 
caused an increase in the crossover modulus.  The higher cross-over modulus is 
indicative of increased cross-linking, which reduces polymer relaxation and, 
therefore, reduces the swelling ability of the gel.  The reduction in polymer 
relaxation and swelling means that the pores within the polymer network are not as 
large, sterically hindering the release of the larger haemoglobin molecule (64.5 kDa) 
out of the gel network.  This may be the reason why the 0.10 % w/w haemoglobin 
loaded hydrogel achieved a lower cumulative percentage release of 50.62 ± 1.52 %, 
in comparison to the 0.10 % w/w BSA loaded gel.  Similarly, Khoury et al. (2003) 
found that by increasing the cross-linking density of multi-polymer cross-linked 
hydrogels, there was a sharp decline in the release of loaded proteins. 
 The 0.05 % and 0.10 % w/w trypsin-loaded hydrogels gave poor and erratic 
release of trypsin, with the mean values having large standard deviations.  Yet, the 
0.20 % w/w gel gave a release profile indicative of sustained release, however, the 
mean values also had large standard deviations.  As mentioned previously, the 
trypsin is positively charged in the PVA-borate hydrogel environment and could 
possibly be interacting with the borate anion.  There may also be interactions 
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between specific amino acid residues and specific regions of the polymer backbone.  
If opposite charge attraction or interaction are occurring, then this may explain why 
no trypsin release was detected for the first 4 hours from the 0.05 % and 0.10 % w/w 
hydrogels.  Also, with the concentration of trypsin loaded into these two hydrogels 
being low, all the trypsin may be involved in electrostatic or other bonding 
interactions.  This would then suggest that the initial diffusive-burst release from the 
water-filled pores of the hydrogel is not taking place.  Both Loughlin et al. (2008) 
and Haung & Brazel (2001) suggest that the initial burst release is brought about by 
migration of the loaded drug to the surface, leading to high surface concentrations.  
However, Khoury et al. (2003) stated that if the protein loaded in the hydrogel is of 
the opposite charge to the hydrogel itself, then the protein will be immobile in the 
hydrogel.  They demonstrated this theory by a diffusive study using lysozyme, which 
was positively charged, in a negatively charged poly(acrylic) acid hydrogel displayed 
no diffusion through the hydrogel matrix.  In comparison, BSA, which was 
negatively charged in the hydrogel, did diffuse through the gel.  Therefore, a 
combination of low trypsin concentration and low diffusivity could be responsible 
for the low erratic release of trypsin from these gels.  Once the concentration of 
trypsin in the hydrogel is increased (0.20 % w/w), there is excess trypsin available, 
which may not be irreversibly bound or hindered by electrostatic interaction.  
Therefore, this trypsin can freely diffuse through the hydrogel and be released 
immediately on contact with the receiver phase, as seen in other PVA hydrogel 
systems (Huang & Brazel, 2001; Loughlin et al., 2008) and with the BSA and 
haemoglobin in this study.  It was found in Chapter Two that prolonged exposure of 
the PVA-borate hydrogels to an aqueous solution caused it to swell until it reached 
appoint were the hydrogel matrix began to erode and disintegrate.  This could 
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explain the release of trypsin seen after four hours from the 0.05 % and 0.10 % gels, 
with the initial release up to hour four observed for the 0.20 % w/w trypsin hydrogel 
being by diffusion only.  This suggests that the mechanism of protein release from 
the PVA-borate hydrogels is anomalous (non-Fickian) transport, as it is a 
combination of both diffusion, polymer relaxation, erosion and degradation.  
Likewise, Loughlin et al. (2008) found that the PVA-borate hydrogels released 
lidocaine in an anomalous (non-Fickian) manner.  Preliminary work completed by 
Winder (2013), demonstrated that the PVA-borate hydrogels released sodium 
fusidate, mupirocin calcium and poly(hexamethylene) biguanide hydrochloride by 
the anomalous (non-Fickian) mechanism.  Polymeric hydrogel microspheres made 
from poly(acrylamide) grafted with guar gum and cross-linked with glutaraldehyde 
displayed Fickian release initially, but, on swelling displayed non-Fickian release, 
concluding that the drug released mechanism was anomalous (non-Fickian) 
(Soppirnath & Aminabhavi, 2002). 
 Sodium dodecyl sulphate poly(acrylamide) gel electrophoresis (SDS-PAGE) 
was used to check the molecular weight of the protein molecules released from the 
hydrogel, in comparison to standard samples of each protein and a protein molecular 
weight marker ladder.  It was found that none of three proteins undergone any 
degradation while within the PVA-borate of hydrogel matrix or upon release from 
the gel.  SDS-PAGE is a common standard technique for protein sizing, which is still 
widely used despite advances in protein analysing technologies (Goetz et al., 2004).  
SDS is an anionic detergent, which gives the protein to be sized an overall negative 
charge.  As the protein samples in question all have the same overall charge the 
proteins are separated solely by size when an electric field is applied across the 
poly(acrylamide) gel (Goetz et al., 2004).  The higher the molecular weight of the 
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protein the slower it migrates down the gel, with lower molecular weight proteins 
traveling much faster, resulting in size separation.  BSA released from the PVA-
borate hydrogel showed similar structural integrity to the BSA encapsulated and 
released from poly(D,L-lactide-co-glycolide) (PLGA) microspheres (Igartua et al., 
1998).  Using SDS-PAGE, Igartua et al. (1998) determined that BSA remained 




The work completed in this chapter has shown that the PVA-borate hydrogel is 
capable of delivering a sustained release of all three concentrations of BSA and 
haemoglobin over 8 hours at 37 °C.  The hydrogel also displayed partial release of 
trypsin from 0.05% and 0.10 % w/w loaded hydrogels, after 4 hours and release from 
a 0.20 % w/w trypsin-loaded gel over 8 hours at 37 °C.  However, the 
uncharacteristic release profiles for trypsin accompanied with large standard 
deviations of the mean values, may indicate certain limitations to the gels potential to 
provide a sustained release of specific proteins.  It has found that addition of all three 
concentrations of each of the different model proteins caused changes in the 
viscoelastic properties of the hydrogel.  On analysis of the released proteins using 
SDS-PAGE it was concluded that all three proteins were released from the hydrogel 
without degradation.  To conclude, results from this study indicate that the most 
suitable protein payloads for incorporation into the PVA-borate hydrogel are those 
which will have a net negative charge when incorporated into the hydrogel matrix.  
The negatively charged proteins were released in sustained manner from the 
hydrogel system, unlike the positively charged trypsin.  The results also indicate that 
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the high molecular weight proteins are released in a sustained manner.  Therefore, it 
would be presumed that if the hydrogel can release large bulky high molecular 











4 Formulation, characterisation, in vitro release, stability and 




In the previous chapter, it was determined that the PVA-borate hydrogel was capable 
of providing a sustained release of incorporated proteins, without any degradation of 
the protein structure.  In this chapter, another protein, the enzyme pepsin, was chosen 
to undergo the same testing as detailed in the previous chapter with the addition of 
enzymatic studies.  The important question to be answered in this chapter was to 
determine if the PVA-borate could deliver an enzyme, which still retained its 
enzymatic activity. 
 Enzymes are proteins, which work as catalysts for biochemical reactions.  
Catalysts for any chemical reaction, whether biological or non-biological, increase 
the rate of reaction by lowering the activation energy.  This allows reactions to take 
place in a timely manner under less extreme conditions, such as physiological 
conditions.  Enzymes do not change the equilibrium constant of the reaction, only the 
rate at which equilibrium is reached (Denniston et al., 2008).  Therefore, the energy 
difference between the products and reactants remains the same and only the 





Figure 4.1 Schematic diagram showing how the addition of a catalyst, such as an enzyme lowers the 
activation energy (Ea) of the reaction.  A+B represent the reactants and C+D the products.  Ea1 
represents the non-catalysed and Ea2 represents the catalysed reaction. 
 
For a non-catalysed biochemical reaction, the rate of reaction is directly proportional 
to the substrate concentration, as seen in Figure 4.2a.  However, for an enzyme-
catalysed reaction, the rate of reaction is only directly proportional to the substrate 
concentration initially (Figure 4.2b).  As the substrate concentration increases 
further, the rate of reaction begins to slow down and is no longer directly 
proportional to the substrate concentration.  At a specific substrate concentration, the 
reaction reaches its maximum velocity (Vmax), as seen in Figure 4.2b.  At Vmax, all the 
enzymes active sites are occupied and any further increase in the substrate 










Figure 4.2 Schematic plots of the rate of reaction against substrate concentration for, a) a non-
catalysed reaction, were the substrate concentration is directly proportional to the rate of reaction and 
b) an enzyme-catalysed reaction were the rate of reaction reaches a maximum velocity (Vmax) when all 
the available enzymes’ active sites are occupied.  
 
The active site of an enzyme is the region of the molecule that binds the substrate 
molecules and gives enzymes their high specificity.  Within the active site of an 
enzyme, there are specific functional groups, which bind the substrate molecule and 
other groups, which take no part in the binding process and are involved in the 
catalytic process (Voet et al., 1999).  The shape of the active site is thought to be 
complementary to the shape of the substrate molecule, increasing enzyme specificity.  
Emil Fischer in 1894, introduced the lock-and-key model for enzyme-substrate 
binding (Steed et al., 2012).  Fischer concluded that the substrate molecule simply 
clicked into the active site of the enzyme in a similar way to which a key fits a 
specific lock precisely.  Building on Emil’s theory, Daniel Koshland Jr. proposed 
that the active site of the enzyme was not completely rigid, like a lock receiving a 
key, but instead, flexible (Koshland, 1994).  Koshland proposed that the active site 
was approximately similar in shape to the substrate and on binding of the substrate 
the active site orientates itself around the substrate providing the perfect, precise fit.  
Koshland named this the induced-fit model.  Enzymes display different degrees of 
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specificity and can be classed according to their substrate specificity (Denniston et 
al., 2008), as summarised in Table 4.1.  However, enzymes are more commonly 
classified and named according to the type of chemical reaction they catalyse, as 
summarised in Table 4.2. 
 
Table 4.1 Classification of enzymes according to specificity 
 
Classification  Degree of specificity 
Absolute Catalyses only one specific substrate  
Group Catalyses molecules with the same functional groups 
Linkage Catalyses molecules with specific bonds 
Stereochemical  Catalyses only one of the enantiomers 
 
Table 4.2 Classification of enzymes according to type of chemical reaction (Voet et al., 1999) 
 
Classification  Type of chemical reaction  
Oxidoreductases Oxidation, reduction reaction 
Transferases Transfer of functional group 
Hydrolases Hydrolysis reaction 
Lyases Group elimination to form double bond 
Isomerases Isomerisation 
Ligases Bond formation coupled with ATP hydrolysis  
 
Once the enzyme has bound the substrate in its active site forming the enzyme-
substrate complex, which is a reversible reaction, the complex enters the transition 
state.  During the transition state, the enzyme begins to change the substrate, which 
now has characteristics of both the original substrate and the new product (Denniston 
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et al., 2008).  The transition state is where the rate of reaction can be increased.  
Examples of how the enzymes may do this are by applying stress to a bond, thus 
promoting its breakage or they can bring two reactants together in the correct 
orientation for the reaction to occur (Denniston et al., 2008).  The resultant complex 
formed from the transition state is the enzyme-product complex.  The enzyme then 
releases the product or products and continues to bind another molecule of the 
substrate and commence the process over again.  The classic enzyme mechanism is 
summarised in Equation 4.1, where E represents the enzyme, S the substrate, ES the 
enzyme-substrate complex, P the resultant product and K1–3 are the rate constants for 
the particular parts of the catalytic reaction.  The enzyme throughout this whole 




Environmental factors, such as pH and temperature, also affect the activity of 
enzymes.  Certain enzymes are designed to function within a narrow pH range.  For 
example, pepsin and trypsin are both proteolytic enzymes with similar mechanisms 
of action.  Yet, pepsin is found in the stomach and has an optimum pH of 2 (Piper & 
Fenton, 1965), whereas, trypsin is found in the small intestine and has an optimum 
pH of 7.5 (Cheison et al., 2011).  Denniston et al. (2008) state that when the pH 
deviates from the optimum pH for that particular enzyme the degree of ionisation of 
the functional groups within the active site changes.  This results in reduced ability of 
the substrate to bind to the active site.  The further the pH deviates from the optimum 




denatured.  Similarly, enzyme reactions have an optimum temperature at which the 
rate of reaction is at the maximum velocity.  All the enzymes present in the human 
body naturally have an optimum temperature of 37 °C.  Although enzymes are stable 
at temperatures lower than 37 °C, hence, they are stored in refrigerators and freezers 
when not being used in clinical or experimental work.  As the temperature increases 
towards 37 °C, the rate of reaction increases.  Increasing the temperature until the 
optimum temperature is reached causes an increase in the number of viable collisions 
between the enzymes and molecules of substrate, therefore, increasing the rate of the 
reaction (Laidler & Peterman, 1979).  Above the optimal temperature, thermal 
inactivation of the enzyme occurs as a result of increased vibrational energy of the 
bonds, which eventually leads to complete disruption of the bonds and other 
interactions causing the enzyme structure to breakdown, deforming the active site 
rendering it inactive (Laidler & Peterman, 1979). 
 In recent years, enzymes have been studied widely as possible therapeutic 
drugs for several diseases (Vellard, 2003).  The majority of these disease are rare 
genetic diseases resulting in the loss of vital enzyme synthesis or function.  These 
diseases are treated with enzymes, as summarised in Table 4.3.  These therapeutic 
enzymes are delivered orally and intravenously, with the exception of Pulmozyme®, 
which is administered by inhalation (Quan et al., 2001; Vellard, 2003).  
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Table 4.3 Summary of therapeutic enzymes for genetic diseases 
 
Several other enzymes have shown potential therapeutic use when delivered 
topically to burn wounds.  The proteolytic enzyme vibriolysin, which originates from 
the marine microorganism Vibrio proteolyticus, has shown to be effective against 
debridement of denatured proteins in burn patients (Durham et al., 1993).  The 
treatment was successfully put through a Phase Ib clinical trial by BioMarin under 
Trade name Generic name Indication 
Adagen® 
(Alconcel et al., 2011) 
Pegademase bovine 
Adenosine deaminase-severe combined 
immunodeficiency (ADA-SCID) 
Pulmozyme® 
(Quan et al., 2001) 
Dornase-α Cystic fibrosis (CF) 
Cerezyme® 
(Weinreb et al., 2007) 
Imiglucerase Type I, II and III Gaucher’s disease 
Ceredase® 
(Friedman et al., 1993) 
Alglucerase Type I Gaucher’s disease 
Sucraid 





(Tsuboi & Yamamoto, 
2012) 
α-Galactosidase A Fabry’s disease, long-term treatment 
Oncasper® 
(Alconcel et al., 2011) 
Pegaspargase Acute lymphocytic leukaemia 
Fabrazyme® 
(Tsuboi & Yamamoto, 
2012) 












(Kuhn et al., 2010) 
Pancreatin 
Cystic fibrosis, chronic pancreatitis, 
pancreatectomy and gastrectomy 
Nutrizym 22® 
(Shah et al., 1993) 
Pancreatin 
Cystic fibrosis, chronic pancreatitis, 
pancreatectomy and gastrectomy 
Vimizin™ 
(Sanford & Lo, 2014) 
Elosulfase alfa Marquio A syndrome (MPS-IVA) 
Naglazyme® 











the brand name Vibrilase™, but progress has stalled since this trial.  Another enzyme 
delivered topically to partial-thickness burn wounds in children for debridement with 
promising results was clostridiopeptidase, a collagenase (Rutter et al., 2000).  A 
topical gel base dressing called Debrase® containing a proteolytic enzyme bromelain 
extracted from the stem of a pineapple plant is indicated for burn wound debridement 
(Klasen, 2000; Vellard, 2003).  The dressing has shown to be effective at 
debridement of necrotic eschar for partial to full-thickness burns, promoting re-
epithelisation (Singer et al., 2011).  Therefore, although pepsin used in this chapter 
has no recognised use as a topically delivered therapeutic drug, at present, the results 
from this chapter and the overall project may highlight that the PVA-borate hydrogel 
has a potential use for delivering topically other types of enzymes for the 
management and repair of chronic wounds.   
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 Aims and objectives 
The aim of the work in this chapter was to formulate, characterise and complete in 
vitro release studies for pepsin-loaded PVA-borate hydrogels (PVA 6.0 % w/w 
borate 2.0 % w/w), and determine if the enzymatic activity of pepsin could be 
maintained upon release from the hydrogel. 
 
Objectives; 
 determine pepsin enzyme kinetics, 
 formulate PVA-borate hydrogels loaded with varying concentrations of 
pepsin, 
 characterise the viscoelastic properties of the pepsin-loaded PVA-borate 
hydrogels using oscillatory rheometry, 
 complete in vitro release studies for the pepsin-loaded hydrogels using Franz 
diffusion cells, 
 detect and quantify pepsin released from the hydrogels using a bicinchoninic 
acid (BCA) assay and UV-Vis spectroscopy, 
 check degradation of the released pepsin from the hydrogel using sodium 
dodecyl sulphate poly(acrylamide) gel electrophoresis (SDS-PAGE),  
 determine if the released pepsin has retained its enzymatic activity.  
 
 Materials 
Chemicals and reagents 
Poly(vinyl alcohol) (PVA) (Mw = 31–50 kDa, 98–99 % hydrolysed), sodium 
tetraborate decahydrate (ACS reagent ≥ 99.5 %), pepsin from porcine gastric mucosa 
(lyophilised powder 3,200–4,500 units/mg protein), haemoglobin from bovine blood, 
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trichloroacetic acid (ACS reagent ≥ 99.5 %), buffer solution, phosphate buffer 
solution, borax buffer solution and Transwell® tissue culture inserts (Poly(carbonate) 
membrane, pore size 8.0 µm) were purchased from Sigma-Aldrich Ltd. (Gillingham, 
Dorset, UK). 
NuPage® Bis-Tris gel 4–12 % (1.0 mm x 10 well) Novex®, NuPage® MOPS SDS 
running buffer (20x) Novex®, SeeBlue® Plus2 Prestained standard Novex® were 
purchased from Life Technologies Ltd. (Paisley, UK).  
Coomassie brilliant blue R-250 staining solution, Bio-rad laboratories Inc. 
(Hertfordshire, UK). 
Pierce™ BCA Protein assay kit, Medical Supply Company. (Dublin, Ireland).  




Kinexus Pro rheometer, Malvern instruments (Malvern, Worcestershire, UK). 
XCell SureLock™ Mini-Cell electrophoresis system, Invitrogen, Life Technologies 
Ltd. (Paisley, UK).   
Varian Cary 50 Scan UV-Vis spectrophotometer supplied by Manson Technology. 
(Dublin, Ireland); with a 10 mm quartz cuvette.  
FLUOstar® Omega microplate reader, BMG LABTECH Ltd. (Ortenburg, Germany).   
Franz diffusion cells, Perme-Gear diffusion cells & systems. (USA) and Techne TE 




4.4.1 Determination of pepsin enzyme kinetics  
Twelve test tubes were placed in a water bath at 37 °C.  To each test tube, 0.5 mL of 
filtered bovine haemoglobin (0.25 % w/v, pH 2.0 ± 0.5) was added and allowed to 
reach 37 °C.  To each test tube, 0.5 mL of pepsin (20 µg mL-1) was added and a stop 
watch started.  The reaction in each test tube was stopped at defined times (1, 2, 3, 4, 
5, 10, 20, 30, 40, 50, 60 and 70 minutes) by addition of 5 % w/v trichloroacetic acid 
(5 mL) for 5 minutes.  The solution was then filtered (0.45 µm) to remove any non-
acid soluble material.  Acid-soluble peptides were detected using UV-Vis 
spectrometry at a wavelength of 280 nm.  A quartz cuvette with a path length of 10 
mm was used and rinsed with deionised water between each sample.  Three 
replicates were performed for each filtrate (n=3). 
This method was repeated a further seven times varying the concentration of 
bovine haemoglobin (0.375, 0.450, 0.500, 0.625, 0.750, 1.000, 1.250 % w/v).  For 
each concentration of haemoglobin, an absorbance against time graph was plotted 
from which the enzyme activity was calculated, using Equation 4.2, where d(A280) is 
the change in product and d(t) is the change in time.  GraphPad Prism® software was 
used to plot the initial velocities against the corresponding haemoglobin 
concentrations to produce a Michaelis-Menten curve and Lineweaver-Burk plot. 
 
Unit mg-1 min-1 = 
(𝑑(A280) −A280 blank) x 1000
(𝑑(t) x mg of enzyme in reaction)
 
 
From the Michaelis-Menten plot, the Michaelis-Menten constant KM and Vmax can be 




maximum rate of the reaction, KM is the Michaelis-Menten constant and [S] is the 
substrate concentration.  
 





4.4.2 Formulation of pepsin-loaded PVA-borate hydrogels 
An optimum hydrogel formulation of 6.0 % w/w PVA and 2.0 % w/w borate was 
selected from previous studies to be loaded with various quantities of pepsin (0.05, 
0.10, 0.20 % w/w).  A sample (25 g) of this formulation was prepared by mixing 6.25 
g of PVA stock solution (24 % w/w) and 10.00 g of borax stock solution (5% w/w).  
A homogenous fluid-like gel was formed upon heating to 80 °C for approximately 
three hours, with periodic stirring.  Hydrogels were weighed and any lost weight was 
replenished with deionised water.  The gels were then transferred to poly(propylene) 
storage containers and left for 48 hours at room temperature and pressure (RTP) to 
allow for complete gelation.  To a desired quantity of hydrogel the appropriate 
volume of a pepsin stock solution (5 mg mL-1) was added and mixed in using a 
stainless steel spatula.  The hydrogels were stored in the fridge (2–8 °C) until used. 
Final formulations were clear and homogenous in appearance with no air bubbles 
present. 
 
4.4.3 Viscoelastic analysis 
Analysis of the viscoelastic properties was carried out using a Kinexus Pro rheometer 
(Malvern Instruments Ltd., Worcestershire, UK) on all hydrogel formulations, as 
described previously in sections 2.4.2.  Briefly, a strain (1.0 %) controlled frequency 




determined.  All tests were carried out at 25 °C ± 0.2 °C, using 20 mm diameter 
stainless steel parallel plate geometry and a working gap of 1 mm.  Three replicates 
were performed for each formulation (n=3).  Student’s t-test statistical analysis was 
carried out on the data. 
 
4.4.4 In vitro release study 
Pepsin release studies were carried out using Franz diffusion cells (Perme Gear cells 
& Systems, USA) and a Techne TE 10D Tempette® water bath & Pump (Bibby 
scientific Ltd. Staffordshire, UK).  All release studies were carried out at 37 °C using 
poly(carbonate) membranes cut to size (pore size 8.0 µm, Sigma Aldrich).  A sample 
(1.00 g) of pepsin-loaded hydrogel (PVA 6.0 %w/w, borate 2.0 % w/w, pepsin 0.20 
% w/v) was placed in each donor chamber at time zero.  Samples (0.5 mL) were 
withdrawn at specific time intervals (0, 1, 2, 3, 4, 5, 6, 7 and 8 hours) and replaced 
with 0.5 mL fresh receiver phase.  A blank PVA-borate hydrogel of the same 
formulation was ran as a control. 
 
4.4.5 Detection and quantification of pepsin released from PVA-borate 
hydrogels. 
Samples were analysed for the presence of pepsin and quantified using a 
bicinchoninic acid (BCA) assay, as previously described in section 3.4.7. A 
calibration plot was produced using nine dilutions (20–2000 μg mL-1) from a stock 
solution (2 mg mL-1) of pepsin.  Samples (25 μL) of each dilution and samples from 
the in vitro release study were pipetted into a 96-well plate.  To each of these wells, 
200 μL of BCA assay working reagent was added.  The 96-well plate was then 
placed on an orbital shaking incubator at 37 °C at 100 rpm for 30 minutes.  The plate 
173 
 
was then removed and allowed to cool to room temperature prior to the absorbance 
of each well being measured at 562 nm using a FLUOstar® Omega microplate 
reader, (BMG LABTECH Ltd. Ortenburg, Germany).  
 
4.4.6 Sodium dodecyl sulfate poly(acrylamide) gel electrophoresis  
Sodium dodecyl sulphate gel electrophoresis (SDS-PAGE) was carried out using an 
XCell SureLock™ Mini-Cell electrophoresis system (Invitrogen, Life Technologies 
Ltd, Paisley, UK), as described previously in section 3.4.8.  Briefly, samples (20 µl) 
from the in vitro release study and protein standards dissolved in deionised water, 
were prepared under reducing conditions and loaded onto a Bis-Tris NuPAGE 4–12 
% resolving gel.  Electrophoresis was run using NuPAGE MOPS SDS running buffer 
(x1), in constant voltage mode of 200 V and a varied current of 100–125 mA and 60-
80 mA during stacking and running, respectively.  The gel was stained with 
coomassie brilliant blue R-250 stain for 60 minutes on an orbital shaker (45 rpm), at 
room temperature.  The coomassie blue stain was removed and the gel was rinsed 
twice with deionised water for 5 minutes each time.  The gel was then de-stained 
with a solution of methanol, acetic acid and deionised water at the ratio of 50:10:40 
% v/v on an orbital shaker (45 rpm) for 30 minutes, at room temperature.  After 30 
minutes, the de-staining solution was diluted to methanol 12.5 %, acetic acid 2.5 %, 
using deionised water.  The gel was then left overnight on the orbital shaker at room 
temperature, after which it was imaged. 
 
4.4.7 pH related enzyme activity of pepsin 
Bovine haemoglobin was dissolved in several solutions (0.01 M HCl, phosphate 
buffer, borax buffer, buffer solution pH 4 and 6) to achieve five haemoglobin 1 % 
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w/w solutions, of varying pH (2.0, 4.0, 6.0, 7.0, 9.0).  A volume (5 mL) of each 
solution of haemoglobin was placed into separate test tubes in a preheated water bath 
(37 °C).  To each of the five test tubes, 0.5 mL of a pepsin solution (30 μg mL-1) was 
added and a countdown timer, set for 10 minutes, was started.  After this time had 
elapsed, 5 mL of TCA (5 % w/w) was added to each test tube and incubated for a 
further 5 minutes before being filtered through a 0.45 μm sterile filter to remove any 
non-acid soluble material.  The absorbance of the filtrate was measured using a UV-
Vis spectrophotometer at 280 nm.  The enzymatic activity of the pepsin in each 
solution was calculated using Equation 4.4. 
 
Unit mg-1 min-1 = 
(A280 filtrate −A280 blank) x 1000
(10 mintues x mg of enzyme in reaction)
 
 
4.4.8 Altering the overall pH of the PVA-borate hydrogel 
A volume (1 mL) of different concentrations of hydrochloric acid (2.000, 1.000, 
0.500, 0.250, 0.125 M) were added to 4.0 g samples of hydrogels (PVA 6.0 % w/w 
borate 2.0 % w/w) and left for 48 hours.  After 48 hours the pH of each gel was 







Eight graphs showing the absorbance of each of the filtered samples containing acid-
soluble hydrolysed haemoglobin plotted against time can be seen in Figure 4.3a and 
4.3b.  It can be seen that increasing the concentration of haemoglobin caused an 
increase in the time it took for the graph to plateau. 

























Figure 4.3a Curves showing absorbance plotted against time for hydrolysed acid-soluble bovine 
haemoglobin digest, measured using UV-Vis spectroscopy, λ = 280 nm.  Haemoglobin concentration 
varied (0.250, 0.375, 0.450 and 0.500 % w/v), while pepsin concentration remained constant at 20 μg 
mL-1.  All experiments were carried out at 37 °C and haemoglobin solution were pH 2.0 ± 0.5.  Data 
shown as the mean value ± standard deviation (n=3). 
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Figure 4.3b Curves showing absorbance plotted against time for hydrolysed acid-soluble bovine 
haemoglobin digest, measured using UV-Vis spectroscopy, λ = 280 nm.  Haemoglobin concentration 
varied (0.625, 0.750, 1.000 and 1.250 % w/v), while pepsin concentration remained constant at 20 μg 
mL-1.  All experiments were carried out at 37 °C and haemoglobin solution were pH 2.0 ± 0.5.  Data 
shown as the mean value ± standard deviation (n=3). 
 
The initial velocities values calculated from graphs in Figure 4.3a and 4.3b, using 
Equation 4.2, were plotted against the corresponding haemoglobin concentrations to 
produce the Michaelis-Menten plot, which displays pepsin’s enzymatic kinetics, as 
seen in Figure 4.4. 
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Figure 4.4 Michaelis-Menten plot for porcine pepsin at 37 °C.  Haemoglobin concentration varied 
0.25–1.25 % w/v, while pepsin concentration remained constant at 20 μg mL-1. 
 
The KM and Vmax for the plot in Figure 4.4 are 0.6099 % w/v and 1791 U mg
-1 min-1, 
respectively.  Another method to determine the KM and Vmax values was developed by 
Hans Lineweaver and Dean Burk. This involves using the reciprocal of the 
Michaelis-Menten equation to obtain a linear plot called the Lineweaver-Burk plot.  
The lineweaver-Burk plot is also known as the double-reciprocal plot.  Figure 4.5 
shows the Lineweaver-Burk plot for the data plotted in the Michaelis-Menten plot in 
Figure 4.4. 
R2 = 0.9761 






































Figure 4.5 Lineweaver-Burk plot also known as the double reciprocal plot for porcine pepsin at 37 °C.  
Haemoglobin concentration varied 0.25–1.25 % w/v, while pepsin concentration remained constant at 
20 μg mL-1. 
 
 Once the values were plotted, the regression line of the Lineweaver-Burk plot 
was extrapolated using GraphPad Prism® software.  The software determined the y 
intercept, which equates to 1/ Vmax and the x intercept, which equates to -1/ KM.  
From the x and y intercept values Vmax and KM was calculated to be 1149 U mg
-1 min-
1 and 0.6099 % w/v, respectively.  It can be seen that the KM value for both the 
Michaelis-Menten plot and the Lineweaver-Burk plot are the same.  The Vmax value 
for the Lineweaver-Burk plot was 642 U-1 mg min lower than that for the Michaelis-
Menten plot.  The KM and Vmax are unique to each enzyme and substrate.  Therefore, 
once it has been ascertained if the pepsin released from the hydrogel has enzymatic 
activity then another Michaelis-Menten and Lineweaver-Burk plot will be produced 




PVA-borate hydrogels (PVA 6.0 % w/w; borate 2.0 % w/w) loaded with the 
three concentrations of pepsin (0.05, 0.10, 0.20 % w/w) were clear and homogenous 
once fully re-congealed and stored in the fridge.  Each pepsin-loaded hydrogel was 
then subject to a frequency sweep oscillating rheometry investigation to determine if 
incorporating the various concentrations of pepsin into the hydrogel matrix had any 
effect on the viscoelastic properties of the hydrogel.  This was achieved by 
comparing the crossover modulus obtained for each pepsin-loaded hydrogel to a 
hydrogel of the same formulation, which had no pepsin incorporated into the gel 
network.  It can be seen from Figure 4.6 that on incorporation of all three 
concentrations of pepsin, there was a significant (p<0.01) decrease in the crossover 
modulus, compared to the blank hydrogel.  However, there was no significant 
difference in the crossover modulus when increasing the pepsin concentration from 
0.05 to 0.10 % w/v (p = 0.3384) and from 0.10 to 0.20 % w/w (p = 0.5425).  The 
lowest crossover modulus (2283 ± 79 Pa) was recorded for the 0.20 % w/w pepsin 
compared to the blank hydrogel with a crossover modulus of 2747 ± 91 Pa. 
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Graph showing the effect of increasing Pepsin concentration on the
 crossover modulus of a PVA borate hydrogel






















Figure 4.6 Graph showing the effect of incorporating three concentrations of pepsin into a PVA (6.0 
% w/w) borate (2.0 % w/w) hydrogel has on the crossover modulus, compared to a blank hydrogel, of 
the same formulation.  Data shown as the mean ± standard deviation (n=3).  All measurements carried 
out at 25°C ± 0.2°C. p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
A BCA assay was used to detect and quantify the pepsin released from the PVA-
borate hydrogel system.  Figure 4.7 shows a typical BCA assay calibration plot that 
was used to determine the pepsin concentration in each sample.  A calibration plot 
was carried out on each plate of samples to account for day-to-day, and plate-to-plate 
optical variability.  As the r2 is 0.99 the data is correlated, and confidence can be had 
in any values calculated using the line equation. 
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Pepsin BCA assay calibration plot









y = 0.001x + 0.06













Figure 4.7 BCA assay calibration plot produced using several dilutions of a pepsin stock solution 2 
mg mL-1.  The standard dilutions concentration range 20–2000 µg mL-1.  The λ = 562 nm, data shown 
as mean ± standard deviation (n=3). 
 
The percentage cumulative release profiles of each of the three concentrations of 
pepsin from the PVA-borate hydrogel can be seen in Figure 4.8.  The hydrogel 
loaded with 0.05 % w/w pepsin released the least amount of pepsin (71.06 ± 1.05 %), 
after 8 hours.  The 0.10 % w/w pepsin-loaded gel released 80.37 ± 0.42 % of the 
loaded pepsin and the 0.20 % w/w pepsin-loaded hydrogel released the largest 
quantity of pepsin at 8 hours (84.84 ± 0.79 %).  At the second and third hour 
sampling points, the 0.05 % w/w pepsin-loaded hydrogel gave a higher release of 
pepsin, compared to the 0.10 % w/w loaded hydrogel.  However, from the fourth to 
eight hour, the 0.10 % w/w loaded hydrogel released a larger quantity of pepsin than 
the 0.05 % w/w loaded hydrogel, as seen in Figure 4.8.  The general trend exhibited 
by all three concentrations is as time increased so did the quantity of pepsin released 
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from the PVA-borate hydrogels.  It can also be seen from the fourth to eight hour the 
hydrogels containing the higher concentrations of pepsin released the largest quantity 
of pepsin at each time point. 
Percentage cumulative release profiles for pepsin loaded
 PVA borate hydrogels


































Figure 4.8 Percentage cumulative release profiles for three pepsin loaded PVA (6.0 % w/w) borate 
(2.0 % w/w) hydrogels of varying pepsin concentration, over 8 hours.  Release studies were carried 
out at 37 °C using poly(carbonate) membranes with a pore size 8.0 µm, on Franz diffusion cells.  Data 
shown as the mean ± standard deviation (n=3). 
 
Figure 4.9 shows the resultant SDS-PAGE gel for the molecular weight of pepsin 
released from the PVA-borate hydrogel matrix.  Pepsin released from the hydrogel 
can be seen in lanes 4–6 with a standard sample of pepsin of the same concentration 
seen in lane 3 (Figure 4.9).  As the protein band seen in lane 3 for the pepsin standard 
is located in proximity to the 38 kDa molecular marker band of the protein ladder, it 
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can be assumed that this is pepsin, which has a molecular weight of 35 kDa.  
Furthermore, it can be seen that the pepsin samples released from the hydrogel are 
also in close proximity to the pepsin standard band in lane 3 and the 38 kDa 
molecular marker band.  Therefore, the pepsin released from the PVA-borate 
hydrogel has not been subject to degradation, upon release or whilst in the hydrogel 
matrix. 
 
Figure 4.9 Image of the SDS-PAGE NuPAGE® Bis–Tris 4-12 % resolving gel (1.0 mm x 10 well), 
stained with coomassie blue for pepsin released from a hydrogel (PVA 6.0 %w/w borate 2.0 % w/w) 
and a pepsin standard.  Lane 1 molecular markers, Lane 2 was intentionally left blank, Lanes 4–6 
pepsin samples released from the PVA-borate hydrogel.  
 
The activity of pepsin released from the hydrogel was compared to the activity of a 
pepsin standard of the same concentration.  It can be seen from Table 4.4 that the 
pepsin released from the hydrogel had no activity, compared to the standard pepsin 
sample, which had an enzymatic activity of 3093 ± 42 U mg-1 min-1.  After 10 
kDa 













minutes, the pepsin standard in test tube C had broken down the haemoglobin.  This 
is because on addition of the TCA (5 % w/v), it produced a homogenous light brown 
translucent solution, compared to the test tubes A and B, which contained the pepsin 
released from the hydrogel, as seen in Figure 4.10.  On addition of TCA to test tubes 
A and B, the solutions became cloudy with large undigested acid-insoluble clumps of 
haemoglobin present at the surface and throughout the solution (Figure 4.10).  This 
indicates visually that there is limited to no pepsin activity compared to test tube C. 
 
Table 4.4 Activity of pepsin released from a hydrogel compared to standard stock solution.  Data 









Figure 4.10 A representative photograph of one set of the three replicates of test tubes from the pepsin 
enzyme activity experiment.  Haemoglobin concentration was 1.0 % w/w pH 2.0 ± 0.2, incubation for 
10 minutes at 37 °C with 30 μg mL-1 pepsin.  Test tubes A and B contain pepsin released from 
hydrogels (PVA 6.0 % w/w borate 2 % w/w) and test tube C is the pepsin standard. 
Test Tube Absorbance 
(a.u.) 
Activity 
(U mg-1 min-1) 
A 0.0000 0 
B 0.0000 0 
C 0.4640 ± 0.0100 3093 ± 42 
A B C 
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To determine if the pH of the hydrogel environment that the pepsin was exposed to 
was a factor for no enzymatic activity, the experiment outlined in section 4.4.7 was 
completed.  It can be seen from Figure 4.11 that pepsin showed the highest 
enzymatic activity (3705 ± 8 U mg-1 min-1) at pH 2.0.  On increasing the pH of the 
haemoglobin solution to 4.0, there was a decline in pepsin activity to 996 ± 22 U mg-
1.  At a pH 7.0 (neutral) the enzymatic activity further decreased to 381 ± 27 U mg-1 
min-1 and exhibiting its lowest activity, 337 ± 5 U mg-1 min-1, at pH 9.0 (weak 
alkaline). 
Effect pH has on pepsin activity

























Figure 4.11 Graph showing enzymatic activity of pepsin (30 μg mL-1) over a pH range of 2.0–9.0 
incubated for 10 minutes with 1 % w/w haemoglobin at 37 °C.  Data shown as mean ± standard 
deviation (n=3).  
 
In order to try and achieve a more stable environment for the pepsin within the 
hydrogel, an attempt was made to lower the pH of the hydrogel system, to an acidic 
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environment.  It can be seen from Table 4.5 that on adding 1 mL of 2.000, 1.000 and 
0.050 M HCl to the hydrogel the pH was reduced from a basic (pH 8.03 ± 0.03) to  
an acidic (pH 1.26 ± 0.07) environment. 
 
Table 4.5  The effect adding varying concentrations of HCl, has on the pH of a PVA 6 % w/w borate 
2.0 % w/w hydrogel.  Data shown as mean ± Standard Deviation (n=3). 
 
HCl concentration (M) pH (Average ± SD) 
2.000 1.26 ± 0.07 
1.000 1.59 ± 0.15 
0.500 3.52 ± 0.16 
0.250 7.25 ± 0.25 
0.125 7.38 ± 0.04 
0.000 8.03 ± 0.03 
 
Although the addition of HCl to the PVA-borate hydrogel was effective at creating 
an acidic environment within the hydrogel, it caused the formulations to become 
white and cloudy in appearance (Figure 4.12), with phase separation also evident on 
visual inspection.  On examination, it was observed that the hydrogels had de-mixed 
to a solid and liquid phase. 
 
 
Figure 4.12 Photograph showing six glass vials containing 4.0 g of PVA-borate hydrogel (PVA 6.0 % 
w/w, borate 2.0 % w/w).  Each vial, except vial F, contained 1 mL of HCl of varying concentration.  
Vial A) 2.000 M, B) 1.000 M, C) 0.500 M, D) 0.250 M, E) 0.125 M, F) Blank (no HCl).  




Utilising the PVA-borate hydrogel delivery system for administering enzymes 
topically is a novel application.  However, a gel-based dressing has been used to 
deliver an enzyme, topically, to burn wounds for debridement with positive results 
(Klasen, 2000).  Topical application of other enzymes to burns wounds for 
debridement has also proven to be beneficial (Durham et al., 1993; Rutter et al., 
2000; Vellard, 2003).  Therefore, the findings of this chapter may indicate 
worthwhile future research, whereby the PVA-borate hydrogel has the potential to 
deliver enzymes topically, which promote wound management and repair.  The 
enzyme pepsin is irreversibly denatured at pH ≥ 8.0 and has an optimal pH of 2.0 
(Piper & Fenton, 1965).  The reason for choosing to deliver pepsin in this study was 
to determine if its enzymatic activity could be maintained during entrapment in the 
hydrogel and upon release from the hydrogel. 
 Pepsin belongs to the family of aspartic peptidases and is found in the 
stomach of mammals (Tang et al., 1973).  Its main purpose is to aid in the digestion 
of large proteins by hydrolysing peptide bonds.  Enzymatic hydrolysis breaks down 
the large proteins into small peptides and single amino acids, which can be readily 
absorbed through the intestine mucosa.  Pepsin is initially synthesised as a pro-
enzyme known as pepsinogen.  Pepsinogen has an extra 44 amino acid pro-peptide 
portion, which blocks the active site (Goodsell, 2000), as seen in Figure 4.13.  This is 
so that the pepsin does not digest components of the cell synthesis apparatus prior to 
being released into the stomach.  Once in the acidic environment of the stomach, the 
pro-peptide segment is cleaved off in an autocatalytic manner (Davies, 1990), 




Figure 4.13 Space-filling model diagram of a) the pepsin pro-enzyme pepsinogen where the green 
block represents the extra 44 amino acid chain that blocks the active site and b) the active pepsin with 
the additional segment removed from the active site (Goodsell, 2000).  
 
Porcine pepsin, which was used in this study, is a 327-amino acid single 
poly(peptide) chain folded into a 3D structure, which is strengthened by three 
disulphide bridges between cysteine residues at positions 45 and 50, 206 and 210, 
and, 250 and 283 (Tang et al., 1973), as seen in Figure 4.14.  The two aspartate 
residues situated in the active site, which are known to partake in the catalytic 
reaction, can be seen in Figure 4.14 (Tang et al., 1973). 
 
 
Figure 4.14 Wireframe diagram of pepsin where the red and white components represent the two 
aspartate residues in the active site and the yellow and white residues represent the three disulphide 
bridges (Goodsell, 2000). 
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 The two aspartic residues found in a hydrophobic region of the active site at 
positions 32 (Asp 32) and 215 (Asp 215) play an active role in the catalytic reaction.  
Although structurally the same, the two aspartic groups are thought to have different 
pKa values, 1.0 and 4.7, respectively (Knowles, 1970).  The carboxyl groups present 
on each of these residues must be different for the catalytic process to occur.  One 
carboxyl group needs to be in the ionised form and the other in the non-ionised form 
(Polgar, 1987).  The exact mechanism of action of pepsin and other aspartic residues 
has been extensively studied (Fruton, 1976; Bott et al., 1982; James et al., 1982; 
James & Sielecki, 1985), however, certain aspects of the mechanism are still not 
fully understood.  In summarising, Davies (1990) and Dunn (2002) in their review 
articles conclude that the majority of researchers agree that the mechanism of peptide 
bond hydrolysis by aspartic proteases is by general acid-base catalysis.  The general 
acid-base mechanism proposes that Asp 215 acts as a base and removes a proton 
from the water molecule located between the two aspartate groups.  This in turn 
activates the water molecule, which then carries out a nucleophilic attack on the 
carbonyl group of the peptide bond and at the same time Asp 32 donates a proton to 
the carbonyl oxygen atom, resulting in a tetrahedral intermediate (Davies, 1990).  
Re-configuration of this intermediate results in the protonation of the nitrogen atom 
in the peptide bond by Asp 215, resulting in the peptide bond (C-N) breaking and 
leaving the Asp 215 negatively charged to catalyse another reaction.  The carboxyl 
product from the N-terminal side of the peptide is thought to remain hydrogen 
bonded to the Asp 32 (Dunn, 2002).  Recent research into the aspartic proteases 
cleavage mechanism suggests that the water molecule is in a low-barrier hydrogen 
bond between the two aspartate residues, detected by nuclear magnetic resonance 
(NMR) (Piana & Carloni, 2000; Northrop, 2001). 
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 In this chapter, haemoglobin was used as a substrate to determine the 
enzymatic activity of pepsin prior to loading into the PVA-borate hydrogel and then 
again on release.  The use of haemoglobin as the substrate to quantity the enzymatic 
activity of pepsin was first developed by Anson & Mirsky in 1932.  This specific 
method and variations of it are still widely used to determine the enzymatic activity 
of proteases (Sigma-Aldrich; Worthington Biochemical Corporation, 2017).  
Haemoglobin contains several amino acid residues that are known to be cleavage 
sites for pepsin at the C-terminal side of the amino acid (Scaloni et al., 1998).  These 
amino acid residues are phenylalanine, leucine, methionine, cysteine, glutamate, 
tyrosine and tryptophan (Tomita et al., 1991; Cao et al., 1997; Hamuro et al., 2008).  
Phenylalanine and leucine are the two most favourable sites of cleavage (Hamuro et 
al., 2008).  Therefore, this explains the successful digestion of haemoglobin by 
pepsin to achieve the Michaelis-Menten plot and the corresponding Lineweaver-Burk 
plot.  
 The Michaelis-Menten plot is a plot of enzyme velocity against substrate 
concentration.  The Michaelis-Menten equation was first developed in 1913, and 
named after the two scientists, Leoner Michaelis and Maud Leonora Menten who 
developed the equation (Johnson & Goody, 2011).  From the plot, two values can be 
obtained, which are specific to each enzyme and substrate, they are the Michaelis 
constant (KM) and the maximum velocity (Vmax).  KM is the substrate concentration 
that corresponds to half the maximum velocity.  Vmax is the maximum velocity that 
the enzyme can catalyse the reaction at (Voet et al., 1999).  At the Vmax, all the 
enzyme present has been saturated with substrate, in other words, all the active sites 
are occupied by substrate. 
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 The Lineweaver-Burk plot is a linear transformation of the Michaelis-Menten 
plot also known as the double reciprocal plot, as seen in Equation 4.5, where Vo is 
initial velocity of the reaction, Vmax is the maximum rate of the reaction, KM is the 
Michaelis-Menten constant and [S] is the substrate concentration.  The plot is the 
reciprocal of the velocity against the reciprocal of the substrate concentration.  A 
straight line is then fitted to the data and the Vmax is calculated by taking the 
reciprocal of the y intercept.  KM can be found by two methods; first by taking the 
value of the slope of the line and multiplying it by Vmax; second, is by extrapolating 
















It can be seen from the enzyme kinetic studies carried out in this chapter that the 
pepsin is enzymatically active as shown in the Michaelis-Menten plot were KM value 
of 0.6099 % w/w and Vmax value of 1791 U mg
-1 min-1 was obtained.  Therefore, a 
Lineweaver-Burk plot was also achieved, where the KM value was 0.6099 % w/v and 
the Vmax value 1149 U mg
-1 min-1.  Comparing the KM and Vmax values obtained in 
this study to those in published work is difficult due to differences in experimental 
parameters, such as temperature, pH, origin of pepsin, substrate, concentration of 
pepsin, concentration of substrate and origin of substrate, which are all known to 
affect the enzyme activity.  However, Hu et al. (2006) found the Vmax value of the 
free pepsin used in their study to be 52 U mg-1 min-1, which is lower than the Vmax 
value found for the pepsin in this chapter.  But, the origin of the pepsin in the study is 




those used in investigation in this chapter.  Altun & Cetinus. (2007) in their work 
used porcine pepsin and bovine haemoglobin as the substrate, similar to the work in 
this chapter.  However, they completed the enzymatic activity experiments at 40 °C 
and not 37 °C.  The documented Vmax value for free pepsin, which was not bound to 
chitosan microbeads was 5220 U g-1 min-1 and the corresponding KM value was 12.0 
g L-1 (Altun & Cetinus, 2007).  In similar work, Poojari et al. (2009) found that free 
pepsin, which was not bound to silicone elastomer had KM and Vmax values of 4.5 g L
-
1 and 14000 U mg-1 min-1, respectively.  The product specification sheet for the 
porcine pepsin used in this study states that its enzymatic activity should be within 
the range of approximately 3200–4500 U mg-1 min-1 (Sigma-Aldrich, 2015).  
Therefore, it can be confirmed that the pepsin was enzymatically active prior to 
loading into the hydrogel as values of 3094 ± 42 U mg-1 min-1 and 3705 ± 8 U mg-1 
min-1 were obtained for the stock pepsin used in this investigation. 
Dowds & Riggs (1965) determined and compared the KM and Vmax values 
from a Michaelis-Menten plot and Lineweaver-Burk plot.  They concluded that the 
estimation of the two parameters using the Lineweaver-Burk plot is less reliable than 
the Michaelis-Menten plot.  The main error in the Lineweaver-Burk plot was 
believed to arise when plotting the reciprocal of the enzyme velocity (v).  They stated 
that the lowest value of v plays a crucial role in the fitting of the regression line to the 
data.  Therefore, if there is a large error in the determination of the lowest v value 
then the corresponding plotted reciprocal value will be too large and lead to 
inaccurate placing of the regression line, thus unreliable KM and Vmax values.  
However, both models were used to determine if pepsin catalysed synthetic N-acetyl 
dipeptides faster with phenylalanine or tyrosine residues (Jackson et al., 1965).  
Enzyme kinetic parameters KM and Vmax for the digestion of bovine β-lactoglobulin 
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by pepsin was also determined by plotting a Lineweaver-Burk plot, which provided 
reliable results (Izquierdo et al., 2007).  English et al. (2006) state that an enzyme 
does not catalyse reactions in the classic way set out by Michaelis and Menten, 
which looks solely at a large group of enzymes.  With advances in technology and 
using single-molecule fluorescence studies several researchers have confirmed that 
when an enzyme catalyses a reaction it is an ever-fluctuating dynamic entity, 
experiencing fluctuations in catalytic rates due to temporal fluctuations in 
conformation (Zhuang et al., 2002; van Oijen et al., 2003; Velonia et al., 2005; 
Flomenbom et al., 2005; English et al., 2006; Zheng & Lu, 2014).  However, English 
et al. (2006) state that the Michaelis-Menten equation is still useful when 
determining activity of large quantities of enzymes as the fluctuation will be less 
significant to the overall values obtained for KM and Vmax.  Therefore, the steady state 
assumption of the Michaelis-Menten equation is more feasible.  Despite the 
Michaelis-Menten equation being over 100 years old and with a better understanding 
of enzymes by enzymologists, the equation and its linear transformation, the 
Lineweaver-Burk plot, is still used widely to quantify enzyme activity in a plethora 
of scientific research areas, such as biotechnology antibody fabrication (Boushaba et 
al., 2003), bioanalytical technology (Orosco et al., 2009; Ponomareva et al., 2010) 
and the food industry (Castillo-Yanez et al., 2006; Marques et al., 2015).   
 On loading three concentrations of pepsin into the PVA-borate hydrogel, 
crossover modulus analysis was completed to determine if incorporation of the 
pepsin into the hydrogel matrix caused any changes in the viscoelastic properties of 
the hydrogel.  All three pepsin concentrations were found to decrease the crossover 
modulus significantly in comparison to a hydrogel of the same formulation, which 
contained no pepsin.  When pepsin is dissolved in deionised water and added to the 
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hydrogel it will have an overall negative charge, due to having an isoelectric point in 
the range of 2.2–3.2 (Jonsson, 1972; Chaiyasut & Tsuda, 2001).  One possible 
explanation for the reduction in crossover modulus may be due to the interaction of 
the negatively charged pepsin and the Na+ cation.  The Na+ cation is a product of the 
dissociation of the sodium tetraborate decahydrate and plays a role in the cross-
linking and overall shape of the polymer chains.  The first complex formed in the 
two part reaction of the PVA-borate crosslink is a negatively charged 
poly(electrolyte) (Loughlin et al., 2008).  The cation exerts a shielding effect on the 
poly(electrolytes), reducing the repulsion between them.  This allows the polymer 
chains to re-orientate and reside closer together, thus, increasing polymer 
entanglement and cross-linking (Lin et al., 2005).  Therefore, if the negatively 
charged pepsin is interacting with the Na+ cation then the shielding effect of the 
cation may be diminished resulting in less cross-linking and polymer entanglement, 
thus, reducing the crossover modulus.  Jenson et al. (2002) found that on addition of 
BSA to a polymer hydrogel there was electrostatic repulsion between the negatively 
charged BSA and the negatively charged regions on the polymer.  A similar 
occurrence was observed on addition of BSA to the PVA-borate hydrogel in chapter 
3.  A similar phenomena may be occurring with the addition of the negatively 
charged pepsin and negative regions of the PVA polymer.   If complete cross-linking 
does not occur fully or as a result of the reversible nature of the PVA-borate cross-
link there may be negatively charged regions present within the hydrogel.  This 
would result in repulsion with the pepsin with the possibility of reducing the cross-
linking density and as result reduce the gel viscosity and crossover modulus. 
 The three pepsin-loaded hydrogels gave sustained release profiles over 8 
hours with the 0.20 % w/w hydrogel giving the highest release (84.84 ± 0.79 %).  
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Release studies were carried out at 37 °C, similar to those in Chapter Three, to mimic 
body temperature.  The reason for the PVA-borate hydrogel giving a high sustained 
release of pepsin is most likely due to the combination of the electrostatic repulsion, 
between the hydrogel components and the pepsin, and the decrease in viscosity 
because of this repulsion.  Lysozyme is an enzyme, which is used frequently as a 
model protein in polymeric hydrogel studies (Jensen et al., 2002; Khoury et al., 
2003; Verheyen et al., 2010; Appel et al., 2012).  Jensen et al. (2002), Verheyen et 
al. (2010) and Appel et al. (2012) all achieved sustained release of the enzyme 
lysozyme, similar to what was found in this study with pepsin.  However, Jensen et 
al. (2002) did not achieve passive release of lysozyme from the chondroitin 4-
sulphate hydrogel due to opposite charge interaction between the positively charged 
lysozyme and the negative charges in the polymeric backbone.  But, they were able 
to achieve the release on applying a pulsating electric field across the hydrogel, 
driving out the lysozyme by a process known as electro-simulative release. 
 Sodium dodecyl sulphate poly(acrylamide) gel electrophoresis was used to 
determine the molecular weight of pepsin prior to loading into the PVA-borate 
hydrogel and after release from the hydrogel.  It was found that the pepsin released 
from the hydrogel remained intact and had not been broken down, when compared to 
the pepsin standard.  The enzymatic activity of the released pepsin was determined 
against a pepsin standard using haemoglobin as the substrate, as discussed 
previously.  It was found that upon release from the hydrogel, the pepsin had no 
enzymatic activity in comparison to the pepsin standard.  It was thought that the 
reason for no activity was due to the pepsin being exposed to a basic environment, 
for its duration of time encapsulated in the PVA-borate hydrogel.  It was found from 
the pH analysis of the PVA-borate hydrogels in Chapter Two that the PVA 6.0 % 
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w/w borate 2.0 % w/w hydrogel, which was used in this pepsin study, had an average 
pH of 8.3.  As mentioned at the start of this discussion, pepsin is found in the acidic 
environment of the stomach and, therefore, has an optimum pH of 2.0.  From the 
pepsin activity study carried out in this chapter it was also found that the pepsin had 
the highest enzymatic activity at pH 2.0 and low activity at pH 8.0.  It is well 
documented that the aspartic proteases have an optimum pH range of 2.0–4.0 (Piper 
& Fenton, 1965; Lin et al., 1992).  It was also found that hydrolysis of haemoglobin 
by pepsin extracted from tuna fish also had an optimum pH of 2.0 (Nalinanon et al., 
2008).  Piper & Fenton (1965) document that pepsin has maximum activity at pH 
2.0, but, on increasing to pH 4.0, the pepsin exhibited only 70 % of its maximal 
activity.  On further increasing the pH to 8.0 it was observed that the pepsin was 
irreversibly inactivated and, therefore, had no enzymatic activity.  It is thought that 
the change in pH may influence both the dissociation of the substrate and the 
ionisation of the aspartic residues in the active site of the pepsin, therefore, rendering 
it inactive (Piper & Fenton, 1965; Denniston et al., 2008).  Similarly, Nalinanon et 
al. (2008) found that the activity of the tuna pepsin had diminished upon the mixture 
reaching pH 5.0.  Ruan et al. (2010) found that the degree and rate of hydrolysis of 
egg white protein by pepsin decreased on increasing the pH from 2.0 to 3.0.  They 
also stated that if the pH of the mixture was > 5.0, the pepsin began to denature and 
become inactive (Ruan et al., 2010).  Admittedly, the pH dependent stability of 
pepsin should have been taken into consideration when choosing an appropriate 
enzyme.  However, it was thought that as the pH of the hydrogel was borderline on 
the limit of the pepsin’s irreversible denaturing pH that on returning it back to an 
acidic pH there was the possibility it may re-activate.  Appel et al. (2012) achieved 
sustained released of the enzyme lysozyme from a PVA-viologen-
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hydroxyethylcellulose-N-methylpyrrolidone hydrogel.  Appel et al. (2012) also 
found that the lysozyme was bioactive on released from the hydrogel. 
 An attempt was made to lower the pH of the hydrogel using hydrochloric acid 
(HCl).  On adding a small volume (1 mL) of HCl 0.125 M and 0.250 M to the PVA-
borate hydrogel the pH did drop below 8.0.  But, the addition of HCl to the hydrogel 
caused a similar white de-mixing, as was seen previously in Chapter Three when the 
hydrogel was exposed to a high concentration of NaCl.  A similar phenomena was 
seen by Loughlin et al. (2008) on addition of lidocaine HCl to the PVA-Borate 
formulation.  The de-mixing or collapse of the network is thought to be caused by an 
increase in the free ion concentration within the formulation (Loughlin et al., 2008).  
The increase in the free ion concentration (H+ and Cl-) brought about by the addition 
of the HCl caused a decrease in the repulsive forces between the poly(electrolytes).  
This results in an increase in the complexation constant, leading to hyper-cross-
linking, which leads to de-mixing and phase separation (Pezron et al., 1988a; Pezron 
et al., 1989a; Pezron et al., 1989b).  
 
 Conclusion 
The work completed in this chapter has shown that addition of all three 
concentrations of pepsin (0.05, 0.10 and 0.20 % w/w) resulted in significant (p<0.01) 
decreases in the crossover moduli, in comparison to a hydrogel of the same 
formulation, but, containing no pepsin.  The change in the crossover modulus 
detected using oscillation rheometry indicates that the viscoelastic properties of the 
hydrogel have changed on addition of the pepsin, which may have aided the release.   
The PVA-borate hydrogel provided a sustained release of pepsin over an 8-hour 
period at 37 °C, with a maximum percentage cumulative release of 84.84 ± 0.79 % 
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from the 0.20 % w/w pepsin-loaded hydrogel.  This indicates that the PVA-borate 
hydrogel may be able to provide a sustained release for protein payloads of a similar 
molecular weight and isoelectric point.  SDS-PAGE was used to analysis the 
molecular weight of the pepsin, which was released from the hydrogel, in 
comparison to a sample of the stock pepsin.  It was concluded that the pepsin had not 
undergone degradation, in terms of changes in molecular weight, on being released 
from the hydrogel.  This investigation showed that the enzymatic activity of the 
pepsin could not be maintained upon release from the PVA-borate hydrogel.  
To conclude, the results from this study indicate that in moving forward with 
the overall aim of the project, careful consideration needs to be taken when choosing 
a suitable protein payload, which promotes wound management and repair.  This is 
to ensure that the biological activity of the payload can be maintained when 












5 Formulation, characterisation, in vitro release, stability and 




Based on the results in Chapter Three and Four it was decided to proceed with the 
incorporation and release of insulin-like growth factor-1 (IGF-1).  IGF-1 is known to 
cause an increase in cell migration and proliferation.   Therefore, research has been 
conducted to determine if the topical application of exogenous IGF-1 to wounds can 
enhance healing (Tsuboi et al., 1995; Koshizuka et al., 1997; Nagano et al., 2003; 
Emmerson et al., 2012; Nunes Achar et al., 2014). 
 The structure, biological function, therapeutic use and experimental use of 
IGF-1 was discussed in detail in Chapter One, section 1.4.6.  Briefly, IGF-1 is a 7.6 
kDa poly(peptide) consisting of 70 amino acids, with an A and B chain linked 
together by disulphide bonds (Laron, 2001).  The major source of circulating IGF-1 
is the liver and its main function is to control cell differentiation (Dercole et al., 
1984).  The majority of circulating IGF-1 (approx. 80 %) is bound with high affinity 
in a ternary complex with insulin-like growth factor binding protein-3 (IGFBP-3) and 
an acid labile glycoprotein subunit.  The ternary complex prolongs the half-life of 
IGF-1, protecting it from proteolytic degradation (Laviola et al., 2007).  In order to 
mediate its intra-cellular effect IGF-1 binds to a 1326-amino acid tyrosine kinase 
transmembrane receptor, known as insulin-like growth factor-1 receptor (IGF-1R) 
(Jones & Clemmons, 1995). 
 A commercially available recombinant preparation of IGF-1 for clinical use 
is Increlex™.  Increlex™ is indicated for the treatment of growth retardation in 
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children aged 2–17 years, who have severe primary IGF-1 deficiency (BNF, 2017).  
Increlex™ is given by subcutaneous injection with a maximum maintenance dose of 
120 μg kg-1 twice daily.  Increlex™ is to be discontinued if there is no evident 
response after one year of treatment (BNF, 2017).  
 Nunes Achar et al. (2014) applied creams containing IGF-1 (1 % and 3 %) to 
wounds on non-diabetic and diabetic rats, to evaluate the effect of topically delivered 
IGF-1 on wound healing.  They found that both creams increased re-epithelisation in 
all the treated groups compared to the control group.  Similarly, Provenzano et al. 
(2007) concluded that subcutaneous injection of IGF-1 to ligament wounds in rats 
caused increased healing in comparison to the control group and a group treated with 
growth hormone.  IGF-1 is a potent therapeutic agent demonstrating a median 
effective dose (ED50) of 0.3–1.5 ng mL
-1 when used in a cell proliferation assay 
using MCF-7 human breast cancer cells (Karey & Sirbasku, 1988).  Due to the low 
concentration of IGF-1 being loaded and released in this study, an enzyme-linked 
immunosorbent assay (ELISA) was used to detect and quantify IGF-1 released from 
the PVA-borate hydrogel.   
ELISA is an assay-based technique, which can be used to detect and quantify 
a range of substances, such as proteins, peptides, hormones and antibodies (Gan & 
Patel, 2013).  The molecule to be detected, known as the antigen, must first be 
immobilised.  The antigen is then complexed with an antibody, which is conjugated 
to an enzyme.  A substrate for the enzyme is then added and the product of the 
enzymatic reaction gives a measurable signal.  The measurable signal is most 
commonly fluorescent or chemiluminescent, measured on a spectrometer (Crowther, 
1995).  There are a number of modifications to the basic ELISA procedure, such as 
direct assay, indirect assay and a capture assay also known as a sandwich assay (Gan 
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& Patel, 2013).  A direct assay involves the antigen being adsorbed onto a solid 
surface and the primary antibody conjugated with the enzyme then attaches to the 
antigen (Guidi et al., 2001), as seen in Figure 5.1a.  The advantages of a direct assay 
are, (i) it is less time consuming as there is only one antibody to be added and, 
therefore, fewer steps in the procedure in comparison to the indirect and sandwich 
assay, and (ii) cross-reactivity of the secondary antibody is eliminated as there is 
only the primary antibody present.  Disadvantages of the direct assay are, minimum 
signal amplification and the immunoreactivity of the primary antibody could be 
affected by conjugation with the enzyme, leading to reduced binding with the 
antigen. 
 
Figure 5.1 Schematic diagram showing an antigen adsorbed onto a solid plate and then assayed using 
a) a direct ELISA and b) an indirect ELISA.  
 
An indirect assay also requires the adsorption of the antigen onto a solid surface prior 
















the primary antibody in an indirect assay is not conjugated to the enzyme.  Instead, 
there is a secondary enzyme-conjugated antibody, which binds to the primary 
antibody, as seen in Figure 5.b.  The advantages of the indirect assay method are (i) 
maximum immunoreactivity of the primary antibody is achieved due to no 
conjugation, (ii) increased sensitivity as each primary antibody has several binding 
regions for secondary conjugated antibodies, thus, increasing signal amplification, 
and (iii) different conjugated secondary antibodies are commercially available for 
use with the one primary antibody.  The two main disadvantages are non-specific 
signalling may occur due to cross-reactivity of the secondary antibody and it is time 
consuming due to second antibody needing to be added.  A capture or sandwich 
assay is similar to the indirect assay with the difference being that the antigen is 
captured by a third antibody, which is prefixed to a solid surface, usually a 96-well 
plate.  The advantages and disadvantages of the sandwich assay are similar to those 
of the indirect assay.  However, the sandwich assay gives higher specificity due to 
the capturing of the antigen by a highly specific third antibody (Gan & Patel, 2013).  
In this chapter, a modified sandwich assay was used for the detection and 
quantification of IGF-1.  The modification was that the secondary detection antibody 
was eliminated, leaving the prefixed capture antibody and the enzyme conjugated 




Figure 5.2 Schematic diagram illustrating the detection and quantification of the antigen, IGF-1, using 
a sandwich chemiluminescence ELISA.   
 
 
 Aims and objectives 
The aim of this study was to formulate, characterise and complete in vitro release 
studies for IGF-1-loaded PVA-borate hydrogels (PVA 6.0 % w/w borate 2.0 % w/w). 
 
Objectives; 
 formulate PVA-borate hydrogels loaded with varying concentrations of IGF-
1, 
 characterise the viscoelastic properties of the IGF-1-loaded PVA-borate 
hydrogels using oscillatory rheometry, 
 complete in vitro release studies for the IGF-1-loaded hydrogels using Franz 
diffusion cells, 
 detect and quantify IGF-1 released from the hydrogels using an enzyme-














Chemicals and reagents 
Poly(vinyl alcohol) (PVA) (Mw = 31–50 kDa, 98-99 % hydrolysed), sodium 
tetraborate decahydrate (ACS reagent ≥ 99.5 %), dialysis tubing cellulose membrane 
(Mw cut off 14 kDa, average flat width 43 mm), α-cyano-4-hydroxycinnamic acid 
(CHCA), sinapinic acid and trifluroacetic acid were purchased from Sigma-Aldrich 
Ltd. (Gillingham, Dorset, UK). 
Peptide Calibration Mix 2 (LaserBio Labs, Spohia-Antipolis, Cedex, France).  
Recombinant human Insulin growth-like factor-1 and Human Quantikine® ELISA 
kits were purchased from R & D Systems a biotechne® brand (Abingdon, UK). 
All reagents were of appropriate laboratory standard and used without further 
purification. 
Deionised water (R ≥ 18 MΩ cm) was obtained from a Purelab Ultra, purification 
system, Egla (Marlow, UK).  
 
Apparatus  
Kinexus Pro rheometer, Malvern instruments (Malvern, Worcestershire, UK). 
FLUOstar® Omega microplate reader, BMG LABTECH Ltd. (Ortenburg, Germany).   
Franz diffusion cells, Perme-Gear diffusion cells & systems. (USA) and Techne TE 
10D Tempette® water bath & Pump, Bibby scientific Ltd. Staffordshire. (UK) 





5.4.1 Formulation of IGF-1-loaded PVA-borate hydrogels 
An optimum hydrogel formulation of 6.0 % w/w PVA and 2.0 % w/w borate was 
selected and loaded with various quantities of IGF-1 (50, 100, 200 ng).  A sample 
(25 g) of this formulation was prepared by mixing 6.25 g of PVA stock solution (24 
% w/w) and 10.00 g of borax stock solution (5 % w/w), as previously described.  To 
a desired quantity of hydrogel the appropriate volume of the IGF-1 stock solution (1 
μg mL-1) was added and mixed in using a stainless steel spatula.  The hydrogel was 
then stored in the fridge (2–8 °C) until used.  Final formulations were clear and 
homogenous in appearance with no air bubbles present. 
 
5.4.2 Viscoelastic analysis 
Analysis of the viscoelastic properties was carried out using a Kinexus Pro rheometer 
(Malvern Instruments Ltd., Worcestershire, UK) on all hydrogel formulations, as 
described previously in sections 2.4.2.  Briefly, a strain (1.0 %) controlled frequency 
sweep (0.1–10 Hz) was completed from which, the crossover modulus (Gc) was 
determined.  All tests were carried out at 25 °C ± 0.2 °C, using 20 mm diameter 
stainless steel parallel plate geometry and a working gap of 1 mm.  Three replicates 
were performed for each formulation (n=3).  Student’s t-test statistical analysis was 
carried out on the data. 
 
5.4.3 In vitro release study 
IGF-1 release studies were carried out using Franz diffusion cells (Perme Gear cells 
& Systems, USA) and a Techne TE 10D Tempette® water bath & Pump (Bibby 
scientific Ltd. Staffordshire, UK).  All release studies were carried out at 37 °C using 
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cellulose dialysis membrane cut to size (MW cut off 14 kDa Sigma Aldrich). A 
sample (1.00 g) of hydrogel (PVA 6.0 % w/w borate 2.0 % w/w) containing 200 ng 
of IGF-1 was placed in each donor chamber at time zero.  Samples (0.5 mL) were 
withdrawn at specified time intervals (0–8 hours) and replaced with 0.5 mL of fresh 
receiver phase.  A blank PVA-borate hydrogel of the same formulation was ran as a 
control. 
 
5.4.4 Detection and quantification of IGF-1 released from the PVA-borate 
hydrogel using an enzyme-linked immunosorbent assay (ELISA) 
A solid phase Quantikine® ELISA kit (R & D systems, bio-techne®) was used to 
detect and quantify the IGF-1 in the samples taken from the receiver phase of the 
Franz cell.  Each well of the supplied 96-well plate is pre-coated with a monoclonal 
capture antibody specific for IGF-1.  To each well, 150 μL of assay diluent RD1-53 
was added, followed by 50 μL of standards (0.094–6.000 ng mL-1) or the samples to 
be tested.  The wells were then covered with an adhesive strip and incubated at 
between 2–8 °C for 2 hours.  Once this time had passed, all the liquid was removed 
from each well and washed four times with wash buffer.  The plate was flicked over 
a sink after each wash to ensure removal of all liquid.  After the fourth wash, the 
plate was inverted and blotted against clean tissue paper to ensure all the wash buffer 
was removed.  Human IGF-1 conjugate polyclonal detection antibody (200 μl) was 
added to each well.  The plate was covered with a new adhesive strip and incubated 
for 1 hour between 2–8 °C.  All of the solution in each well was removed and each 
well was washed another four times, as described previously.  To each well, 200 μL 
of substrate solution was added and incubated for 30 minutes at room temperature, 
wrapped in tin foil and placed in a cupboard to protect it from light. After 30 
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minutes, 50 μL of sulfuric acid (9.8%) was added to each well to stop the reaction 
and a colour change from blue to yellow occurred.  The optical density of each well 
was read at 450 nm using a FLUOstar® Omega microplate reader, (BMG LABTECH 
Ltd. Ortenburg, Germany).  Wavelength correction was set at 540 nm to compensate 
for any optical imperfections in the plate. Six replicates were completed for each 
sample and standard (n=6), with three optical density readings taken for each well 
(n=3).  
 
5.4.5 Matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry. (MALDI-TOF MS) analysis of IGF-1 
MALDI-TOF MS was performed using a PerSeptive Biosystems Voyager-DE 
Biospectrometer (Hertfordshire, UK) equipped with a 1 m time-of-flight tube.  A 10 
mg mL-1 solution of the appropriate matrix of either α-cyano-4-hydroxycinnamic 
acid (α-CHCA) or sinapinic acid was prepared in 80 % acetonitrile, 20 % water with 
0.1 % trifluroacetic acid.  The matrix was vortexed thoroughly to mix and 
centrifuged for 2 minutes to ensure any undissolved matrix settled to the bottom of 
the tube.  Only the supernatant was used.  A 10 µL aliquot of matrix was vortexed 
with 10 µL of each sample, to mix thoroughly.  A 1.5 µL aliquot of the mixture was 
pipetted onto a predefined well of a 100-well stainless steel plate.  Once the spotted 
samples had dried on the plate, the plate was inserted into the MALDI-TOF.  An 
internal mass calibration of the instrument was performed prior to sample analysis 
using Peptide Calibration Mix 2 (LaserBio Labs, Spohia-Antipolis, Cedex, France) 
containing four individual peptides; Neurotensin, ACTH fragment 18–39, Insulin 
bovine β-chain oxidised and Insulin bovine, with monoisotopic masses of 1672.9176, 
2465.1989, 3494.6514 and 5730.6087 Da, respectively.  All sample measurements 
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were collected in linear positive ionisation mode using 100 laser shots/spectrum.  
When using CHCA matrix, the accelerating voltage was maintained at 20,000 V, 
with the grid voltage and guide wire voltages set at 93 % and 0.05 %, respectively, of 
the accelerating voltage.  When using sinapinic acid matrix, the accelerating voltage 
was maintained at 25,000 V, with the grid voltage and guide wire voltages set at 92 
% and 0.3 %, respectively, of the accelerating voltage.  The nitrogen laser set at 337 
nm and directed toward a dense area of the sample spot.  The laser intensity was 
adjusted to obtain the best spectral response and mass/ charge ratio (m/z) was plotted 
against relative abundance. 
 
 Results 
Three concentrations of IGF-1 were incorporated into samples of a PVA 6.0 % w/w 
borate 2.0 % w/w hydrogel, after which rheological and statistical analysis were 
carried out.  It can be seen in Figure 5.3 that the addition of 50 ng g-1 of IGF-1 into 
the hydrogel caused a small increase in the crossover modulus from 3831 ± 187 Pa to 


























Figure 5.3 Graph showing the effect of incorporating 50 ng g-1 of IGF-1 into a PVA (6.0 % w/w) 
borate (2.0 % w/w) hydrogel has on the crossover modulus, compared to a blank hydrogel, of the 
same formulation.  Data shown as the mean ± standard deviation (n=3).  All measurements carried out 
at 25°C ± 0.2°C. 
 
Figure 5.4 shows that on adding 100 ng g-1 of IGF-1 to the hydrogel there was again 
a small increase in the crossover modulus from 3524 ± 136 Pa to 3562 ± 116 Pa.  A 
difference of 38 Pa, which is smaller than the difference (335 Pa) seen between the 
blank hydrogel and the hydrogel loaded with 50 ng g-1 of IGF-1, as seen in Figure 
5.3.  The increase caused by the loading of 100 ng g-1 of IGF-1 was not significant (p 
= 0.8843), similar, to the increase caused by the 50 ng g-1.  
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Figure 5.4 Graph showing the effect of incorporating 100 ng g-1 of IGF-1 into a PVA (6.0 % w/w) 
borate (2.0 % w/w) hydrogel has on the crossover modulus, compared to a blank hydrogel, of the 
same formulation.  Data shown as the mean ± standard deviation (n=3).  All measurements carried out 
at 25°C ± 0.2°C. 
 
On adding 200 ng g-1 of IGF-1 to the hydrogel, the crossover modulus decreased 
from 2689 ± 105 Pa to 2591 ± 239 Pa.  This is the opposite effect from that observed 
previously, when adding 50 and 100 ng g-1 of IGF-1 to the hydrogel.  The decrease in 
the crossover modulus seen in Figure 5.5 is small (98 Pa) and is again not significant 
(p = 0.7264).  Overall there is no general trend seen between the three concentrations 
and the change in the crossover modulus caused by all three concentrations are 
deemed not significant. 
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Figure 5.5 Graph showing the effect of incorporating 200 ng g-1 of IGF-1 into a PVA (6.0 % w/w) 
borate (2.0 % w/w) hydrogel has on the crossover modulus, compared to a blank hydrogel, of the 
same formulation.  Data shown as the mean ± standard deviation (n=3).  All measurements carried out 
at 25°C ± 0.2°C. 
 
Having failed to detect IGF-1 released from the hydrogel in the receiver phase using 
HPLC and a commercially available fluorometric assay kit, due to lack of adequate 
sensitivity, it was decided to use an ELISA assay kit.  The ELISA was both specific 
and highly sensitive at detecting IGF-1 in the receiver phase, having a minimum 
detectable concentration of 0.026 ng mL-1.  Figure 5.6, shows the calibration plot 
achieved for the Human IGF-1 ELISA assay.  As seen in Figure 5.6 the r2 value is 
0.9996 showing that the data is correlated and, therefore, confidence can be had in 




Human IGF-1 ELISA Calibration plot







y = 0.2743x - 0.0146
r2 = 0.9996











Figure 5.6 Human IGF-1 ELISA calibration plot produced using several dilutions of an IGF-1 stock 
solution 60 ng mL-1.  The standard dilutions concentration range was 0.094–6.000 ng mL-1.  The 
optical density λ = 450 nm and the wavelength correction set at 540 nm.  The data is shown as mean ± 
standard deviation (n=6). 
 
A percentage cumulative release profile for a PVA 6.0 % w/w borate 2.0 % w/w 
hydrogel loaded with 200 ng of IGF-1 can be seen in Figure 5.7.  Due to the high 
cost of both the IGF-1 drug and the ELISA kit, only three replicates of a release 
profile for one concentration was achieved.  However, this is the quantity of IGF-1 
which will be used in the hydrogel for further cell culture studies.  Therefore, it is 
imperative that an understanding of how this quantity of IGF-1 is released from the 
hydrogel over a set period of time.  After 7 hours, a maximum percentage release of 
58.15 ± 4.88 % was achieved equating to approximately 116.3 ng of IGF-1.  The 
release profile shows a slower release of IGF-1 from hours 1 to 4, followed by a 
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period of a more rapid release from hours 4 to 6.  The release profile then begins to 
plateau between hours 6 and 8.  
 
Percentage cumulative release profiles for a IGF-1 loaded PVA borate hydrogel






























Figure 5.7 Percentage cumulative release profiles a PVA (6.0 % w/w) borate (2.0 % w/w) hydrogel 
loaded with 200 ng g-1, over 8 hours.  Release studies were carried out at 37 °C using cellulose 
dialysis membrane (MW cut off 14 kDa), on Franz diffusion cells.  The data is shown as the mean ± 
standard deviation (n=3). 
 
Samples were taking from the receiver phase of the Franz diffusion cells and subject 
to MALDI-TOF analysis to determine if any changes in the molecular weight of the 
IGF-1 had occurred during its time in the hydrogel, or during the release process.  
Any changes in molecular weight compared to an IGF-1 standard would be 
indicative of degradation of the poly(peptide).  Figure 5.8 shows the MALDI-TOF 
spectra for the internal standard calibration.  It can be seen from the spectra that the 
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peaks for the four proteins are found to be at the correct molecular weights as stated 
in method section 5.4.5 (1672.9176, 2465.1989, 3494.6514 and 5730.6087 Da). 
 
Figure 5.8 MALDI-TOF spectra for Peptide Calibration Mix 2 containing four individual peptides; 
Neurotensin, ACTH fragment 18–39, Insulin bovine β-chain oxidised and Insulin bovine with 
monoisotopic masses of 1672.9176, 2465.1989, 3494.6514 and 5730.6087 Da, respectively.  A 
sinapinic acid matrix was used and, therefore, the accelerating voltage was maintained at 25,000 V, 
with the grid voltage and guide wire voltage set at 92 % and 0.3 %, respectively, of the accelerating 
voltage.  The nitrogen laser set at 337 nm and the time-of-flight tube was 1 m. 
 
The MALDI-TOF spectra for the IGF-1 standard can be seen in Figure 5.9.  It can be 
seen that there is a sharp peak at 7664.41 Da, which is the same as the documented 
molecular weight for the IGF-1 protein (7.6 kDa), stated on the certificate of 
analysis.  This confirms that the protein sent from the company is IGF-1 and also 
serves as the comparison for the released IGF-1 from the hydrogel.  The peak at 
7755.87 Da to the left of the main 7664.41 Da peak is thought to be a matrix cluster 
adduct.  
 





































Figure 5.9 MALDI-TOF spectra for IGF-1 standard (molecular weight 7.6 kDa), using sinapinic acid 
matrix.  The accelerating voltage was maintained at 25,000 V, with the grid voltage and guide wire 
voltage set at 92 % and 0.3 %, respectively, of the accelerating voltage.  The nitrogen laser set at 337 
nm and the time-of-flight tube was 1 m.  
 
Figure 5.10 shows the MALDI-TOF spectra for the IGF-1 released from the hydrogel 
into the receiver phase of the Franz diffusion cells.  It can be seen that there is a peak 
at 7640.49 Da, although it is not as intense as the peak seen in Figure 5.9 and is 
23.92 Da less.  However, confidence can be had that IGF-1 has not been subject to 
extensive degradation during the formulation and release process.  There is also a 
peak of lower intensity to the left of the 7640.49 Da peak at 7676.31 Da.  This is 
similar to what was seen in Figure 5.9 for the standard IGF-1 sample and again is 
thought to be a matrix cluster adduct. 
 



































Figure 5.10 MALDI-TOF spectra for IGF-1 released from a PVA 6.0 % w/w borate 2.0 % w/w 
hydrogel over an 8-hour period.  A sinapinic acid matrix was used and therefore, the accelerating 
voltage was maintained at 25,000 V, with the grid voltage and guide wire voltage set at 92 % and 0.3 
%, respectively, of the accelerating voltage.  The nitrogen laser set at 337 nm and the time-of-flight 
tube was 1 m. 
 
 Discussion 
Several different delivery systems have been investigated for administration of 
insulin-like growth factor-1 (IGF-1), such as poly(lactic acid-co-glycolic acid) 
(PLGA) microspheres (Elisseeff et al., 2001), alginate cross-linked biomaterial 
(Ruvinov et al., 2011), chitosan-tripolyphosphate microspheres (Mantripragada & 
Jayasuriya, 2014), a topical solution (Tsuboi et al., 1995), multivesicular liposomes 
(Katre et al., 1998) and topical cream (Nunes Achar et al., 2014).  However, there 
has been no published data in relation to the use of a PVA-borate hydrogel as a 
sustained delivery system for growth factors, and IGF-1 in particular. 
 On loading three concentrations of IGF-1 (50, 100 and 200 ng g-1) into 
samples of a PVA 6.0 % w/w borate 2.0 % w/w hydrogel, it was found that there was 
no significant (p = 0.2023, 0.8843 and 0.7264, respectively) change in the 
viscoelastic properties of the hydrogel, compared to a hydrogel of the same 
formulation with no IGF-1.  IGF-1 has an isoelectric point of approximately 8.6 

































(Chen et al., 2006) and as the pH of the PVA 6.0 % w/w borate 2.0 % w/w hydrogel 
is 8.3 the IGF-1 will most likely have a weak positive net charge.  However, due to 
the pH of the hydrogel being close to the isoelectric point of IGF-1, a proportion of 
the IGF-1 may have no overall net charge and as a result will not have any charge 
interaction with the hydrogel.  This may explain why there is no significant change in 
the viscoelastic properties of the gel.  Chen et al. (2006) state that ionic interactions 
between opposite charged molecules can dissociate overtime, but, that it is 
statistically unlikely that they will all dissociate simultaneously.  If the IGF-1 is 
positively charged, there is the possibility of electrostatic interaction with the 
negatively charge poly(electrolyte) that is formed in the complexation process of the 
PVA and borate (Loughlin et al. 2008) or, with negatively charged regions on the 
polymers due to the reversible nature of the PVA-borate cross-link.  This may 
explain the small increase observed in the crossover modulus, although, as 
mentioned previously, it is not statistically significant.  Nanogram quantities of IGF-
1 were incorporated in the hydrogel, and therefore, any electrostatic interactions that 
do occur may be insignificant.  This could be another reason why the small increase 
in crossover modulus is not statistically significant and has no overall effect on the 
viscoelastic properties of the hydrogel.  If the IGF-1 has a hydrodynamic diameter 
smaller than the pore size of the hydrogel matrix, the IGF-1 may reside within the 
pores without causing any change in the viscoelastic properties of the gel itself 
(Mantripragada & Jayasuriya, 2014), especially if the IGF-1 has no overall net 
charge.  This may be possible as the IGF-1 has the lowest molecular weight (7.6 
kDa) of the five proteins loaded into the PVA-borate hydrogel in this thesis and is the 
only one which did not cause a change in the viscoelastic properties of the hydrogel.  
However, further work involving the measurement of the diameter of the pores 
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within the hydrogel and the hydrodynamic diameter of IGF-1 would need to be 
completed in order to confirm this theory. 
 Due to the high cost of the ELISA kits and difficulties obtaining data initially, 
only three replicates of one concentration (200 ng g-1) of an IGF-1-loaded hydrogel 
were achieved.  However, this is the concentration of IGF-1, which would be used in 
cell culture studies in future work.  Therefore, it was important that release data was 
obtained for the 200 ng g-1 IGF-1-loaded hydrogel, to determine the quantity released 
over a defined period of time.  The PVA-borate hydrogel delivered a sustained 
release of IGF-1 over 8 hours at 37 °C.  The reason for the hydrogel giving a 
sustained release of IGF-1 is thought to be due to a combination of effects.  If the 
IGF-1 has no overall net charge and the hydrodynamic size of the IGF-1 molecule is 
smaller than that of the pore size within the hydrogel matrix then it can be assumed 
that the IGF-1 will freely move through the gel matrix and into the receiver phase by 
passive diffusion.  This may still partially occur if the IGF-1 has a weak positive 
charge, if the interactions were to dissociate gradually over a period of time, as 
suggested by Chen et al. (2006), but, this would give a slower rate of release.  
Mantripragada & Jayasuriya (2015) concluded that when the chitosan-
tripolyphosphate cross-linking density was reduced and the delivery system was 
exposed to an acidic environment, the mesh size became larger than the encapsulated 
IGF-1 molecules, resulting in an increase in the release of IGF-1.  In an acidic 
environment, the chitosan-tripolyphosphate complex became positively charged 
resulting in repulsion between protonated amino residues, enlarging the mesh size 
and allowing free passage of the positive charged IGF-1 through the matrix 
(Mantripragada & Jayasuriya, 2014).  Conversely, on exposure of the chitosan-
tripolyphosphate microspheres to a basic environment, the mesh size decreases due 
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to the chitosan molecules taking on a globular shape.  This entraps the protein, 
decreasing the rate of release.  Any release that occurred when exposed to a basic 
environment was deemed to be due to enzymatic degradation of the chitosan 
microspheres (Mantripragada & Jayasuriya, 2014).  If the IGF-1 is positively charged 
and involved in opposite charge interaction or has a larger hydrodynamic diameter 
than the pore size of the hydrogel, then the release is most likely governed by 
degradation of the hydrogel matrix.  If the loaded protein has a larger hydrodynamic 
radius than the polymeric matrix (Censi et al., 2012) or is involved in opposite 
charge interaction with the delivery system (Chen et al., 2006), swelling and erosion 
or degradation of the PVA-borate hydrogel must occur, for release to take place.  
From the swelling studies carried out in Chapter Two, it was determined that after 
180 minutes the PVA-borate hydrogels began to disintegrate in the deionised water 
due to extensive swelling.  This may explain why the release profile indicates a 
greater rate of release for 4 to 6 hours as during this time period the hydrogel began 
to disintegrate, increasing the IGF-1 release.  Katre et al. (1998), Elisseeff et al. 
(2001), Chen et al. (2006), Ruvinov et al. (2011) and Mantripragada & Jayasuriya 
(2015) all demonstrated sustained release of IGF-1 from their respective delivery 
systems, similar to the PVA-borate hydrogel.  They all also used ELISAs to detect 
and quantify the IGF-1 released from their delivery systems.  This indicates that the 
ELISA was an appropriate technique to use for detection of low concentrations of 
IGF-1 (ng g-1), due to the high specificity and sensitivity of the ELISA test. 
 The molecular weight of IGF-1 was analysed using MALDI-TOF mass 
spectrometry to determine if the IGF-1 was subject to degradation after release from 
the gel.  On analysis of the spectra, it was found that there was a peak present at 
7640.49 Da.  The certificate of analysis for the IGF-1 states that the molecular 
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weight of the IGF-1, determined by MALDI-TOF, is 7.6 kDa (R&D Systems, 2015).  
Therefore, confidence can be had that this peak is IGF-1 and that it has not 
undergone any degradation according to its molecular weight.  There was, however, 
a small discrepancy of 23.92 Da between the standard sample of IGF-1, which 
produced a peak at 7664.41 Da and the molecular weight of the released IGF-1.  This 
difference (23.92 Da) is smaller than the molecular weight of a single residues of 
glycine (75.1 Da), which is the amino acid with the lowest molecular weight.  
Therefore, this would indicate that the IGF-1 released from the hydrogel has not lost 
any amino acid residues from its chain.  A lower intensity peak at a higher molecular 
weight was observed on the left-hand-side of the main peak of IGF-1.  This 
additional peak was observed for both the standard IGF-1 sample and released IGF-1 
sample.  These additional peaks can also be seen on some of the peptide calibration 
mix peaks, in particular the peak at 5734.64 Da.  As these extra peaks are present in 
the calibration spectra and the peaks belonging to proteins within the calibration mix 
are all at the correct molecular weight, it could be assumed that they are 
characteristic to the matrix that is used.  One possible explanation is protein-matrix 
cluster adducts, which become evident in MALDI-TOF spectra when the 
concentration of peptide or protein being analysed is low (Keller & Li, 2000; Zbu & 
Papayannopoulos, 2003).  Matrix cluster adducts are thought to occur due to salts 
being present in the sample itself or which have been extracted from contaminated 
plastics and equipment used to prepare the samples or matrix (Keller & Li, 2000).  
Matrix cluster adducts can cause several interference peaks, peak broadening, peak 
tailing and increase the size of the protein (Sachon et al., 2007).  Other factors that 
can cause matrix cluster peaks are; the pH of sample, high laser intensity and the 
matrix used.  Zbu & Papayannopoulos (2003) observed matrix clusters when using 
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α-cyano-4-hydroxycinnamic acid (α-CHCA) matrix and Sachon et al. (2007) 
observed matrix clusters using sinapinic acid matrix.  Both these matrices were used 
in the analyses of IGF-1 in this chapter and also the IGF-1 stock solution was 
reconstituted in phosphate buffer saline (PBS).  
 
 Conclusion 
It was found that upon incorporating any of the three concentrations (50, 100 and 200 
ng g-1) of IGF-1 into the PVA (6.0 % w/w)-borate (2.0 % w/w) hydrogel that there 
was no change in the viscoelastic properties.  This was determined using oscillating 
rheometry, whereby, no significant (p = 0.2023, 0.8843 and 0.7264, respectively) 
change in the crossover moduli was observed for any of the three concentrations, in 
comparison to a blank hydrogel.  The PVA-borate hydrogel loaded with 200 ng g-1 of 
IGF-1 was found to provide a sustained release over an 8-hour period at 37 °C.  The 
maximum percentage cumulative release (58.15 ± 4.88 %) was observed after 7 
hours.  The median effective dose (ED50) of the IGF-1 used in this study, in human 
cell lines, is 0.3-1.5 ng mL-1, as stated by the manufacture in the certificate of 
analysis (R&D Systems, 2015).  Therefore, with 58.15 ± 4.88 % cumulative release 
over 8 hours, confidence can be had in the PVA-borate hydrogel delivering a 
sufficient quantity of IGF-1 in future cell culture work to observe any effect it may 
have on the cells.  Molecular weight analysis of the IGF-1 poly(peptide) prior to 
incorporation into the PVA-borate hydrogel and on release from the hydrogel 
confirmed that no degradation had occurred that resulted in a change in molecular 
weight of the growth factor.  It can be concluded that the PVA-borate hydrogel has 
the potential to be a suitable topical delivery system for sustained release of growth 












6 Cell culture and cell signaling pathway investigation 
 Introduction 
In the previous Chapter (Five), it was established that the PVA-borate hydrogel is 
capable of delivering a sustained release of IGF-1, over an 8-hour period at 37 °C.  
The key question to be answered in this chapter was to determine if the IGF-1 
released from the hydrogel was biologically active.  In order to do this, cell culture-
based investigations were completed using two human skin cell types of keratinocyte 
and fibroblast origin.  Both these cell types were chosen due to their dermatological 
role in the wound healing process. 
 Fibroblasts are the most common cell type found in the dermal layer 
of the skin and are a member of the connective tissue family (Tracy et al., 2016).  
Fibroblasts are heterogeneous cells, changing their appearance and function 
depending on their location within the body (Tracy et al., 2016).  In the skin, the 
main role of the fibroblasts is to synthesise proteins, such as fibronectin, hyaluronan, 
proteoglycans and collagen, which are components of the extracellular matrix (ECM) 
(Velnar et al., 2009).  Therefore, without the presence of fibroblasts, there would be 
no ECM scaffold for keratinocytes to migrate over in the later stages of the 
proliferation phase (Li et al., 2007).  Growth factors, such as TGF-β and PDGF 
secreted by platelets and other inflammatory cells stimulate fibroblasts to migrate 
into the wound from surrounding tissue (Velnar et al., 2009).  Fibroblasts undertake 
a phenotype change to myofibroblasts, on completion of the secretion of ECM 
proteins and proliferation.  The myofibroblasts aid in wound contraction, after which 
they are removed by apoptosis (Velnar et al., 2009). 
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 Keratinocytes play an important role in the re-epithelialisation during the 
proliferation phase of wound healing and are regulated by keratinocyte growth factor 
(KGF), predominately secreted from fibroblasts (Werner, 1998).  A major source of 
keratinocyte stem cells is from hair follicles in the dermis layer of the skin (Hirobe, 
2014).  As the keratinocyte stem cells begin to travel upward towards the epidermal 
layer, they differentiate.  During differentiation, the keratinocytes produce and store 
keratin in their cytoplasm, a process known as keratinisation or cornification (Hirobe, 
2014).  The keratinised keratinocytes form the majority of the epidermis with dead 
keratinised keratinocytes forming the outermost layer of the skin, known as the 
stratum corneum (Martini & Nath, 2009), as seen in Figure 6.1.  Therefore, the 
homeostasis of the epidermis is dependent on the proliferation and differentiation of 
keratinocytes (Hirobe, 2014).  During re-epithelialisation, keratinocytes migrate over 
the top of the newly formed granulation tissue from the edges of the wound.  The 
migrating edges are steered in the correct direction by binding to fibronectin in the 
newly formed ECM (Baum & Arpey, 2005).  Once the leading edges meet, migration 
is stopped by a mechanism known as contact inhibition.  The cells then begin to form 





Figure 6.1 Histological picture showing the various layers of the epidermis and the beginning of the 
dermis.  This is taken from a thick-skinned area, such as the palm of the hands or soles of the feet, as 
evidenced by the depth of the stratum corneum (approximately 0.5 mm) and the presence of the 
stratum lucidum, which is not found in thin-skinned areas. The stratum corneum is approximately 
0.08 mm deep in thin-skinned areas, which covers most of the body (Martini & Nath, 2009).  Light 
magnification x 210. 
 
 Current research indicates that the application of IGF-1 to wounds causes 
increased cell proliferation, migration and, therefore, increased wound healing 
(Tsuboi et al., 1995; Koshizuka et al., 1997; Nagano et al., 2003; Emmerson et al., 
2012; Nunes Achar et al., 2014).  In addition, Loughlin et al. (2008), McCarron et al. 
(2011) and Murphy et al. (2012) conclude that the PVA-borate hydrogel is a suitable 
delivery system for topical application to wounds.  Therefore, an IGF-1-loaded PVA-




Insulin-like growth factor-1 (IGF-1) is known to trigger cell proliferation and 
migration.  As a result of this, research has been conducted to establish if exogenous 
topical application of IGF-1 can stimulate wound healing (Tsuboi et al., 1995; Nunes 
Achar et al., 2014).  Tsuboi et al. (1995) concluded that topical application of eye 
drops containing IGF-1 stimulates corneal epithelial wound healing in neurotrophic 
keratopathy in a rat model.  Likewise, Nunes & Achar (2014) concluded that topical 
application of a cream containing IGF-1 increases the expression of myofibroblasts 
in skin wounds on rats, resulting in increased wound healing.  Binding of IGF-1 to 
the transmembrane IGF-1 receptor (IGF-1R) triggers a complex interconnected 
network of cell signalling pathways.  On activation of IGF-1R, a cascade of 
interactions and reactions occur, which leads to the activation of Akt and ERK 
(Vincent & Feldman, 2002).  Stimulation of both these pathways leads to an increase 
in anti-apoptotic factors, such as nuclear factor-Kβ (NF-Kβ), Bcl2 and BclX, and 
inhibition of pro-apoptotic factors, such as caspase-9, Bad, GSK-3β, FasL and FKH 
(Vincent & Feldman, 2002).  This was found to result in increased cell proliferation 
and migration.  Therefore, in this chapter, an immunofluorescent chemistry technique 
was used to determine if IGF-1 delivered by the PVA-borate hydrogel caused 
upregulation of the Akt pathway in the two cell lines.  
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 Aims and objectives 
The aim of this study was to evaluate the effect that applying an IGF-1-loaded PVA-
borate hydrogel had on two human skin cell lines and to determine activation of an 
intracellular signaling pathway by IGF-1. 
 
Objectives; 
 determine the growth rate of the HaCaT and Hs27 cell lines, 
 evaluate the effect of free IGF-1 on the growth rate of both human skin cell 
lines, 
 evaluate hydrogel toxicity towards both human skin cell lines, 
 evaluate the effect of IGF-1 has on cell proliferation and migration using a 
scratch assay, 
 determine if IGF-1 causes upregulation of the Akt cell signaling pathway, 
using immunofluorescent microscopy.  
 
 Materials 
Chemicals and reagents  
Dulbecco Modified Eagle Medium (DMEM), Foetal Bovine Serum (FBS), 
penicillin-streptomycin (Pen-Strep), trypsin EDTA x10, phosphate-buffered saline 
tablets (Dulbecco A tablets) Oxoid and goat anti-rabbit IgG secondary antibody, 
Alexa Fluor 488 were purchased from Thermofisher Scientific Ltd. (Paisley, UK).  
Trypan blue 0.4 % solution, MTT (3-(4, 5 dimethylthiazol-2-yl)-2, 5-diphenyl-
tetrazolium bromide), Triton X100, Tween® 20, bovine serum albumin (BSA), goat 
serum,  dimethyl sulfoxide (DMSO), paraformaldehyde, phalloidin-
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tetramethylrhodamine B isothiocyanate and propidium iodide solution were all 
purchased from Sigma-Aldrich Ltd. (Gillingham, Dorset, UK). 
Recombinant human Insulin growth-like factor-1 was purchased from R & D 
Systems a biotechne brand (Abingdon, UK).  
Phospho-AKt (Ser473) (D9E) XP® Rabbit monoclonal antibody was purchased from 
Cell Signaling Technology® via Brennan and Company (Dublin, Ireland).  
UltraCruz® Mounting Medium was purchased from Santa Cruz Biotechnology 
(Heidelberg, Germany).  
HaCaT and Hs27 cell lines were purchased from ATCC in partnership with LGC 
standards (Middlesex, UK). 
All reagents were of appropriate laboratory standard and used without further 
purification. 
Deionised water (R ≥ 18 MΩcm) was obtained from a Purelab Ultra, purification 
system, Egla (Marlow, UK). 
 
Apparatus 
FLUOstar® Omega microplate reader, BMG LABTECH Ltd. (Ortenburg, Germany). 
Carl Zeiss Primo Vert microscope (Cambridge, UK) equipped with an Axiocam ERC 
5s. 
Carl Zeiss Axio Scope A1 Microscope Nikon, (Japan) and Axiovisio Rel 4.8 
software (Gottingen, Germany).  
Leica TCS SP2 confocal microscope (Milton Keynes, UK). 
Countess™ Automated Cell Counter Invitrogen (USA). 




6.4.1 Culturing of human skin cells 
Human skin cells, HaCaT and Hs27 were cultured in either T75 or T175 culture 
flasks containing 15–20 mL or 20–30 mL of DMEM media supplemented with 1 % 
penicillin-streptomycin and 10 % foetal bovine serum.  Cells were incubated at 37 °C 
in an atmosphere of 5 % CO2 until 70–80 % confluent.  Once the desired confluency 
was reached, spent media was removed from the culture flask and discarded.  Cells 
were washed twice using pre-warmed (37 °C) sterile PBS.  Cells were then 
dissociated from the flask by addition of pre-warmed trypsin-EDTA solution (3 mL 
for T75 and 6 mL for T175) and incubated for 5 minutes at 37 °C.  The cell 
suspension was transferred to a centrifuge tube and the trypsin neutralised by 
addition of an equal volume of media.  Cells were centrifuged at 1200 rpm for 5 
minutes, after which the supernatant was discarded and the pellet of cells re-
suspended in fresh media.  Cells were counted by mixing 10 µL of cell suspension 
with 10 µL of trypan blue solution and loading 10 µL of the mixture onto a 
Countess™ cell counting chamber slide.  The slide was then inserted into the 
Countess™ Automated Cell Counter to obtain the total number of live cells per mL of 
media.  Cells were then seeded at the desired seeding density in the required plates 
for experimental work. 
 
6.4.2 Skin cell growth curves 
HaCaT and Hs27 cells were seeded in 96-well plates at the following seeding 
densities; 1000, 2000, 4000, 6000, 8000 and 10000 cells mL-1.  Cells were seeded in 
replicates of six (n=6) on each plate and two plates were seeded for each cell line.  
Cells were incubated at 37 °C in an atmosphere of 5 % CO2 in 200 μL of DMEM 
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media supplemented with 1 % penicillin-streptomycin and 10 % foetal bovine serum.  
One plate of each cell line was incubated for 24 hours and the other for 48 hours, 
after which an MTT (3-(4, 5 dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium 
bromide) assay was carried out on the cells to determine any increase in cell quantity.  
After incubation, all media were removed and each well washed twice with 200 μL 
of sterile PBS.  A sample (40 μL) of MTT solution (5 mg mL-1 in sterile PBS) was 
added to each well, in minimal light.  To each well, 160 μL of complete DMEM was 
added to achieve a total well volume of 200 μL.  The plates were wrapped in tin foil 
and incubated for 3 hours at 37 °C.  After 3 hours, all media and MTT solution were 
removed from wells and 200 μL of dimethyl sulfoxide (DMSO) added to each well 
to dissolve the insoluble formazan.  The optical density of each well was read at 570 
nm using a FLUOstar® Omega microplate reader, (BMG LABTECH Ltd. Ortenburg, 
Germany). 
 
6.4.3 Skin cells dose-response curve  
HaCaT and Hs27 cells were seeded at a density of 4000 cells mL-1 in 96-well plates.  
Each well was treated with a different concentration of IGF-1 (1, 2, 5, 10, 20, 40, 60, 
80 and 100 ng mL-1).  Six replicates were performed for each treatment (n=6) and a 
MTT assay used to determine any increase in the quantity of cells compared to the 
control group.  Each plate was incubated for 24 hours at 37 °C in 5 % CO2 in DMEM 
media, supplemented with 1 % penicillin-streptomycin and 10 % foetal bovine 
serum.  Student’s t-test statistical analysis was carried out on the data to determine 
any significant responses to IGF-1.   
232 
 
6.4.4  PVA-borate hydrogel toxicity study 
HaCaT and Hs27 cells were seeded in 96-well plate at a density of 10000 cells mL-1 
and a 24-well plate at 0.05 x 106 cell mL-1 in complete DMEM media to a final well 
volume of 200 µL and 500 μL, respectively.  After 24 hours of incubation at 37 °C in 
5 % CO2, the spent medium was removed and the cells washed twice with sterile 
PBS.  A sample of hydrogel was placed on top of the cells in the 24-well plate for 1 
hour and then removed, after which an MTT assay was used to determine cell 
viability.  Six replicates were performed for each treatment (n=6) and cell viability 
was expressed as a percentage relative to the non-treated control cells.  Cells were 
also treated with a range of concentrations of borate (0.5, 1.0, 1.5, 2.0, 2.5 % v/v) and 
a range of concentrations of PVA (6.0, 8.0, 10.0, 12.0 % v/v) in the 96-well plates, 
diluted to the desired concentration with complete DMEM media.  The cells were 
then incubated for 60 minutes, after which an MTT assay was used to determine cell 
viability.  Student’s t-test statistical analysis was carried out on the data. 
 
6.4.5 Scratch assay 
HaCaT and Hs27 cells were seeded at a density of 0.1 x 106 cells mL-1 in 12-well 
plates in complete DMEM media to a final well volume of 1.5 mL.  Cells were 
incubated at 37 °C in 5 % CO2 until a monolayer was formed (approximately 24 
hours later).  A sterile 1 mL plastic pipette tip was used to scratch the surface of the 
monolayer along the diameter of each well.  All wells were washed twice with 1 mL 
of sterile PBS to remove the detached cells.  A volume of 1.5 mL of complete 
DMEM was added to each well along with the desired treatment; i) media only, ii) 
20 ng of free IGF-1, iii) 1.00 g of hydrogel loaded with 200 ng of IFG-1, iv) 1.00 g 
of blank hydrogel.  Twelve-well hanging cell culture inserts with a poly(ethylene 
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terephthalate) membrane (pore size 8.0 μm) were used to deliver IGF-1 directly to 
the cells without the hydrogel coming in direct contact with the cells (Figure 6.2).  
Photographs were taken of each well using a Carl Zeiss Primo Vert microscope 
(Cambridge, UK) equipped with an Axiocam ERC 5s at 0, 12, 24, 36 hours for the 
HaCaT cell line and 0, 6, 12, 24 hours for the Hs27 cell line.  The area of the scratch 
was then measured using ImageJ® software and the percentage scratch closure was 
expressed relative to the time zero area for each well.  All treatments were performed 
in triplicate (n=3).  Statistical analysis was used to determine any significant changes 
in the scratch area by applying two-way analysis of the variance (ANOVA) to the 
data. 
 
Figure 6.2 Schematic diagram of a twelve-well hanging cell culture inserts setup, used to deliver IGF-
1 from PVA-borate hydrogels to the cell monolayer, without direct contact with the cells. 
 
6.4.6 Immunofluorescent microscopy 
Round glass cover slips (13 mm diameter) were placed in the bottom of each well of 
a 12-well tissue culture plate.  HaCaT and Hs27 cells were seeded at a density of 
4000 cells mL-1 in each well, in complete DMEM media to a final well volume of 1.5 
mL.  The seeded cells were then incubated at 37 °C in 5 % CO2 for approximately 24 
hours.  After 24 hours, the desired treatment comprising; i) media only, ii) 20 ng of 
free IGF-1, iii) 1.00 g of hydrogel loaded with 200 ng of IFG-1, iv) 1.00 g of blank 
hydrogel were added to the appropriate wells.  Twelve-well hanging cell culture 
Hydrogel loaded with 
IGF-1 
Monolayer of cells  
Hanging cell culture insert 





inserts with a poly(ethylene terephthalate) membrane (pore size 8.0 μm) were used to 
deliver IGF-1 directly to the cells without the hydrogel coming in direct contact with 
the cell, as seen in Figure 6.2 in section 6.4.5.  After a further 4 hours of incubation 
with each treatment at 37 °C in 5 % CO2, the cells were fixed with 4 % 
paraformaldehyde (PFA) at room temperature for 30 minutes.  Each well was then 
washed three times with PBS for approximately 15 minutes (5 minutes for each 
wash).  The fixed cells were then permeabilised with 0.5 % Triton X-100 in PBS for 
40 minutes at room temperature.  Each well was washed three times for a total of 15 
minutes (5 minutes each wash), first with PBS, second with PBS-Tween 20 and third 
with PBS.  A 1 mL aliquot of blocking buffer, consisting of 10 % goat serum and 1 
% BSA diluted in PBS, was added to each well and left for one hour at room 
temperature.  Remaining blocking buffer solution was removed after the hour had 
passed.  An aliquot of 100 μL of a 1:100 dilution of the primary antibody, Phospho-
Akt (Ser473) rabbit monoclonal antibody in 1 % BSA dissolved in PBS, was added 
to each well.  A small piece of parafilm was cut and placed on top of each slide to 
keep the antibody in contact with the cells at all times and help maintain a humidified 
environment.  Each plate was wrapped in tin foil and placed in the fridge (2–8 °C) 
overnight.  The plates were removed from the fridge the following morning and left 
for 45 minutes at room temperature.  Each well was washed three times for a total of 
15 minutes (5 minutes each wash), first with PBS, second with PBS-Tween 20 and 
third with PBS.  A 100 μL aliquot of goat anti-rabbit IgG secondary antibody Alexa 
fluor 488, diluted 1:1000 in 1 % BSA dissolve in PBS, was added to each well and 
covered with a small piece of parafilm.  Each plate was wrapped in tin foil and 
incubated at 37 °C for 1 hour.  After the hour had passed, any remaining secondary 
antibody solution was removed and each well washed three times as previously 
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mentioned with PBS and PBS-Tween 20, for a total of 15 minutes.  A small volume 
of phalloidin solution was added to each well and incubated for 15 minutes at room 
temperature.  Excess stain was removed and all wells washed three times with PBS.  
This process was repeated for propidium iodide stain.  Each cover slip was removed 
from the well and placed cell side down on top of a single drop of mounting media 
on a glass microscope slide.  Excess mounting solution was blotted off using clean 
tissue paper.  Each slide was labelled and left to dry for approximately 30 minutes.  
The edge of each cover slip was sealed using nail polish and left to dry for 2–3 hours, 
wrapped in tin foil.  Images of each slide were then take using Leica TCS SP2 
confocal microscope (Milton Keynes, UK) and a Carl Zeiss Axio Scope A1 
Microscope Nikon, (Japan). 
 
 Results 
To determine the seeding densities for further experiments, two growth curves were 
produced to ascertain the rate at which both cell lines proliferate.  Each cell line was 
seeded in a 96-well plate at a range of seeding densities (1000–10000 cells mL-1) for 
24 and 48 hours. 
 Figure 6.3 shows that the keratinocytes (HaCaT cells) proliferate faster, in 
both a 24-hour and 48-hour period, in comparison to the fibroblasts (Hs27 cells), as 
seen in Figure 6.4.  It can also be seen that there is a greater increase in proliferation 
at all the seeding densities between the 24-hour and 48-hour plates for the HaCaT 




HaCaT cell growth plot






















Figure 6.3 Graph showing MTT assay absorbance values, which are representative of HaCaT cell 
proliferation at different cell seeding densities (1000–10000 cells mL-1) over a 24-hour and 48-hour 
period.  The cells were cultured in DMEM media supplemented with 1 % penicillin-streptomycin and 
10 % foetal bovine serum.  Cells were incubated at 37 °C in an atmosphere of 5 % CO2.  Data shown 




Hs27 cell growth plot





















Figure 6.4 Graph showing MTT assay absorbance values, which are representative of Hs27 cell 
proliferation at different cell seeding densities (1000–10000 cells mL-1) over a 24-hour and 48-hour 
period.  The cells were cultured in DMEM media supplemented with 1 % penicillin-streptomycin and 
10 % foetal bovine serum.  Cells were incubated at 37 °C in an atmosphere of 5 % CO2.  Data shown 
as mean ± standard deviation (n=6). 
 
A range of IGF-1 concentrations were added to a constant number of cells for both 
cell lines in order to obtain a dose-response curve.  It can be seen from Figure 6.5 
that all the concentrations of IGF-1 (2–100 ng mL-1) caused a significant (p<0.01) 
increase in the MTT assay absorbance values, compared to the non-treated HaCaT 
cells.  A high absorbance value corresponds to a large number of viable cells being 
present.  For the HaCaT cells, the general trend seen was as the concentration of 
IGF-1 increased so did the absorbance value.  Figure 6.6 shows that on addition of 
IGF-1 to the Hs27 cells there was an increase in the MTT absorbance value 
indicating an increase in cell proliferation.  Similarly, addition of IGF-1 
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concentrations (2–80 ng mL-1) caused a significant (p<0.05) increase in the number 
of viable Hs27 cells.  However, the 100 ng mL-1 concentration (0.618 ± 0.115 a.u.) 
did not cause a significant (p = 0.3850) increase in the absorbance value compared to 
the control group, which had an absorbance of 0.535 ± 0.092 a.u.  The Hs27 cells do 
not show any general trend in response to increasing the IGF-1 concentration. 
IGF-1 dose-dependent stimulation of HaCaT proliferation




























Figure 6.5 Graph showing MTT assay absorbance values, which are representative of HaCaT cell 
proliferation at a cell seeding density of 4000 cells mL-1 while varying the concentration of IGF-1 (2–
100 ng mL-1).  The cells were cultured in DMEM media supplemented with 1 % penicillin-
streptomycin and 10 % foetal bovine serum.  Cells were incubated for 24 hours at 37 °C in an 
atmosphere of 5 % CO2.  Data shown as mean ± standard deviation (n=6), p < 0.05 (*), p < 0.01 (**), 




IGF-1 dose-dependent stimulation of Hs27 proliferation






















Figure 6.6 Graph showing MTT assay absorbance values, which are representative of Hs27 cell 
proliferation at a cell seeding density of 4000 cells mL-1 while varying the concentration of IGF-1 (2–
100 ng mL-1).  The cells were cultured in DMEM media supplemented with 1 % penicillin-
streptomycin and 10 % foetal bovine serum.  Cells were incubated for 24 hours at 37 °C in an 
atmosphere of 5 % CO2.  Data shown as mean ± SD (n=6). ), p < 0.05 (*), p < 0.01 (**), p < 0.001 
(***). 
 
The toxicity of the PVA-borate hydrogel towards each cell line was tested before 
applying IGF-1-loaded hydrogels to the cells.  On applying a sample of the hydrogel 
directly on top of the cells for 1 hour, it was found to decrease cell viability 
significantly (HaCaT p<0.01 and Hs27 p<0.001) for both cell lines, as seen in Figure 
6.7 and 6.8.  The HaCaT cell viability decreased from 100.0 % to 28.9 ± 1.2 % and 
the Hs27 viability decreased from 100.0 % to 20.0 ± 0.8 %.  Cells were also seeded 
on top of the hydrogel, but did not survive reaching zero viability within an hour.  An 
alternative method was tried, whereby, the hydrogel was in contact with the media 
rather than in direct contact with the cells, as seen in Figure 6.2 in section 6.4.5.  In 
using cell culture inserts, this mimicked the set up seen in the Franz diffusion cell 
240 
 
apparatus.  The cell viability still decreased for both cells lines, but not to the same 
extent as it did on direct contact with the hydrogel.  The HaCaT and Hs27 cell 
viability decreased to 62.0 ± 4.3 % and 48.0 ± 1.2 %, respectively on using a cell 
insert. 
Hydrogel toxicity on HaCaT cells






























Figure 6.7 Graph showing hydrogel toxicity towards HaCaT cells when applied directly onto the cells 
(without insert) and non-direct contact (with insert).  The cells were cultured in DMEM media 
supplemented with 1 % penicillin-streptomycin and 10 % foetal bovine serum.  Cells were incubated 
at 37 °C in an atmosphere of 5 % CO2.  A PVA 6.0 % w/w borate 2.0 % w/w hydrogel was used.  





Figure 6.8 Graph showing hydrogel toxicity towards Hs27 cells when applied directly onto the cells 
(without insert) and non-direct contact (with insert).  A PVA 6.0 % w/w borate 2.0 % w/w hydrogel 
was used.  The cells were cultured in DMEM media supplemented with 1 % penicillin-streptomycin 
and 10 % foetal bovine serum.  Cells were incubated at 37 °C in an atmosphere of 5 % CO2.  Data 
shown as mean ± standard deviation (n=6), p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
As a result of the findings seen in Figure 6.7 and 6.8, the decision was made to split 
the hydrogel into its two main components to investigate further if one had a more 
detrimental effect than the other.  It can be seen in Figure 6.9 that as the PVA 
concentration in the media was increased from 8.0–12.0 % w/w the HaCaT cell 
percentage viability increased to a maximum of 146.4 ± 9.6 % relative to the control 
at 100.0 ± 9.5 %.  However, on addition of 6.0 % w/w PVA the percentage cell 
viability decreased to 81.0 ± 5.1 %, but it is not a significant decrease (p = 0.0788).  
PVA 10.0 and 12.0 % w/w both caused significant increases with p values of 0.0051 
and 0.0149, respectively. 
 
 
Hydrogel toxicity on Hs27 cells





























Effect of PVA concentration on HaCaT cell viability































Figure 6.9 Graph showing the effect PVA concentration (6.0–12.0 % w/w) had on HaCaT cell 
viability when mixed directly into the media and incubated for 60 minutes.  Cells were incubated at 37 
°C in an atmosphere of 5 % CO2.  Data shown as mean ± standard deviation (n=6), p < 0.05 (*), p < 
0.01 (**), p < 0.001 (***). 
 
PVA had the same effect on the Hs27 cells but to a lesser extent (Figure 6.10).  Only 
the 10.0 and 12.0 % w/w PVA concentrations caused an increase in percentage cell 
viability (110.7 ± 1.8 % and 128.5 ± 18.1 %), compared to the control group.  Both 
the 6.0 and 8.0 % w/w PVA concentrations caused a decrease in cell viability 88.2 ± 
6.3 % and 96.6 ± 9.5 %, respectively, compared to the control group.  However, none 
of the changes were statistically significant (p>0.05).  Therefore, it would seem that 
PVA being present in the media has less of an effect on the Hs27 cell viability, 




Effect of PVA concentration on Hs27 cell viability





























Figure 6.10 Graph showing the effect PVA concentration (6.0–12.0 % w/w) had on Hs27 cell viability 
when mixed directly into the media and incubated for 60 minutes.  Cells were incubated at 37 °C in an 
atmosphere of 5 % CO2.  Data shown as mean ± standard deviation (n=6), p < 0.05 (*), p < 0.01 (**), 
p < 0.001 (***). 
 
Borate, the second component of the hydrogel system, was added to the media in the 
same way as the PVA in a range of concentrations (0.5–2.5 % w/w).  It was found 
that as the borate concentration increased in the media, the HaCaT percentage cell 
viability decreased significantly (p<0.01), as seen in Figure 6.11.  The highest 
concentration of borate (2.5 % w/w) gave the largest decrease in percentage cell 
viability from 100.0 ± 6.0 % for the control group to 12.4 ± 0.1 %.  The same trend 
was seen for the Hs27 cell line (Figure 6.12), with increasing borate concentration 
the cell viability decreased.  Again, the largest decrease was observed in the group 
treated with 2.5 % w/w borate, which reduced the cell viability from 100.0 ± 8.1 % 
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to 38.7 ± 6.5 %. However, the decrease in percentage cell viability was not as 
significant across all the borate concentrations in the Hs27 cell line as it was for the 
HaCaT cells.  Therefore, it would seem that borate also has a lesser effect on the 
Hs27 cells, compared to the HaCaT cells, the same trend seen for PVA. 
 
Effect of borate concentration on HaCaT cell viability
































Figure 6.11 Graph showing the effect borate concentration (1.0–2.5 % w/w) had on HaCaT cell 
viability when mixed directly into the media and incubated for 60 minutes.  Cells were incubated at 37 
°C in an atmosphere of 5 % CO2.  Data shown as mean ± standard deviation (n=6), p < 0.05 (*), p < 




Effect of borate concentration on Hs27cell viability































Figure 6.12 Graph showing the effect borate concentration (1.0–2.5 % w/w) had on Hs27 cell viability 
when mixed directly into the media and incubated for 60 minutes.  Cells were incubated at 37 °C in an 
atmosphere of 5 % CO2.  Data shown as mean ± standard deviation (n=6), p < 0.05 (*), p < 0.01 (**), 
p < 0.001 (***). 
 
Scratch assays were carried out on monolayers of both cell lines and treated with the 
appropriate treatments, as stated in the method section 6.4.5.  Figure 6.13 shows the 
rate at which the HaCaT cells closed the scratch when exposed to each of the 
treatments.  It can be seen that free IGF-1 (20 ng) caused the scratch to close within 
24 hours post scratching.  The IGF-1-loaded hydrogel had almost closed the scratch 
within 24 hours as only as small part at either end of the scratch remained not closed 
(Figure 6.13).  However, the scratch treated with the IGF-1-loaded hydrogel had 
completely closed by hour 36.  The blank hydrogel closed the scratch faster than the 
negative control, but, slower than the IGF-1-loaded hydrogel.  A larger portion of the 
scratch had not closed at 24 hours for the blank hydrogel treated cells, compared to 
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the IGF-1-loaded hydrogel.  Interestingly, the blank hydrogel did cause the scratch to 
be completely closed by hour 36, in comparison to the control group, which was still 
partially open at hour 36.
 
 
Figure 6.13 Representative images at each time point for each of the four treatment groups of a scratch assay study on HaCaT cells.  Cells were 
incubated for 36 hours at 37 °C in an atmosphere of 5 % CO2.  
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Figure 6.14 quantifies the qualitative data seen in Figure 6.13.  After 12 hours, the 
free IGF-1 and IGF-1-loaded hydrogel had closed 97.32 ± 0.27 % and 96.32 ± 0.13 
% of the scratch, respectively, compared to the control, which had achieved 50.00 ± 
10.08 % closure after 12 hours.  The blank hydrogel had closed 38.06 ± 6.48 % of 
the scratch, which was less than the control at 12 hours.  By 24 hours, the rate of 
closure slowed down, with the HaCaT scratch treated with the IGF-1-loaded 
hydrogel only closing a further 1.40 % to a total closure of 98.72 ± 0.32 %.  The cells 
treated with free IGF-1 achieved a scratch closure of 97.54 ± 0.27 %, at 24 hours. 
 
Figure 6.14 Graph showing percentage scratch closure HaCaT cells over a 36-hour period when 
exposed to three different treatments.  Cells were incubated at 37 °C in an atmosphere of 5 % CO2.  
Data shown as mean ± standard deviation (n=3). ), p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
The Hs27 fibroblasts closed the scratch faster than the HaCaT keratinocytes.  It can 
be seen in Figure 6.15 that by 24 hours, all 4 treatment groups had achieved 100.00 
% scratch closure, compared to the HaCaT cells, which took 36 hours.  The Hs27 
Percentage scratch closure of HaCaT cells over 36 hours







































cells followed the same general pattern as the HaCaT cells with the free IGF-1 and 
IGF-1-loaded hydrogel achieving the quickest scratch closure, in comparison to the 
blank hydrogel and control group.  By hour 12, the free IGF-1 and IGF-1-loaded 
hydrogel had caused the cells to achieve 100.00 % scratch closure with the blank 
hydrogel and control group achieving 100 % closure by hour 24. 
 The graph seen in Figure 6.16 quantifies the qualitative data seen in Figure 
6.15.  It can be seen that at 6 hours the hydrogel loaded with IGF-1 and the free IGF-
1 drug had caused 62.31 ± 2.28 % and 77.91 ± 2.51 % of the scratch to close, 
respectively, compared to the control group, which had achieved 44.34 ± 6.51 % 
closure.  By hour 12, the free IGF-1 and the hydrogel loaded with IGF-1 had both 
achieved complete scratch closure.  The cells treated with the blank hydrogel had 
achieved 86.42 ± 13.58 % closure, compared to the control group, which had 54.42 ± 
8.69 % closure at 12 hours.  At 24 hours, these two treated groups had reached 
100.00 % closure.  Therefore, in comparison to the HaCaT cells, the Hs27 cells 
achieved total scratch closure over a shorter time period.  The free IGF-1 and IGF-1-
loaded hydrogel treated HaCaT groups reached 100.00 % closure by 24 and 36 
hours, respectively, compared to the Hs27 groups, which reached 100 % closure by 
12 and 24 hours for the same treatment groups.  The Hs27 cell group treated with 
blank hydrogel and the control group both achieved 100.00 % scratch closure by 24 
hours. Whereas, the HaCaT group treated with blank hydrogel took 36 hours to reach 




Figure 6.15 Representative images at each time point for each of the four treatment groups of a scratch assay study on Hs27 cells.  Cells were 
incubated for 36 hours at 37 °C in an atmosphere of 5 % CO2. 
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Figure 6.16 Graph showing percentage scratch closure Hs27 cells over a 36-hour period when 
exposed to three different treatments.  Cells were incubated at 37 °C in an atmosphere of 5 % CO2.  
Data shown as mean ± standard deviation (n=3). ), p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). 
 
Immunofluorescent chemistry was used to determine if IGF-1 caused upregulation of 
the Akt cell signalling pathway.  Figure 6.17 shows that HaCaT cells treated with 
raw IGF-1 (20 ng) displayed an increase in expression of phospho-Akt (p-Akt) 
protein, represented by green fluorescence, compared to the non-treated cells.  It can 
be seen in Figure 6.18 that HaCaT cells treated with an IGF-1-loaded hydrogel also 
showed an increase in p-AKt expression, compared to the control, but to a lesser 
extent than the raw IGF-1 treated cells.  Interestingly, it was also seen that the blank 
hydrogel used as another control also caused expression of p-AKt although less than 





Figure 6.17 representative confocal immunofluorescent images of HaCaT cells A) no treatement and 
B) treated with 20 ng of raw IGF-1.  Phospho-AKt (Ser473) (D9E) XP® rabbit mAb (green), actin 







Figure 6.18 representative confocal immunofluorescent images of HaCaT cells A) treated with an 
IGF-1-loaded hydrogel and B) treated with blank hydrogel.  Phospho-AKt (Ser473) (D9E) XP® rabbit 






There was no green fluorescence exhibited by any of the Hs27 cell groups.  
Therefore, either there was experimental error or IGF-1 triggers a different cell 
signaling pathway in fibroblast cells, compared to the HaCaT cells.  Representative 
images taken of each the different treated groups of the Hs27 fibroblasts can be seen 
in Figures 6.19. 
 
 
Figure 6.19 representative confocal immunofluorescent microscope images of Hs27 cells A) treated 
with 20 ng of raw IGF-1 and B) no treatment.  Phospho-AKt (Ser473) (D9E) XP® rabbit mAb (green), 






Insulin-like growth factor-1 has been studied extensively in cell cultures as a 
potential therapeutic drug to aid wound healing due to its ability to stimulate cell 
proliferation and migration (Ando & Jensen, 1993; Bhora et al., 1995; Beckert et al., 
2005; Lee et al., 2006).  In this chapter, the aim was to determine if the PVA-borate 
hydrogel could deliver biologically active IGF-1 to keratinocytes and fibroblasts, 
stimulating an increase in cell proliferation and migration. 
 The keratinocytes (HaCaT) and fibroblasts (Hs27) used in this study both 
demonstrated time-dependent proliferation in serum-supplemented media.  This was 
an expected finding, as the longer the cells are incubated, the more time they have to 
proliferate.  On completion of a dose-response curve, it was found that as the 
concentration of IGF-1 increased (2–100 ng mL-1) so did HaCaT cell proliferation.  
This indicates that stimulation of proliferation by IGF-1 is dose-dependent for 
HaCaT cells.  Similarly, Pozzi et al. (2004) demonstrated IGF-1 dose-dependent 
HaCaT proliferation.  Pozzi et al. (2004) used an IGF-1 concentration range of 1–100 
ng mL-1, with the increase in proliferation not significant until 5 ng mL-1 was reached 
(Pozzi et al., 2004).  In comparison, there was a significant (p<0.001) increase in cell 
proliferation by the HaCaT cells in this investigation at 2 ng mL-1.  The Hs27 cells 
displayed a significant (p<0.01) increase in cell proliferation on addition of 2–80 ng 
mL-1 of IGF-1.  However, the general trend seen for the HaCaTs was not observed 
for the Hs27 cells.  The 100 ng mL-1 IGF-1 concentration did not cause a significant 
(p = 0.3850) increase in Hs27 proliferation compared to the control.  Yet, Telasky et 
al. (1998) found 100 ng mL-1 of IGF-1 to cause a significant (p<0.05) increase in 
proliferation of human dermal fibroblast cells over a period of 5 days.  IGF-1 was 
found to increase cell proliferation of the MCF-7 breast cancer cell line in a dose-
256 
 
dependent manner, indicating that increased levels of IGF-1 promotes the metastasis, 
survival and motility of cancer cells (Surmacz et al., 1998; Borowiec et al., 2007). 
 PVA is used widely in the pharmaceutical industry due to it being a 
biocompatible polymer (Kadajji & Betageri, 2011).  Hans et al. (2014) and Loughlin 
et al. (2008) both state the PVA-borate hydrogel is a non-toxic, biocompatible 
delivery system.  However, on application of a sample of PVA-borate hydrogel 
directly on top of the keratinocytes and fibroblasts used in this work, both cell types 
exhibited a significant (p<0.01 and p<0.001, respectively) decrease in cell viability.  
An explanation for this may be due to the unique viscoelastic flow properties of the 
PVA-borate hydrogel.  It may be that on application to the top of the cells, the 
hydrogel began to flow over the cells until flow was inhibited by the edge of the 
well.  This would result in the cells being completely starved of oxygen as gas 
exchange could no longer take place efficiently.  Also, as the hydrogel is denser than 
the DMEM media the gel sank down to the bottom of the well on top of the cells 
displacing the media.  This meant that the media was no longer in contact with the 
cells, starving them of vital nutrients.  Another reason may be due to the leaching of 
borate from the hydrogel into the media.  Murphy et al. (2012) documented that 
boron species do diffuse out of the PVA-borate hydrogel over a period of time, when 
in contact with a liquid phase.  However, the quantity released was deemed to be not 
toxic to humans (Murphy et al., 2012).  Nevertheless, cells are fragile in comparison 
to the whole human body.  Therefore, if a small quantity of borate is diffusing into 
the media it may kill the cells directly or through changing the pH of the media.  
Borate is a low toxic mineral, which can exhibit toxicity towards cell cultures and to 
humans if ingested in large quantities (Pongsavee, 2009).  An experiment was 
devised, whereby, the hydrogel was indirectly in contact with cells via the media, 
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rather than being directly in contact with the cells themselves.  This was achieved 
using cell culture inserts, as seen in Figure 6.2, section 6.4.5.  Interestingly, this 
approach was found to reduce the decrease in cell viability observed in both cell lines 
caused by direct contact.  Likewise, Smith et al. (2006) found that when a poly(N-
vinylpyrrolidinone) (PNVP) gel was in contact with the media and not in direct 
contact with the cells, the drop in cell viability was also reduced.  Smith et al. (2006) 
proposed two reasons why the gel may increase cell proliferation and maintain cell 
viability when not in direct contact with the cells.  First, the gel may uptake small 
quantities of nutrients from the media and mitogenic factors released from the cells.  
The gel may then release these at a later time, or, as the gel uptakes mitogens, it 
stimulates more mitogens to be released by the cells resulting in the gel acting as a 
mitogen factor reservoir (Smith et al., 2006).  Second, the gel may be acting as a 
filter, removing metabolic waste from the media across a concentration gradient, 
helping to maintain a favourable  environment for cell survival and proliferation 
(Smith et al., 2006). 
The hydrogel was split into its two components, PVA and borate, and added 
to both cell types separately.  This was to ascertain if one component was more toxic 
towards either of the cell types than the other.  It was observed that on increasing the 
PVA concentration, the cell viability of both the cell types increased, indicating an 
increase in cell proliferation.  In a similar manner, PNVP was found to have a 
stimulatory effect on the proliferation of human dermal fibroblasts (Smith et al., 
2006).  Yang et al. (2010) stated that extracts of a PVA-ws-chitosan-glycerol 
hydrogel when applied to L929 mouse fibroblasts show no toxicity and increases the 
cell viability.  Addition of PVA to the culture media of 3T3 mouse fibroblast cells, 
which were then incubated for 24 hours was found to have no toxic effect towards 
258 
 
the fibroblasts and have no negative effect on mitochondrial activity (Oliveira et al., 
2014).  Similarly in this study, PVA was found to have no toxic effect on Hs27 
human fibroblast or HaCaT keratinocytes. 
On adding a range of concentrations of borate to both cell types, it was found 
that on increasing the borate concentration, the cell viability decreased for both cell 
lines.  Therefore, this suggests that it is the borate within the hydrogel that is causing 
the cytotoxic effects of the PVA-borate hydrogel.  Pongsavee (2009) found that 
borate concentrations of 0.1–0.6 mg mL-1 causes a decrease in lymphocyte cell 
proliferation and changes within the DNA of lymphocytes. 
 From the scratch assays, it was confirmed that free IGF-1, IGF-1-loaded 
PVA-borate hydrogel and, interestingly, the blank hydrogel all closed the scratch 
faster than the control, for both cell lines.  Topical application of a PVA-ws-chitosan-
glycerol hydrogel, containing no therapeutic drug, to full-thickness wounds on 
Sprague-Dawlrey rats was found to increase the rate of wound healing in comparison 
to a normal gauze dressing (Yang et al., 2010).  The increase in wound healing is 
thought to be attributed to the hydrogel’s ability to maintain adequate moisture in the 
wound, which is thought to increase the migration of the cells in the epidermis (Yang 
et al., 2010).  Chitosan is also believed to stimulate fibroblast migration and 
inflammatory cells, enhancing wound healing (Yang et al., 2010).  However, in this 
investigation, the scratch in the cells was already kept hydrated, due to the liquid 
media and also there was no chitosan present.  Another explanation could be that the 
PVA from the hydrogel is leaching into the media as the hydrogel begins to swell 
and disintegrate.  However, as previously mentioned, boron species will also be 
present, most likely as boric acid (Murphy et al., 2012).  As the scratch assays are 
carried out in larger 12-well plates, the volume of media required in each well is 
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more than that required for the 96-well plates that the PVA and borate toxicity 
studies where completed in.  Therefore, the borate that is released into this larger 
volume of media may result in a lower borate concentration in the media.  A lower 
concentration of borate may not affect the cell viability to the same extent as higher 
concentrations in the toxicity studies.  If this is the case, then the stimulatory effect 
seen by the PVA in the toxicity study may have a greater effect on the cells than the 
toxic effect of the borate.  Thus, explaining why the rate of the scratch closure was 
faster for the blank hydrogel than the control group.  
The free IGF-1 and IGF-1-loaded hydrogels both exhibited a greater 
reduction in the scratch area over the allocated time, compared to the blank hydrogel 
and control group, for both cell types.  Similarly, Ando & Jensen (1993) found that 
addition of IGF-1 (1–50 ng mL-1) to keratinocyte cells caused a dose-dependent 
increase in migration of the keratinocyte cells, compared to the control group.  
Therefore, this indicates that IGF-1 is causing a stimulatory effect on cell migration 
and, as a result, covering the scratch area faster than the control group.  Likewise, 
Haase et al. (2003) found that adding 100 ng mL-1 of IGF-1 to primary human 
keratinocytes caused an increase in the rate of the scratch closure in comparison to 
the non-treated group.  Human corneal epithelial cells (HCEC) were cultured until a 
monolayer formed and where then scratched in a similar manner to the method used 
in this investigation (Lee et al., 2006).  The HCEC were treated with 10 and 50 ng 
mL-1 of IGF-1 and incubated for 12 hours.  Similar to what was found in this chapter, 
Lee et al. (2006) found that addition of IGF-1 to the scratched HCEC monolayer 
resulted in increased migration and proliferation in comparison to the control group.  
They also found that IGF-1 stimulated the release of LN-5, an ECM component that 
aids in epithelial cell migration and adhesion (Lee et al., 2006).  Emmerson et al. 
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(2012) carried out scratch assays on monolayers of primary human epidermal 
keratinocytes and dermal fibroblast, concluding that addition of IGF-1 to the media 
of both cell types resulted in an increase in the percentage closure of the scratch 
compared to the control group.  Beckert et al. (2005) found that addition of IGF-1 
released from a PVA film and methylcellulose gel to L929 mouse fibroblasts caused 
an increase in cell proliferation.  Topical administration of IGF-1 released from a 
PVA film, which was attached to a hydrogel dressing and applied to full-thickness 
wounds on Sprague-Dawley rats was also found to cause an increase in wound 
healing (Beckert et al., 2005).  The findings from the study in this chapter and 
Beckert et al. (2005) would indicate that a topical PVA based delivery system for 
IGF-1 may be beneficial for wound healing.  Other in vivo wound healing 
experiments, which involved the administration of IGF-1 to enhance wound healing 
have been carried out by several researchers (Tsuboi et al., 1995; Koshizuka et al., 
1997; Provenzano et al., 2007; Nunes Achar et al., 2014).  All of these studies 
concluded that administration of IGF-1 alone or in combination with other growth 
factors increased the rate of wound healing in comparison to the non-treated control 
groups.  Interestingly, Tsuboi et al. (1997) found that co-administering insulin-like 
growth factor binding protein-1 (IGFBP-1) along with IGF-1, further enhanced the 
healing of full-thickness skin wounds in diabetic mice and normal rabbits, compared 
to IGF-1 alone.  IGFBPs are a family of binding proteins, whose main function in the 
body are to increase the half-life of circulating IGF-1 from a few minutes to 30 
minutes by preventing proteolytic degradation of the IGF-1 (Laviola et al., 2007).  
Once the IGF-1 is bound to the IGFBP, a third component known as the acid labile 
subunit can also bind forming a tertiary complex (Laron, 2001).  This further extends 
the half-life of the IGF-1 to approximately 12–15 hours (Rosenfeld et al., 1999). 
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IGF-1 is thought to stimulate cell proliferation and migration through 
different intracellular signaling pathways, but mainly by way of the Akt pathway 
(Vincent & Feldman, 2002).  In this investigation, immunofluorescent chemistry was 
used to detect if the Akt pathway within the keratinocyte and fibroblast cells was up-
regulated and, therefore, the reason for increased cell proliferation and migration of 
the cells on addition of IGF-1.  Akt was found to be phosphorylated in the 
keratinocyte cells on addition of both free IGF-1 and IGF-1 that was released from 
the PVA-borate hydrogel, in comparison to the negative control group.  Also, there 
was a modest phosphorylation of Akt in HaCaT cells treated with the blank hydrogel.  
This is in keeping with the scratch closure results mentioned previously.  However, 
the exact mechanism of how the blank hydrogel is activating the Akt pathway is 
unknown.  But, as discussed previously, it may due to the PVA, which was also seen 
to cause an increase in cell proliferation when added alone to the media.  It is 
unlikely, but, not impossible, that the PVA is activating one of the many cell surface 
receptors as these are ligand-specific receptors.  IGF-1 causes phosphorylation of 
Akt through a cascade of events, which occurs on binding of IGF-1 to the IGF-1 
transmembrane receptor.  Several adaptor molecules interact with the activated IGF-
1R, mainly insulin receptor substrate-1 and 2 (IRS-1 and 2) (Laviola et al., 2007).  
On interaction with the receptor, the IRS becomes phosphorylated and activates 
phosphoinositide 3-kinase (PI3K).  PI3K leads to the production of membrane-
associated inositol, which also undergo phosphorylation (Stitt et al., 2004).  The 
inositol then attracts and activates phosphoinositide-dependent kinases (PDKs), 
which activates Akt protein kinase B (Stitt et al., 2004).  Akt then stimulates protein 
synthesis and gene transcription leading to cell proliferation and migration (Laviola 
et al., 2007).  Similar to the results found in this investigation, IGF-1 was found to 
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upregulate the Akt pathway via phosphorylation in primary human keratinocytes 
(Haase et al., 2003), HCECs (Lee et al., 2006), MCF-7 breast cancer cells (Dufourny 
et al., 1997; Borowiec et al., 2007) and mouse lung-tumour epithelial cells (Fritz et 
al., 2011).  Lee et al. (2006) also document that the ERK pathway was already 
phosphorylated on addition of IGF-1, but, that IGF-1 increased ERK 
phosphorylation. 
It is uncertain if IGF-1 caused phosphorylation of the Akt pathway in the 
Hs27 fibroblast cells as no phosphorylated Akt (pAkt) was detected in the 
immunofluorescent visualisation.  This may have been due to error in the 
experimental procedure.  However, the experiment was repeated several times using 
the exact same protocol as for the HaCaT keratinocyte cells.  Another possibility is 
that the fibroblast cells utilise another intracellular pathway to trigger cell 
proliferation, differentiation and migration.  Activation of the IGF-1 receptor has 
been shown to trigger other pathways, such as the ERK and MAPK pathways 
(Vincent & Feldman, 2002; Lee et al. 2006; Laviola et al., 2007; Fritz et al., 2011).  
Both these cell signaling pathways are known to promote cell migration and 
proliferation (Vincent & Feldman, 2002).  Vincent & Feldman (2002) concluded in 
their review of the IGF signaling pathways that activation of the IGF-1R leads to 
activation of multiple signaling pathways through phosphorylation, to promote cell 
survival.  However, IGF-1 was found to phosphorylate Akt through PI3K in human 
foetal lung fibroblast (Chetty et al., 2006).  But, it is hard to compare this to skin 
fibroblast cells as fibroblast cells found in different body tissue and, indeed, within 




The Hs27 fibroblasts displayed a faster rate of closure for the IGF-1-loaded 
hydrogel, blank hydrogel and control groups, compared to the HaCaT keratinocytes.   
Likewise, Walter et al. (2010) found that L929 mouse fibroblasts closed the scratch 
area faster than HaCaT keratinocytes in both the treated and non-treated groups.  It 
was also found that in co-culturing of both cell types the fibroblast cells still 
migrated into the scratch area before the keratinocytes (Walter et al., 2010).   
Haase et al. (2003) state that keratinocyte cells migrate by a crawling-like 
process known as lamellipodial locomotion.  Lamellipodial locomotion of the 
keratinocytes involves the extension of the plasma membrane at the front of the cell 
and contraction of the cell body at the rear of the cell (Sixt, 2012).  In order to crawl 
effectively, Haase et al. (2003) concluded from their investigation that there needs to 
be both IGF-1 and epidermal growth factor (EGF) present in adequate 
concentrations.  They state that IGF-1 triggers the plasma membrane extension, 
facilitating cell spreading and EGF stimulates the contraction at the rear of the cell.  
Haase et al. (2003) deduced that IGF-1 primarily activates the PI3K/Akt signaling 
pathway and EGF activates the MAPK/ERK pathway.  However, they found that 
IGF-1 on its own did cause an increase in random cell migration of the primary 
human keratinocytes, but, concluded that for a complex process of in vivo wound re-
epithelisation both growth factors would need to be present in adequate amounts 
(Haase et al., 2003).  Restricted crawling leading to reduced random migration may 
explain why the HaCaT cells took longer to achieve complete scratch closure for the 
IGF-1-loaded hydrogel, blank hydrogel and control group compared to the same 
treatment groups of Hs27 fibroblast cells.  It is documented that fibroblast cells 
migrate into the scratch as single non-clustering cells (Monsuur et al., 2016).  
Fibroblasts present as spindle-shape, from which several cytoplasmic projections 
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extend outwards providing anchoring points for wound contraction (Velnar et al., 
2009; Trepat et al., 2012).  As a result of this, the fibroblasts may be able to cover 
the scratch area faster than the keratinocytes due to their ability to spread out over a 
large area.  This may explain why the fibroblasts closed the scratch quicker, yet, in 
the growth curve study showed to be slower at proliferating than the keratinocytes.  
Alternatively, the keratinocyte cells are more rounded in shape and are known in an 
in vivo wound to migrate as one continuous edge (Baum & Arpey, 2005).  Baum & 
Arpey (2005) state that the leading edge of keratinocyte cells differentiate to inhibit 
temporarily their ability to proliferate and that a close knitted layer of proliferation 
cells is laid down behind the leading edge.  Fibroblast are known to be activate in 
wound healing prior to the re-epithelisation by keratinocytes (Velnar et al., 2009).  
Fibroblasts are involved in the synthesis of extracellular matrix components, 
secretion of keratinocyte growth factor and the formation of granulation tissue (Li et 
al., 2007; Enoch & Leaper, 2008).  The keratinocytes begin to migrate over the 
granulation tissue as it is formed, re-epithelising the wound.  As a result of this, some 
researchers have seeded keratinocytes on top of a fibroblast feeder layer, which have 
had their ability to proliferate inhibited to investigate the highly complex cross-talk 
and interactions between the two cell types and better replicate wound healing in vivo 
(Werner et al., 2007).  Despite this, no single cell culture or animal model can fully 
replicate the highly orchestrated, complex nature of the wound healing process as it 
occurs in the human body.  
Pastar et al. (2018) state in their review of pre-clinical models for wound 
healing that two-dimensional cell culture models are unable to replicate, completely, 
biological events, such as the immune response, cell-cell interaction and cell-matrix 
interaction that occurs during wound healing in vivo.  However, in recent year’s 
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development of human skin equivalent three-dimensional organotypic models have 
shown to be a beneficial improvement on the two-dimensional model.  The three-
dimensional organotypic human wound model allows the recreation of the 
fundamental skin layers including the stratified epidermis (Pastar et al., 2018).  
These cell models have shown to be able to maintain complex activities, such as hair 
follicle formation and migration (Oh et al., 2013). Organotypic cell cultures display a 
basal keratinocyte proliferation rate similar to an in vivo wound (Garlick & 
Taichman, 1994).  Despite these advantageous properties these models still lack the 
complexity of an in vivo human wound and cannot replicate complex processes, such 
as angiogenesis and inflammation (Oh et al., 2013; Pastar et al., 2018).  Organotypic 
models are produced by seeding layers of fibroblasts harvested from human donors 
onto a dermal substrate.  After several days of incubation, human harvested 
epidermal keratinocyte cells are then seeded on top of the fibroblast layer (Boutrand 
et al., 2017).  As a result, these 3D organotypic models can be fabricated from 
keratinocytes and fibroblasts harvested from chronic wounds, such as diabetic foot 
ulcers (Maione et al., 2016) and keloids (Butler et al., 2008).  This provides in vitro 
models whereby the cells have the characteristic traits of the in vivo cells in the 
chronic wound from which they were harvested.  MatTek Corporation sell a readily 
available 3D human skin equivalent model, called EpiDerm™.  Miyana & Hughes 
(2016) used EpiDerm™ to assess the irritant effects of metallic nanoparticles 
towards the skin.  EpiDerm™ is a reconstructed human epidermis consisting of 
human-derived epidermal keratinocytes for research use in academic and 
pharmaceutical settings (MatTek Corporation, 2018).  Organotypic human skin 
equivalence models can be produced rapidly using a 3D bioprinter, as demonstrated 
by Cubo et al, (2016).  They demonstrated that 100 cm2 of 3D printed skin is 
266 
 
achievable in less than 35 minutes in comparison to several weeks when cultured 
manually (Cubo et al., 2017).  Human ex vivo skin wound models have also been 
used successfully to assess a wide variety of pharmaceutical agents on 
epithelialisation, such as EGF (Pastar et al., 2018).  The human skin isolates used in 
these models are obtained from reduction surgeries with the patients consent.  As a 
result, these skin isolates can be expensive to acquire and are not readily available.  
Human skin isolates are advantageous over the previously mentioned models as the 
basement membrane integrity is maintained, the defined layers of the skin are 
maintained and they have similar gene expression patterns to human in vivo wounds 
(Andrew Chan et al., 2008; Roupe et al., 2010; Xu et al., 2012).  However, 
ultimately they still do not fully replicate an in vivo wound due to the lack of a blood 
supply and, therefore, immune cell infiltration (Pastar et al., 2018). 
 
 Conclusion 
On completion of the experimental work in this chapter, it was found that several 
concentrations of IGF-1 (2–100 ng mL-1) caused an increase in cell proliferation in a 
dose-dependent manner for both HaCaT keratinocyte and Hs27 fibroblast cell lines.  
It was found that both cell lines did not tolerate the PVA-borate hydrogel being in 
direct contact, indicated by the significant (p<0.05 and p<0.001) decrease in cell 
viability.  However, both cell lines tolerated the hydrogel being in contact with the 
media, evident by a smaller decrease in the cell viability.  On further investigation, it 
was found that the PVA showed no toxic effects towards either cell line and caused 
an increase in cell proliferation.  However, the borate species at all concentrations 
(0.5–2.5 % w/w) was found to be toxic towards both cell lines.  Application of free 
IGF-1 and IGF-1 released from the hydrogel to the HaCaT keratinocytes showed to 
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increase the scratch closure rate (100 % closed by 24 hours and 36 hours, 
respectively), in comparison to the control group (>36 hours to achieve 100 % 
closure).  Likewise, for Hs27 fibroblasts, the free IGF-1 and IGF-1 released from the 
hydrogel caused an increase in the rate of closure of the scratch area.  Both these 
treated groups had achieved 100 % closure by 12 hours in comparison to the control 
group, which took 24 hours.  Interestingly, all the groups of the fibroblast cells 
closed the scratch area faster in comparison to the corresponding groups of the 
HaCaT cells.  This is believed to be due to a combination of factors, such as 
migration, proliferation and function of the cell types.  On immunofluorescent 
analysis of the treated cells, it was found that IGF-1 caused activation of the Akt 
intracellular pathway in the HaCaTs, which is linked to stimulation of cell survival, 
migration and proliferation.  However, it is uncertain if the IGF-1 stimulated the Akt 
pathway in the Hs27 fibroblasts due to no detection of phosphorylated Akt.  
However, IGF-1 is known to activate other intracellular signalling pathway such as, 
ERK and MAPK.  Therefore, the fibroblasts may utilise one of these pathways, 
which can also stimulate cell survival, migration and proliferation.  It was shown that 
the PVA-borate hydrogel is capable of delivering biologically active IGF-1 to two 
human skin cell types, stimulating an increase in cell proliferation and migration, 
which is thought to be through the activation of potentially one (Akt) if not more 













7 General conclusion 
Chronic wounds do not progress through the normal stages of healing in a timely and 
efficient manner.  The healing may be disrupted at one or more of the widely-
recognised stages, leading to a chronic state.  The wound healing process can also be 
complicated by patient comorbidities and medication (Menke et al., 2007).  In 2008, 
it was reported that 200,000 people in the UK alone had a chronic wound, costing the 
NHS an estimated £2.3–3.1 billion per year (Posnett & Franks, 2008). 
 Growth factors found to be present in wound serum are thought to have 
multifunctional roles in the activation of the complex, highly orchestrated, 
intracellular signaling network, which controls the wound healing process and the 
many cells involved.  However, in chronic wounds, there is often a deficiency of 
these necessary growth factors.  The main route of administration, currently, is 
parentally for many therapeutic proteins and growth factors.  However, one 
drawback of parenteral administration is the need for frequent injections due to the 
short half-life of many proteins and peptides.  Growth factors involved in wound 
healing act locally as they possess short diffusional distances across the extracellular 
matrix because they degrade within a short period of time.  Platelet-derived growth 
factor, basic fibroblast growth factor and vascular endothelial growth factor after 
intravenous administration have half-lives of 2, 3 and 30 minutes, respectively 
(Edelman et al., 1993; Lee, 2000; Eppler et al., 2002).  The high frequency of 
injections required to maintain an adequate growth factor concentration within a 
defined therapeutic window will lead to reduced patient compliance and concordance 
(Li et al., 1998).  Therefore, there is a need for an alternative controlled release 
delivery system, which is capable of enhancing the pharmacodynamics and 
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pharmacokinetic properties of the therapeutic protein or peptide being delivered. 
Therefore, the overall aim of this thesis was to investigate the ability of the PVA-
borate hydrogels to deliver, topically, a sustained release of a bioactive peptide for 
wound management and repair.  
The viscoelastic properties of the sixteen PVA-borate hydrogels formulated 
were investigated using oscillating rheometry.  It was concluded from the rheological 
characterisation that the viscoelastic properties could be modified by varying the 
PVA and borate concentrations.  The hydrogel formulation, PVA 6.0 % w/w borate 
2.0 % w/w was deemed to be the optimum formulation.  The optimum formulation 
was deemed to be a hydrogel that displayed the correct balance between elastic 
cohesiveness and liquid-like flow, while showing low adhesive properties.  The 
optimum gel when physically manipulated retained its shape for several seconds 
before flowing at an acceptable speed.  Theses viscoelastic properties exhibited by 
the PVA-borate hydrogel are advantageous for topical drug delivery in wound 
management and repair.  The viscoelastic properties allow the PVA-borate hydrogel 
to flow into the wound crevasses, providing maximum wound-hydrogel contact, for 
drug delivery.  Yet, they retain enough cohesive integrity to be removed fully intact 
from the wound.  The low adhesiveness of the PVA-borate hydrogel facilitates 
removal from the wound with minimal disturbance to the new tissue.  The PVA-
borate hydrogels demonstrated the ability to uptake and carry small volumes (10.00g 
approximately 1–2 mL) of deionised water, making them advantageous for wound 
management and potentially suitable for application to lightly exuding wounds. 
 Physically mixing the desired quantity of payload to a pre-formed PVA-
borate hydrogel was found to be a sufficient method to obtain a homogenous mix of 
heat-sensitive payloads throughout the hydrogel matrix.  The in vitro release of 
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several proteins was characterised using Franz diffusion cells at 37 °C.  The PVA-
borate hydrogel demonstrated the ability to deliver a sustained release of three 
concentrations of BSA and haemoglobin over 8 hours.  The hydrogel provided a 
maximum cumulative percentage release of 58.34 ± 1.17 %, after 8 hours, from a 
0.10 % w/w BSA-loaded hydrogel and a maximum cumulative percentage release of 
50.62 ± 1.52 %, after 8 hours, from a 0.10 % w/w haemoglobin-loaded hydrogel.  
The hydrogel also displayed partial release of trypsin from 0.05% and 0.10 % w/w 
loaded hydrogels, after 4 hours and release from a 0.20 % w/w trypsin-loaded gel 
over 8 hours.  However, the uncharacteristic release profiles for trypsin accompanied 
with large standard deviations of the mean values, may indicate certain limitations to 
the gels’ capability of providing a sustained release of specific proteins.  It has been 
found that addition of all three concentrations of each of the different model proteins 
caused changes in the viscoelastic properties of the hydrogel.  On analysis of the 
released proteins using SDS-PAGE, it was concluded that all three proteins were 
released from the hydrogel without undergoing degradation in relation to changes in 
molecular weight.  It would seem that the most suitable protein payloads for 
incorporation into the PVA-borate hydrogel are those which will have a net negative 
charge when incorporated into the hydrogel matrix.  The results also indicated that 
high molecular weight proteins are released in a sustained manner.  Therefore, it was 
presumed that if the hydrogel can release large bulky high molecular weight proteins 
then it could also release lower molecular weight proteins and poly(peptides). 
 Addition of three concentrations of pepsin (0.05, 0.10 and 0.20 % w/w) 
resulted in significant (p<0.01) decreases in the crossover moduli.  The PVA-borate 
hydrogel provided a sustained release of pepsin over an 8-hour period at 37 °C, with 
a maximum percentage cumulative release of 84.84 ± 0.79 % from the 0.20 % w/w 
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pepsin-loaded hydrogel.  This indicates that the PVA-borate hydrogel may be able to 
provide a sustained release for protein payloads of a similar molecular weight and 
isoelectric point.  SDS-PAGE was used to analysise the molecular weight of the 
pepsin, which was released from the hydrogel.  It was concluded that the pepsin had 
not undergone degradation, in terms of changes in molecular weight, on being 
released from the hydrogel.  However, the enzymatic activity of the pepsin could not 
be maintained upon release from the PVA-borate hydrogel.  This indicated that in 
moving forward with the overall aim of the project, careful consideration needed to 
be taken when choosing a suitable protein payload, which promotes wound 
management and repair.  This is to ensure that the biological activity of the payload 
can be maintained when encapsulated in the hydrogel matrix and upon release. 
IGF-1 is a 7.6 kDa poly(peptide) consisting of 70 amino acids.  Its function is 
to control cell differentiation and, therefore, growth of body tissue (Laron, 2001).  Its 
synthesis is stimulated by growth hormone (GH) released from the anterior pituitary 
gland and the major source of circulating IGF-1 in the body is the liver (Dercole et 
al., 1984).  Numerous reports of topical application of IGF-1 to full-thickness skin 
wounds in animal models (Tsuboi et al., 1995; Koshizuka et al., 1997; Provenzano et 
al., 2007; Nunes Achar et al., 2014) and to scratch assays in monolayers of cells 
(Dufourny et al., 1997; Haase et al., 2003; Lee et al., 2006; Borowiec et al., 2007; 
Fritz et al., 2011) have demonstrated an increase in wound healing and scratch 
closure.  IGF-1 circulating in the body has a short half-life, estimated to be a few 
minutes.  Hence, approximately 80 % of circulating IGF-1 is bound in a tertiary 
complex, which increases its half-life to 12–15 hours by protecting it from 
proteolytic degradation (Rosenfeld et al., 1999).  Therefore, if IGF-1 is to be 
delivered to chronic wounds where protease activity is high, a delivery system, 
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which can provide a sustained release over a prolonged period of time, should be 
considered.  The PVA-borate hydrogel is an ideal novel delivery system to 
investigate the sustained release of IGF-1 as it has provided sustained release of 
protein payloads over an 8-hour period.  In addition, McCarron et al. (2011) 
concluded that the PVA-borate hydrogel is suitable for application to wounds in a 
clinical setting. 
It was found that upon incorporating three concentrations of IGF-1 (50, 100 
and 200 ng g-1) into the PVA borate hydrogel that there was no significant (p = 
0.2023, 0.8843 and 0.7264, respectively) change in the viscoelastic properties.  The 
PVA-borate hydrogel loaded with 200 ng g-1 of IGF-1 was found to provide a 
sustained release over an 8-hour period at 37 °C.  The maximum percentage 
cumulative release (58.15 ± 4.88 %) was observed, after 7 hours.  The median 
effective dose (ED50) of the IGF-1 used in this study, in human cell lines, is 0.3-1.5 
ng mL-1, as stated by the manufacture in the certificate of analysis (R&D Systems, 
2015).  Therefore, with 58.15 ± 4.88 % cumulative release over 8 hours, confidence 
can be had in the PVA-borate hydrogel delivering a sufficient quantity of IGF-1 in 
cell culture work to observe any effect it may have on the cells.  Molecular weight 
analysis, by MADLI-TOF MS of the IGF-1 poly(peptide) prior to incorporation into 
the PVA-borate hydrogel and on release from the hydrogel confirmed that no 
degradation had occurred.  This would suggest that the PVA-borate hydrogel has the 
potential to be a suitable and stable topical delivery system for sustained release of 
growth factor payloads for wound management and repair. 
Several concentrations of IGF-1 (2–100 ng mL-1) caused an increase in cell 
proliferation in a dose-dependent manner for both the HaCaT keratinocyte and Hs27 
fibroblast cell lines.  It was found that both cell lines did not tolerate the PVA-borate 
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hydrogel being in direct contact, indicated by the significant (p<0.05 and p<0.001) 
decrease in cell viability.  However, both cell lines tolerated the hydrogel being in 
contact with the media, evident by a smaller decrease in the cell viability.  On further 
investigation, it was found that the PVA showed no toxic effects towards either cell 
line and, in fact, caused an increase in cell proliferation.  However, the borate at all 
concentrations (0.5–2.5 % w/w) was found to be toxic towards both cell lines.  
Application of free IGF-1 and IGF-1 released from the hydrogel to the HaCaT 
keratinocytes increased the scratch closer rate (24 hours and 36 hours to achieve 100 
% closure, respectively), in comparison to the control group (>36 hours to achieve 
100 % closure).  Likewise, for the Hs27 fibroblasts the free IGF-1 and IGF-1 
released from the hydrogel caused an increase in the rate of closer of the scratched 
area.  Both these treated groups had achieved 100 % closure by 12 hours in 
comparison to the control group, which took 24 hours.  Interestingly, all the groups 
of the fibroblast cells closed the scratch area faster, in comparison to the 
corresponding groups of HaCaT cells.  This is believed to be due to a combination of 
factors, such as migration, proliferation and function of the cell types.  On 
immunofluorescent analysis of the treated cells, it was found that IGF-1 caused 
activation of the Akt intracellular pathway in the HaCaT cells, which is linked to 
stimulation of cell survival, migration and proliferation.  However, it is uncertain if 
the IGF-1 stimulated the Akt pathway in the Hs27 fibroblasts due to no detection of 
phosphorylated Akt.  However, IGF-1 is known to activate other intracellular 
signalling pathway, such as ERK and MAPK.  Therefore, the fibroblasts may utilise 
one of these pathways, which can also stimulate cell survival, migration and 
proliferation.   
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To conclude, the experimental work completed in this thesis has shown that 
the PVA-borate hydrogel is capable of delivering several protein payloads and, in 
particular, the poly(peptide) IGF-1.  IGF-1 was shown to maintain its biological 
activity on release from the hydrogel, stimulating an increase in cell proliferation and 
migration.  Therefore, an IGF-1-loaded PVA-borate hydrogel could be a potential 
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